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Hepatic lipase (HL) plays a critical role in the modulation of plasma lipoprotein 
concentrations and specifically the concentrations of high density lipoproteins and 
small low density lipoproteins.  HL is likely to play a role in cellular cholesterol 
homeostasis.  Despite numerous studies aimed at characterizing HL regulation, the 
role of cholesterol in controlling HL expression and/or activity levels remains unclear.  
In Fu5AH and McA-RH7777 rat hepatoma cells, cholesterol treatment resulted in a 
marked decrease in secreted rat HL (rHL) mass.  Similarly, the acyl-CoA:cholesterol 
acyltransferase inhibitor 58-035 decreased rHL secretion, suggesting that unesterified 
cholesterol mediated the downregulation.  Cholesterol alone or in combination with 
25-hydroxy-cholesterol, or 58-035 decreased rHL mRNA levels without affecting 
mRNA degradation rate.  Sterol Regulatory Element Binding Proteins (SREBPs) are 
the major transcription factors mediating the feedback regulation of cholesterol levels.  
Sterol treatments decreased nuclear SREBPs in human HepG2 cells without affecting 
the activity of a -1480/+14 human HL (hHL) promoter luciferase construct in rat or 
human cells.  In HepG2 cells, statin (compactin) treatment or over-expression of 
nuclear SREBP1a (nSREBP1a) decreased the activity of a -117/+14 hHL promoter 
construct and HL mRNA levels.  Forced expression of nSREBP1a reversed the 
Upstream Stimulatory Factor 1 (USF1)-mediated activation of hHL promoter 
constructs.  Gel-shift and supershift assays identified binding sites for Hepatocyte 
Nuclear Factor 1 (HNF1), HNF4 and USF1 within the hHL promoter at -70/-48, -252/-
218, and -317/-298 respectively.  Binding of these factors was diminished using 
nuclear extracts from sterol or compactin treated cells.  No direct binding of nSREBP 
 to the hHL promoter was identified.  SREBP1a bound to USF1 in co-
immunoprecipitation experiments, suggesting inhibition of HL transcription by 
cholesterol or compactin may occur through SREBP1 interaction with USF1 or its co-
activators.  In rat cells, cholesterol or 58-035 decreased rHL protein synthesis while 
protein turnover was unchanged.  In vitro translation assays demonstrated a decrease 
in HL translation efficiency in sterol-treated cytoplasmic extracts.  These experiments 
provide evidence for a novel aspect of the function of SREBPs in the crosstalk 
between cholesterol and fatty acid/triglyceride metabolism. 
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Chapter 1 - Review of literature 
 
High cholesterol levels are associated with increased risk for cardiovascular 
disease.  Hepatic lipase (HL), an enzyme which is active in the liver and to a lesser 
extent in the adrenals, ovaries and in macrophages, is implicated in cholesterol 
metabolism at multiple levels.  Its roles in lipoprotein metabolism stem from both its 
enzymatic role as a phospholipase and a triglyceride hydrolase and from its “bridging” 
role to increase the residency time of lipoproteins in close proximity to their cellular 
receptors.  Its combined role as a lipolytic enzyme and as a ligand increases 
lipoprotein uptake and cholesterol loading in cell culture.  By increasing cholesterol 
uptake, HL affects cell cholesterol levels, and it could be part of a feedback 
mechanism to maintain stable cholesterol levels within the cell.   Because HL may 
play a role in maintaining cellular cholesterol homeostasis, the issue of HL regulation 
by cholesterol is of particular interest.   
Within liver cells, intracellular cholesterol homeostasis is tightly maintained.  
Sterol Regulatory Element Binding Proteins (SREBPs) are the major transcription 
factors mediating the feedback regulation of cholesterol levels by controlling the 
expression of genes involved in cholesterol biosynthesis, lipoprotein uptake, or 
lipoprotein hydrolysis.  Therefore, it became apparent that SREBPs may also play a 
significant role in the cholesterol regulation of HL expression.   
The goal of this thesis is to investigate the regulation of HL by cholesterol and factors 
which affect intracellular cholesterol levels such as SREBPs. 
1.1  Hepatic lipase 
1.1.1  Characteristics 
Hepatic lipase (HL) belongs to a family of lipases that also includes pancreatic 
lipase, lipoprotein lipase (LPL), endothelial lipase, phosphatidyl serine phospholipase 
A1, and lipase H. 
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Most HL is synthesized and secreted by liver parenchymal cells, and then localizes 
mainly at the surface of hepatocytes (in the Space of Disse) and hepatic vascular 
endothelial cells (1), where it binds to heparan sulfate proteoglycans (HSPGs).  HL is 
active mainly in the liver, but also in the adrenals and ovaries (2).  Recently, mouse 
and human macrophages were identified as a site of de novo synthesis of HL.  In 
mouse peritoneal macrophages, RNA levels reached 10-30% of that in liver (3). 
HL displays both phospholipase A1 and mono-triglyceride hydrolase activities and 
hydrolyses fatty acids at the sn-1 position in both phospholipids and mono/di/tri-
glycerides (4).  HL is a serine-protease which hydrolyzes its substrates utilizing a 
single conserved Ser-Asp-His catalytic triad (5;6). 
Seventy per cent of the secreted lipase activity in in vitro assays was found to be 
sensitive to immuno-inhibition by an anti-hHL antibody.  Meanwhile, only 20% of 
intracellular activity was immuno-inhibited, suggesting that HL represents only a 
small fraction of intracellular lipase activity in in vitro assays (7).  This finding points 
out to the importance of having a specific assay for assessing HL mass in order to 
reliably quantify HL levels.   
Human HL (hHL) is a 476 amino acid glycoprotein with an NH2-terminal domain, 
a short spanning region, and a COOH-terminal domain.  The human enzyme has four 
N-linked carbohydrates of the complex type (8;9), with the glycosylated form of the 
hHL monomer running at around 65kDa on SDS-PAGE (10).  The presumed active 
homodimer would have a head to tail orientation (11), with the COOH-terminal 
domain of one protomer (containing the substrate entry site) facing the NH2-terminal 
catalytic domain of the other protomer.  Rat hepatic lipase (rHL) has only two N-
linked oligosaccharides with an apparent monomeric molecular weight 57kDa. 
Heparin in the cell culture medium increases the release of HL activity in HepG2 
cells in a linear fashion for 6-12 hours, time after which the medium activity starts to 
decrease again.  Low concentration of heparin (10U/mL) leads to a release of ~70% of 
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HL activity into the medium, while optimal release is observed at a higher level of 
200U/mL (7;12).   
After two hours of heparin treatment, the observed increase in HL secretion would 
at least partly be due to a decrease in HL degradation with no change in synthesis rate 
(13).  In line with this idea, optimal clearance of HL from the plasma requires both 
HSPGs and the low density lipoprotein receptor (LDLR) related protein (LRP).  Some 
internalization of HL exists in LRP-deficient cells but HSPGs are required for 
internalization/degradation to occur (14).  Heparin competes with HSPGs for binding 
to HL.  Further, the initial binding of HL to HSPGs is a prerequisite before HL can be 
transferred to the LRP and subsequently internalized.  Thus, heparin prevents HL 
binding to both HSPGs and the LRP and strongly inhibits subsequent HL clearance.   
Overall, during the first ten hours, heparin increases HL secretion without a 
change in synthesis.  Over longer incubation times, rHL synthesis may also be 
increased (15;16).   
The use of inhibitors of the glycosylation pathway (17;18) and site-directed 
mutagenesis (19;20) has shown that complete N-linked glycosylation is a pre-requisite 
for the synthesis and secretion of fully active HL.  Upon reaching maturity in the 
endoplasmic reticulum (ER), functional HL would be rapidly glycosylated in the 
Golgi and directly secreted (21) with a half-life in the cell of about an hour. 
1.1.2  Functions of HL in metabolism 
For an overview of the main roles of HL in lipoprotein metabolism, see Figure 1-1.  
By hydrolyzing phospholipids (PL) and triglycerides (TG) in chylomicron 
remnants, HL exposes apolipoprotein determinants such as apoE (14) that target these 
particles for removal by hepatic receptors (22).  The use of heat-inactivated lipase, 
anti-HL antibodies, or expression of catalytically inactive HL protein (HL145G) has 
shown that HL-mediated changes in plasma lipid profile are not all attributable to its 
lipolytic function.  HL functions as a ligand to “bridge” lipoproteins and their hepatic 
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receptors for the uptake of TG-rich lipoproteins by cell surface receptors and HSPGs 
(23).  Its combined role as a lipolytic enzyme and as a ligand increases both the 
hepatic clearance of chylomicron remnants (24-26) and other apo-B containing 
lipoproteins, as well as the scavenger receptor class B type 1 (SR-B1)-mediated (27) 
selective uptake of high density lipoprotein-cholesterol esters (HDL-CE) (28;29) in 
the liver.  HL also increases the uptake of HDL-CE in steoridogenic tissues (such as 
adrenals and ovaries) where SR-B1 is also expressed. 
One human study compared the lipid profiles of three patients with complete HL 
deficiency, without circulating activity but with or without a detectable (20% of 
normal) level of HL mass.  The results suggested that inactive HL protein affects very 
low density lipoprotein (VLDL) and intermediate density lipoprotein (IDL) 
concentrations, as well as HDL concentration to a lesser extent, while HL activity 
influences the TG content of all lipoproteins across the density range (30).  Similarly, 
in HL knockout (-/-) apo E-/- mice, liver-specific expression of inactive HL (HL145G) 
lowers apoB-containing lipoprotein levels but only the wild type mice had decreased 
HDL levels, showing that quantitatively, the ligand bridging function of HL is mainly 
important for the clearance of apoB-containing particles.  Note that the clearance role 
of HL would probably not have been unmasked without the apoE deficiency in this 
model (31). 
Overall, by increasing the chylomicron remnant clearance rate and the selective 
uptake of HDL-CE, HL increases cholesterol uptake by cells.  Accordingly, disruption 
of the HL gene in mice (or in vivo inhibition of HL by antibodies) results in a 
depletion of female adrenal cholesterol stores.  Modification of low density lipoprotein 
(LDL) by HL can increase the uptake and accumulation of LDL cholesterol in cultured 
macrophages (32).  Of interest, it was recently reported that in peritoneal macrophages 
isolated from HL-expressing apoE -/- mice (as compared with HL-/- apoE-/- mice), 
the uptake of CE from oxidized LDL, and the subsequent degradation of oxidized 
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LDL were increased (33).  Given that HL is now known to be expressed in 
macrophages from aortic lesions, this could have profound consequences in 
accelerating the cholesterol loading and thus the development of lesions.  The 
presence of HL in the arterial wall could prove to play a similar role as that which has 
been described for LPL, locally increasing the free fatty acid (FFA) concentration, 
causing increased and prolonged retention of LDL, and increasing cholesterol uptake 
and foam cell formation, which would all lead to increased risk for atherosclerosis. 
HL activity is inversely correlated with HDL-cholesterol (HDL-C) levels.  
Mutations resulting in a decrease in HL activity are rare, but so far they have all been 
associated with elevated HDL-C levels and higher risk for cardiovascular disease 
(CVD) (34;35).  Studies on mice (36) or rabbit (37) transgenic models and HL-/- mice 
(38) clearly show that HL plays a major role in determining HDL-CE levels.  HL 
overexpression is associated (37) with a marked decrease in HDL-C and decreases in 
HDL, HDL-apoA1, HDL-apoCIII, and HDL-apoE.  Androgen administration in men 
also leads to an increase in HL activity which precedes and is highly correlated with a 
decrease in HDL-C (39). 
The hydrolysis of the TG in the core of the HDL2 particle and of PL by HL is 
coupled with a dissociation of apoA1 and a decrease in the HDL2 particle size into 
smaller, denser HDL3 (40).  The HDL3 particles are cleared more rapidly from plasma 
because they are optimal substrates for selective uptake (they are either taken up by 
the liver or excreted by the kidneys).  apoA1 can re-associate with  phospholipids and 
cholesterol to generate preβ1-HDL lipid complexes (41).  These preβ1-HDL particles, 
which are smaller than HDL2, are good acceptors of effluxed cell cholesterol and 
originate reverse cholesterol transport (42). 
HL hydrolyzes IDL (products of the hydrolysis of VLDL by LPL) into LDL (43).  
In patients with HL deficiency, β-VLDL particles (rich in cholesterol) as well as IDL 
particles accumulate and LDL levels are low. 
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The atherogenicity of LDL is linked to the levels of LDL-C, but also to LDL size 
and density.  Small, dense LDL particles are associated with increased risk for CVD 
and with high HL activity, which is a key enzyme involved in their formation.  Some 
of the effects of lipid-lowering therapy that are not mediated by a decrease in LDL-C 
could be due to an HL-mediated change in LDL buoyancy (44). 
 
 
 
Figure 1-1: Main roles of hepatic lipase (HL) in lipoprotein metabolism 
1.1.3  Is HL pro-atherogenic or anti-atherogenic? 
HL has been shown to have proatherogenic effects:  
1) There is an inverse relationship between HL activity and HDL-C concentrations.  
Low levels of HDL-C are in turn positively correlated with higher risk for 
atherosclerosis. 
2) There is a small positive correlation between small LDL and HL activity which 
hydrolyzes IDL into LDL (43). 
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3) apoE -/- HL-/- mice have less atherosclerosis than apoE-/- only mice (45), 
suggesting that mHL (which is mostly circulating) is pro-atherogenic in this model. 
4) Bone marrow transplantation experiments showed that even though macrophage 
HL expression does not affect the lipid profile and lipid content of lipoproteins, 
macrophage HL enhances early lesion formation in apoE-/- HL-/- mice (33).  In these 
experiments, apoE-/- or apoE-/- HL-/- mice were subjected to total body irradiation 
before being injected fetal liver cells of either genotype as a source of hematopoeitic 
cells.  Macrophage expression of HL in apoE-/- HL-/- mice raised lesion size to levels 
similar to that seen in apoE -/- mice which also express HL in liver and other tissues, 
indicating that macrophage HL specifically has a major role in aortic lesion formation 
in mice. 
5) The fact that HL-deficient macrophages have reduced aortic atherogenesis was 
confirmed by similar bone marrow transplantation experiments in the lecithin: 
cholesterol acyltransferase (LCAT) transgenic model, which is independent of apoE 
deficiency (33). 
On the other hand, HL also has been shown to have several antiatherogenic 
effects:  
1) Hypertriglyceridemic mice overexpressing human HL have less atherosclerosis 
(36). 
2) Liver-specific overexpression of hHL (mostly bound to cell surfaces) in LDLR-/- 
HL-/- mice reduces atherosclerosis, and this requires the lipase activity since similar 
expression levels of catalytically inactive human enzyme does not alter atherosclerosis 
rate in this model (46). 
3) During post-prandial lipid clearing, HL favors the clearance of chylomicron 
remnants, which are known to be highly atherogenic. 
4) Expression of inactive HL (HL145G) in the liver of apoE-/- HL-/- mice is (in 
contrast to wild-type mouse HL) protective against proximal aortic atherosclerosis, at 
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least partly because of the lowering of cholesterol-rich remnant concentration in 
plasma via the HL-LRP pathway (31).  This identifies the ligand-bridging function as 
anti-atherogenic in this mouse model. 
5) The role of HL as a lipolytic enzyme and as a ligand increases the selective uptake 
of HDL-CE in the liver (28;29) mediated by the SR-B1 (27). 
6) HL increases formation of preβ-HDL (of discoidal shape).  Thus at several levels 
(5 and 6), HL is implicated in reverse cholesterol transport (RCT). 
7) HL deficiency is a rare lipid disorder that has been identified in only 5 families 
(39;47-50).  The lipid abnormalities associated with this disease include elevated IDL, 
with buoyant HDL and LDL containing abnormally high levels of TG and PL (34;51).  
There is low LDL and accumulation of cholesterol-rich IDL and β-VLDL in plasma 
(consistent for a role of HL in clearance of VLDL and chylomicron remnants, and 
conversion of IDL to LDL).  HL-deficient patients have hypertriglyceridemia (across 
the lipoprotein density spectrum), hypercholesterolemia, and premature atherosclerosis 
(47)(39). 
8) Low HL has been shown to be an independent risk factor for atherosclerosis (52). 
Overall, as Hans Jansen concluded, “HL, is it a friend or foe? [It] seems to depend 
on whether it is in good or bad company” (53).  The site of expression (liver vs. 
macrophages), the circulating levels of small dense LDL or other components of the 
genetic background (e.g. LDLR, ATP-binding cassette transporter A1 (ABCA1), 
cholesterol ester transfer protein (CETP)) may be crucial determinants whether high 
HL can be beneficial or not.  Low LDLR activity or low CETP, which would decrease 
the clearance of cholesterol through apoB-containing particles, may make HL more 
necessary to support the RCT pathway.  An HL-mediated increase in RCT, which is 
antiatherogenic, may outweigh the proatherogenic effect of LDL hydrolysis to smaller 
denser LDL if the LDL levels are low to start with.   
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1.1.4  Regulation of hepatic lipase 
Even though HL is very similar to LPL, regulation of these two enzymes appears 
to be markedly different.  LPL localizes to adipose tissue, skeletal muscle and 
macrophages, whereas HL is present in liver, steroidogenic tissues and macrophages.  
Because of its implications in CVD risk, the study of HL regulation is timely and 
significant.  HL activity is regulated at different levels including synthesis, secretion, 
degradation, transfer, and binding to endothelial cells.  Multiple factors or hormones 
seem to affect HL such as insulin (positively in some but not all in vitro studies, the 
HL gene regulation by insulin has not yet been clearly demonstrated), cAMP, 
estrogens (inhibitory), thyroid hormone, androgens (inhibitory), apolipoproteins 
(although the exact nature of their physiological effect is unknown because in the in 
vitro assays, the effect seems to depend on the surface pressure of the lipid 
monolayer).  HL is regulated by cholesterol and fatty acids, in particular by the level 
of fatty acid in the diet and their degree of saturation, but overall, the effects of foods 
on HL activity are not well known and little is understood with regards to the 
nutritional regulation of the gene.  Postheparin plasma HL activity varies widely in the 
general human population, about 8 fold.  Overall, around 40-60% of HL variability is 
thought to be genetically determined (54).  Male gender, type 2 diabetes, high body 
mass index, intraabdominal fat (independently of total fat content), and the Lipc 
genotype (-514C haplotype, see 1.1.4.3) are all independent predictors of HL activity, 
and all are associated with an increase in HL activity.  HL expression also varies 
depending on ethnicity. 
Some questions regarding work on the regulation of HL have to be addressed, such 
as understanding whether the effects of HL regulators are indirect or direct, or whether 
the experimental system effectively reflects physiological conditions.  The results 
found in different studies are not always concordant, at least partly because of 
heterogeneous experimental conditions and models.  The outcome of clinical studies 
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also varies depending on multiple environmental or genetic interacting factors.  
Divergent results in the literature stress the complexity of HL-associated lipid 
metabolism. 
1.1.4.1  HL gene (lipc) information 
Gene structure 
The human HL gene (lipc) is located on chromosome 15q21-23 (9;55) and consists 
of 9 exons with 8 introns spanning around 135 kilobases (kb) (NCBI# NT_010289).  
Within the hHL promoter region, major and minor transcription sites have been 
located 43 and 54 nucleotides upstream of the translation start codon (56-58).  Some 
potential regulatory elements have been proposed by looking for consensus sequences 
(56;58;59) although few elements of the proximal promoter have yet been submitted 
to detailed analysis.  The rat and human HL genes display no significant similarity 
upstream of hHL-383 and rHL-361.  As a result, some regulatory sequences 
controlling expression of the lipc gene in these species may differ. 
Deoxyribonuclease 1 (DNase 1) protected sites in the hHL promoter 
A map of the human HL proximal promoter is presented in Appendix Q.  
DNase 1 footprint analysis with deoxyribonucleic acid (DNA) fragments spanning 
the –483 to +129 region of hHL and rat liver nuclear extracts identified 8 protected 
regions, 4 upstream of the transcription start site (A, -28/-75, B-96/-106, C -118/-158, 
D –185/-255) and 4 in the first exon of the gene (E1 -5/+20, E2 +36/+55, E3 +58/+83, 
E4 +86/+107).  Region A binds hepatocyte nuclear factor 1(HNF1).  The region from 
+28 to +129 contains a functional negative regulatory element, which deletion 
enhances promoter activity by 17 fold.  E2 would have a dominant negative role while 
E3/E4 would be required for maximal repression (60).   
Oka et al. (59) used sequences from -1865 to -1330 and from -643 to -48 in the 
hHL promoter and nuclear extracts from HepG2 and HeLa cells to identify seven 
protected regions: A (-1540/-1527), B(-1505/-1473), C(-1467/-1460), D(-595/-577), 
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E(-565/-545), F(-234/-220), F(-234/-220) and G (-70/-48).  Promoter activity analyses 
allowed them to identify major negative regulatory elements -1576/-1532, -623/-407 
(in HepG2 cells mainly), -138/-50 (in HeLa cells mostly), as well as positive 
regulatory elements (-50/-9 (in HepG2 cells), -407/-138 (HeLa cells), and -1862/-1576 
(HepG2 cells).  Thus, footprints A-E lie in regions of negative regulatory elements. 
Proposed role of HNF1 in HL gene expression 
Chang et al. (58) have shown that the motif for binding of transcription factor 
hepatocyte nuclear factor (HNF) 1 at rHL-58/-44 or hHL-67/-53 is a functional 
binding site, which binds to HNF1 in vitro and increases the activity of a heterologous 
promoter in primary hepatocytes.  However, in chloramphenicol acetyltransferase 
(CAT) transfection assays, the HNF1 site alone was not sufficient to induce activity in 
the context of the 3.4 kb hHL promoter in a liver-derived HepG2 cell line.  Sequences 
from +1 to +27 in hHL were essential for basal promoter activity, while some negative 
regulatory elements were located upstream of hHL-222.  Some regulatory sequences 
must lie outside of the 3.4kb promoter. 
A mouse model knockout for HNF1α (Tcf1-/- mice) has been developed and 
analyzed using microarray technology (61).  In this model, there is an increase in 
circulating HDL concomitant to an increase in LCAT and a 3.4 fold decrease in HL 
expression.  Whether HNF1α was directly responsible for the downregulation of HL 
was unresolved.  Some other transcription factors were affected by the deficiency in 
HNF1α, including an increase in sterol regulatory element binding protein 1 
(SREBP1) (1.7 fold) and peroxisome proliferator-activated receptor γ (PPARγ) (6 
fold), and a decrease in HNF-3α (2.2 fold) and farnesoid X receptor (FXR) (2 fold).  
Also, liver free cholesterol levels were 14% lower in the knockout mice as compared 
with control mice. 
 12 
1.1.4.2  HL regulation by cholesterol  
Because high cholesterol levels are associated with increased risk for CVD, and 
HL is implicated in cholesterol metabolism at multiple levels, the issue of HL 
regulation by cholesterol is of particular interest, although little is known to date about 
the mechanisms of such a regulation.  Although several studies have looked at 
postheparin plasma levels of HL upon feeding a high cholesterol diet in various animal 
models, results varied greatly depending on the model, diet, and experimental 
procedures used.  Also, measurement of postheparin plasma HL is non-specific, and 
therefore not always reliable by itself.  Very few studies have looked at a more 
simplified model in tissue culture.   
Since HL can affect cell cholesterol levels, in part by increasing cholesterol 
uptake, an attractive hypothesis is that some metabolites in the cholesterol pathway 
(synthesis and degradation) could regulate HL.  Yet, to date, no sterol response 
elements have been identified to be functional in the HL promoter.  Of note, LPL is 
downregulated by sterols, but contrary to HL, LPL is activated by SREBP through 
binding to a seterol responsive element (SRE) in the proximal promoter (62). 
In vivo cholesterol feeding studies 
Cholesterol-feeding was found long ago to increase both cholesterol ester transfer 
protein and HL activity in rabbits (63;64).  HL activity increased three fold upon 
feeding rabbits with cholesterol for two days, and remained high in heparin eluates of 
liver tissues or in post-heparin plasma over a month of feeding.  This increase in 
activity was not paralleled by an increase in liver mRNA levels during the first week, 
and HL mRNA was only increased by 46% on day 28 of treatment (65).  The increase 
in chylomicron remnants and β-VLDL upon cholesterol feeding would induce or 
stabilize HL activity within 4 hours with no change in mRNA levels (66).  In Rhesus 
monkeys (67), post-heparin HL activity increased during the first 21 days of 
cholesterol feeding, then decreased to basal levels when plasma cholesterol 
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accumulation began.  However, this increase in HL activity following a cholesterol-
rich diet seems to be species-specific.  Early reports in guinea pigs were inconclusive 
since cholesterol-fed guinea pigs showed either depressed postheparin plasma HL 
activity (68) or doubled HL activity in hepatic heparin-releasable eluates (69).  In rats, 
0.5-2% cholesterol-enriched diets consistently lead to a decrease in HL activity and/or 
expression.  A 15 to 23% decrease in postheparin plasma hepatic HL activity was 
found in hypercholesterolemic RICO rats (model with increased cholesterol 
biosynthesis in liver) (70) and normocholesterolemic Wistar rats (71).  A decrease in 
HL activity was also found in rat liver homogenates (34%) from female lean Zucker 
rats (good responders to cholesterol) and this was paralleled by a similar 34% decrease 
in HL mRNA in liver (72). 
One study determined the effect of cholesterol feeding on the hepatic mRNA 
expression of various transcription factors involved in cholesterol metabolism (73).  
Relative to a chow diet standard, chow + 2% cholesterol decreased sterol regulatory 
element binding protein (SREBP) 2 levels, but strongly increased SREBP1 levels. 
Tissue culture models 
Perhaps the best designed tissue culture study was that of Busch et al. (74), who 
studied the synthesis and expression of HL in response to changes in cholesterol 
biosynthesis in HepG2 cells, and suggested an inverse correlation between cell 
cholesterol content and HL mRNA/activity in these hepatoma cells.  All experiments 
in the Busch study were done in lipoprotein-deficient serum-containing medium, 
depriving the cells of an exogenous source of cholesterol.  Other papers followed up 
on the Busch study and found concordant or confounding results.  Below is a summary 
of the effects of treatments which interfere with intracellular sterol metabolism on 
hepatic lipase regulation. 
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• Lipoprotein-deficient serum (LPDS) 
LPDS, which reduces intracellular cholesterol availability, was consistently found 
to increase HL secreted activity after 24 (74) or 48 hours (75) by up to 50%.  Longer 
incubation times in LPDS medium resulted in decreased secreted activity in the 
medium, suggesting that some degradation is taking place (74).  One group found a 
simultaneous increase in HL mRNA and secreted activity, indicating a regulation at 
the transcriptional level (15). 
• Statins 
Statins, such as mevinolin or compactin, are inhibitors of 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme catalyzing the rate-
limiting step in cholesterol biosynthesis.  
After a 48-hour pretreatment in LPDS, Busch et al. treated the cells with 37µM 
mevinolin in LPDS medium.  In such conditions, the cells were deprived of exogenous 
lipids and cholesterol biosynthesis was blocked.  It is now known that under such 
conditions the sterol regulatory element binding protein isoforms SREBP2 and 
SREBP1a would have been strongly upregulated, whereas SREBP1c would have been 
downregulated.  After 24 and 48 hours, HL secreted activity was increased by 2.2 and 
4.9 fold respectively compared to LPDS medium control and this was paralleled by an 
increase in HL mass.  After 48 hours, HL mRNA levels were increased by 1.8 fold.  
Without pretreatment, the maximal induction of HL mRNA and activity was observed 
after 24 hour incubation (74).   
In contrast, compactin was found to decrease HL activity in HepG2 cells in other 
studies.  In one study, HepG2 cells in RPMI medium without serum were treated for 
48 hours with 20µM compactin.  The medium was changed and incubated 3 hours 
with 200U/mL heparin for collection.  Cell cholesterol and HL secreted activity 
decreased by 30% and 56% respectively, whereas LDLR activity increased by 122% 
(12).  In another study, 10µM atorvastatin (Pfizer) led to a reproducible yet not 
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significant trend towards a decrease in secreted HL activity and mRNA levels and -
685/+13-CAT promoter activity (76). 
• Mevalonic acid 
After a 48 hour pretreatment in LPDS medium, treatment with 1mM mevalonic 
acid (the product of the HMG-CoA reductase reaction, an intermediate in the 
cholesterol biosynthesis pathway) alone or with 37µM mevinolin for 48 hours resulted 
in a 53-65% decrease in secreted HL activity respectively (compared with LPDS 
medium control) without affecting HL mRNA levels.  Cell cholesterol increased by 26 
and 42% respectively.  Mevalonic acid inhibited the induction of HL expression (74). 
• LDL 
In the Busch paper, 30µg LDL protein/mL or 100µg HDL protein/mL alone in 
LPDS medium had no consistent effect on HL.  However, after a 48 hour 
preincubation in LPDS medium, a 48-hour treatment with mevinolin and LDL further 
induced secreted HL by 43% compared to mevinolin alone, with no change in mRNA 
levels.  This synergistic effect was not yet apparent after 24 hour treatment only (74). 
A few groups have reported that LDL could down-regulate HL secretion.  HepG2 
cells were preincubated for 48 hours with 200µg/mL LDL in RPMI-1640 before the 
medium was changed and collected after 3 hours with heparin.  Addition of LDL led 
to a moderate (25%) increase in cell cholesterol and a marked reduction in LDLR and 
secreted HL activities (12).  When administered in 5% fetal bovine serum (FBS) or 
complete medium, human LDL decreased HL activity in a dose-dependent fashion 
after 48 or 36 hours (with addition of heparin 24 hours within the treatment period) 
down to 10% (75) or 30% (77) of control respectively at 1mM LDL-cholesterol.  
Simultaneously intracellular stocks of unesterified/free cholesterol were increased 
whereas cholesterol biosynthesis was decreased.  However these results were not 
consistently found in other studies and the authors did not raise the problem of cell 
toxicity that arises from adding LDL to serum-containing medium. 
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• 25-hydroxycholesterol  
After a 48 hour pretreatment in LPDS medium, exposure of cells to 25-
hydroxycholesterol (an oxidized metabolite of cholesterol) for 24 hours produced a 
small but reproducible induction of secreted lipolytic activity with no change in 
mRNA levels.  25-OH-cholesterol in combination with mevinolin strongly repressed 
HMG-CoA reductase and resulted in a further induction of secreted HL activity and 
mRNA than with mevinolin alone (74).   
• Bile salts 
Bile salts such as chenodeoxycholic acid (CDCA) are synthesized from 
cholesterol. CDCA decreases HL activity (75) and HL mRNA in a dose-dependent 
manner in HepG2 cells and in primary human hepatocytes (78), an effect which might 
be species-specific.  A physiological level of bile acids (25µM CDCA) is sufficient to 
inhibit HL, while 1µM GW4064 (a non-steroidal synthetic farnesoid X receptor (FXR) 
agonist) has the same effect.  Silencing experiments with small interfering RNAs 
(siRNAs) and treatments with FXR agonists showed that bile acids down-regulate HL 
through the FXR.  In HepG2 cells, FXR/retinoid X receptor α (RXRα) overexpression 
in transactivation assays suggested that the bile acid responsive element lies within the 
-541/-698 region.  There is no inverted repeat-1 (consensus FXR/RXRα binding 
element) in the hHL proximal promoter, and gel shift assays failed to show binding of 
FXR to oligos covering the -541/-698 sequence, suggesting that regulation by FXR 
may be indirect (78), which would also explain the delay in downregulation of HL.  
The possibility of a bile acid-mediated posttranslational modification is not ruled out. 
• Oleic acid 
Addition of oleic acid to HepG2 cells for 36 hours (with addition of heparin within 
24 hours) resulted in an increase in secreted HL activity by up to 30% at 1.2mM oleic 
acid and a decrease in cell cholesterol concentration (77).  In a more recent study, 
treatment of HepG2 cells for 48 hours with 1mM bovine serum albumin (BSA)-bound 
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oleate (1:6 ratio) resulted in a 34% increase in secreted HL activity (with heparin 
present over the last 12 hours), a trend towards an increase in HL mRNA levels, and a 
two-fold increase in the activity of a -685/+13 hHL promoter CAT reporter construct 
(the HL promoter sequence corresponded to the wild-type C-514, G-250 promoter 
variant) (76).  Promoter activity of the same -685/+13 construct with the -C514T allele 
was significantly less stimulated by oleic acid or linoleic acid (79).  Atorvastatin 
inhibited the oleate-induced increase in HL secretion and promoter activity.  However, 
these promoter activity data are confounded by the fact that the normalizing vector 
used was upregulated by changes in SREBP as described below. 
• SREBP / upstream stimulatory factor (USF) 
In order to investigate a potential role of SREBP in regulating HL, a pSRE-luc 
construct containing three sterol responsive elements (SREs) from the HMG-CoA 
synthase gene in the pGL3 backbone was used. Because luciferase expression is 
driven by the SRE elements, this vector can be used to monitor mature SREBP 
transcriptional activity in the nucleus (76).  The activity of this reporter construct 
increased in a dose-dependent fashion by up to 10 fold upon gradual substitution of 
the 20% fetal calf serum (FCS) in the medium by LPDS.  At an intermediate 10% 
LPDS/10% FCS concentration used throughout the study, the pSRE-luc reporter 
construct was sensitive to either a decrease or an increase in mature nuclear SREBP 
(nSREBP) activity.  In these conditions, oleate resulted in a 50% decrease and 
atorvastatin resulted in a 2 to 4 fold increase in SREBP activity.  Co-transfection with 
pcDNA3-SREBP2 resulted in an increase of over 6 fold in pSRE-luc activity.  The 
activity of a -685/+13HL promoter construct decreased by 75% in chloramphenicol 
acetyltransferase (CAT) assays normalized for β-galactosidase mass (as assayed by 
enzyme-linked immunosorbent assays (ELISAs)) while there was only a slight 
significant decrease when using a pGL3 basic construct and normalizing for µg cell 
protein.  RSV-β-galactosidase (Promega), the normalizing vector used in CAT assays, 
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was strongly upregulated by SREBP2.  Thus, the marked decrease in hHL promoter 
activity found in the CAT assays probably reflected an increase in β-galactosidase 
mass, a problem which the authors did not address directly.  Altogether, this study 
could not conclusively show that SREBP and HL promoter activity may be inversely 
regulated. 
Upstream stimulatory factor USF1, like SREBP, is a basic helix-loop-helix leucine 
zipper transcription factor which binds E-boxes.  USF1 is known to upregulate HL 
(80).  Co-transfection with pCX-USF1 (a USF1 expression vector) did not affect 
endogenous SREBP activity but it increased HL promoter activity of the -685/+13-
CAT by about four fold (76).  Atorvastatin or nuclear SREBP2 cotransfection almost 
abolished the USF-mediated stimulation of HL promoter activity.  Conversely oleate 
could not further increase HL promoter activity in USF1-transfected cells, presumably 
because USF levels were high enough to compete with the increased endogenous 
SREBP levels in the absence of oleate (76). Using the luciferase assay with no 
normalizing vector, at constant levels of USF1, there was a dose-responsive decrease 
in HL promoter activity upon increasing levels of SREBP2.  Potential E-boxes were 
found at -514 and -310 of the hHL promoter, while a potential sterol responsive 
element (SRE) was located at -553.  Yet, the regulation by SREBP and USF seems to 
be independent of all three putative sites since a -305/+13-luc construct displayed the 
same regulation pattern as the -685/+13 construct. Based on this, the authors 
concluded that SREBP would interfere with USF-mediated upregulation of the HL 
promoter, at least partly via a non E-box dependent mechanism (76).  USF and 
SREBP2 could either bind to some unknown sequence within the -305/+13 promoter 
region, or recruit other transcription factors to the promoter.  Under basal conditions, 
endogenous SREBP would partly inhibit USF-mediated stimulation of HL, which 
would allow for oleate to increase HL by decreasing mature SREBP levels (76).  Such 
a theory could explain why omental fat mass or type 2 diabetes are associated with 
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high HL activiy, since both conditions are associated with increased fatty acid (FA) 
supply to the liver.  Also, the fact that atorvastatin treatment did not affect basal HL 
expression, but inhibited the oleate-mediated increase in HL expression could explain 
why lipid-lowering therapy has shown to be effective at lowering HL in 
hyperlipidemic patients in some studies (81;82). 
In most cases, SREBP activates gene transcription.  HL could be one of the few 
genes that are downregulated by SREBP.  For a review of the downregulation 
mechanisms of these other genes, see 1.2.3.4. 
1.1.4.3  HL regulation in the context of the HL promoter 
polymorphism 
The HL promoter contains four polymorphisms (G-250A, C-514T, T-710C, A-
763G according to the Ameis nomenclature (56)) which are all in Heidy-Weinberg 
equilibrium (83) and are in almost complete linkage disequilibrium (84).  The mutant 
haplotype is therefore commonly referred to globally as the -514C/T 
polymorphism/haplotype.  Note that earlier papers using the nomenclature of Cai et al. 
described it as the -480 polymorphism (57). 
This minor allele is very common in the hHL promoter, and its frequency in the 
population varies from around 20% in Caucasians to around 50% in African and 
Japanese Americans.   
The C-514T accounts for 38% of the variability of the catalytic activity of the 
enzyme (44;85), and the minor haplotype is associated with lower HL activity in both 
male and female human subjects (86).  In mouse and human (HepG2) hepatoma cell 
lines, promoter/reporter transfection studies have shown that the C-514T mutation 
decreases transcriptional activity of the HL gene by up to 50% independently of (87) 
or only together with the mutation at -250 respectively (80).   
At the level of the lipid profile, the -514T allele is associated with high HDL-C 
(84) with almost no effect of gender, race, or risk factors (88).  High HDL-C reflects 
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mainly high levels of largeTG-enriched HDL2 (89).  Note that there is no association 
with the level of LDL-C.   
HL promoter polymorphism and risk for CVD 
Despite apparently favorable effects on the lipid profile, such as an increase in 
HDL-C, the -514T mutant polymorphism was associated with a marginally increased 
risk for atherosclerosis, as shown by studies which found a greater risk for 
angiographic coronary artery disease (CAD) (52) and an increased risk for ischemic 
heart disease, even after adjustment for HDL-C, age and gender (90), particularly in 
the presence of at least one apoE4 allele.  Another study found that the -514T 
haplotype was associated with subclinical coronary heat disease in the background of 
type I diabetes as measured by an increase in coronary artery calcification (91).  
Higher HDL2 levels could be the consequence of a reduced RCT flux (52) since low 
HL activity could result in lower rate of formation of nascent preβ-HDL and lower 
SR-B1-mediated uptake of HDL-CE in the liver.  Also, there may be an effect of 
altered TG-rich lipoprotein remnant catabolism. 
On the other hand, the -514C wild-type allele was associated with higher carotid 
intima-media thickness in the Northern Manhattan prospective cohort study (92), as 
well as with an abundance of macrophages in the carotid plaque with fewer smooth 
muscle cells, which are features of an unstable atherosclerotic plaque (93). 
Gene-statin therapy interaction 
A substantial number of patients undergoing lipid-lowering therapy for primary 
and secondary coronary heart disease prevention do not respond to treatment and 
eventually develop coronary heart disease.  Zambon et al. (81) have shown that 
intensive cholesterol-lowering therapy in humans with an HMG-CoA reductase 
inhibitor or nicotinic acid in association with colestipol (a bile acid sequestrant), but 
not colestipol alone, lowers LDL-C as expected but also significantly decreases 
plasma HL activity and increases LDL buoyancy, which partly accounts for the drug-
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associated decrease in CAD.  For example, atorvastatin (Lipitor) in 40 patients with 
familial hypercholesterolemia (FH) for 12 weeks decreased HL activity by 18% and 
plasma cholesterol and TG (94).  It is tempting to speculate that the improvement in 
LDL buoyancy is due to the decrease in HL activity and this would make HL a 
potential therapeutic target.   
In the Familial Atherosclerosis Treatment Study, lipid-lowering drugs that appear 
to involve an HL-associated effect have been suggested to be more effective on the -
514 CC genotype (44).  This effect was similar whether the treatment was lovastatin 
and colestipol or niacin and colestipol.  Homozygous -514 CC patients, which 
originally have more small, dense LDL particles and lower HDL-C, showed a greater 
decrease in HL activity, and a greater increase in LDL buoyancy than -514 CT or TT 
patients.  Coronary stenosis improved most in -514 CC patients and to a lesser extent 
in CT patients, but aggravated in TT patients.  Therefore, the HL polymorphism would 
strongly influence the outcome of clinical therapy with lipid-lowering drugs. 
Another study looked at atorvastatin treatment in male and female of the Diabetes 
Atorvastatin Lipid Intervention study, which is a randomized, placebo-controlled 
multicenter study with subjects of various ethnic backgrounds and living in various 
countries.  In this study, in the background of type 2 diabetes, atorvastatin led to a 
dose-dependent decrease in postheparin HL activity, but the magnitude of the effect 
was independent of sex or the C-514T promoter variant.  Again in this case, this raises 
the possibility that diabetes or associated traits (such as FFA or higher waist-to-hip 
ratio) could interfere with the effect of atorvastatin on HL (82). 
Gene-insulin responsiveness interaction, effect on USF binding 
Insulin resistance is associated with increased plasma HL activity and low LDL-C 
in both non-insulin dependent diabetes mellitus (NIDDM) patients and non-diabetic 
subjects (95;96).  HL is elevated in NIDDM (97) and has been implicated in mediating 
the decrease in HDL-C observed in these diabetic patients.  Studies done in the 
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fructose-fed syrian golden hamster, an animal model of insulin resistance linked as 
expected the insulin-resistant diabetic state with increased HL activity, while insulin-
sensitizing drugs such as rosiglitazone normalized HL levels (98).   
The promoter mutation at -514 could alter an insulin response element and 
interfere with insulin responsiveness.  HL post-heparin plasma activity was increased 
at higher insulin concentrations in -514CC homozygotes only (but not in carriers of 
the T allele) (86).  The C-514T base pair substitution is at the center of a CA(c/t)GGG 
E-box.  USF, a putative insulin responsive transcription factor that is expressed in the 
liver, was shown to bind at the -514 site by supershift assay and to induce HL 
transcription as shown by an increase in promoter activity (80).  The -514C/T 
substitution in the HL promoter decreases binding affinity of USF to this site by 
around 2 to 4 fold (as shown by gel shift assays for HL specific oligos).  USF may 
bind to the HL promoter at the –514 site or at other USF consensus present in the –
685/+13 promoter fragment and lead to an increase in transcription of HL. When 
mutated along with -250 G/A (but not alone in this particular study), the -514C/T 
decreased promoter activity of a -685/+13 construct by about half in HepG2 cells, 
suggesting that it may play a role in basal transcriptional rate.   
The mutated G-250A haplotype appears to put carriers at risk for insulin resistance 
in most populations (99;100).  Low HL activities associated with the mutant promoter 
variant are associated with elevated TG, which could be the cause for conversion to 
diabetes.  On the other hand, the G-250A mutation tends to be protective for subjects 
from the Finnish population (101).  The reasons for this specificity remain elusive, but 
dietary habits such as total fat and saturated fat consumption may be involved (102).   
1.2  Tools to study cholesterol regulation 
1.2.1  Methyl-beta-cyclodextrins complexed to cholesterol 
Methyl-β-cyclodextrins (Sigma C-4555) are cyclic oligosaccharides that can 
encapsulate insoluble hydrophobic compounds such as cholesterol, rendering them 
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soluble in an aqueous phase.  They can be used to manipulate the cellular cholesterol 
content (103).  Alone in solution, methyl-β-cyclodextrin (mβ-CD) at high 
concentrations (10-100mM) can efficiently stimulate efflux of cholesterol and deplete 
intracellular cholesterol stocks from a variety of cultured cells much more efficiently 
than physiological concentrations of HDL.  Release of cholesterol from cells occurs 
quickly, mostly during the first two hours (103).  On the other hand, when complexed 
with cholesterol, cyclodextrins can be used to load cells with cholesterol (104).  After 
treatment with 5mM CD, 8:1 cholesterol molar ratio, there is a 2.5 fold enrichment in 
Fu5AH cell cholesterol after a seven hour incubation (103).  Alteration of cellular 
cholesterol levels using cyclodextrins has been used in several studies, including a 
study of the regulation of CD36 in macrophages (105), of SR-B1 in adrenal cells 
(106), and of ABCA1 in mouse aortic smooth muscle cells (107) . 
1.2.2  Acyl Coenzyme A: Cholesterol Acyltransferase inhibitors 
1.2.2.1  Acyl Coenzyme A: Cholesterol Acyltransferase (ACAT) 
Mechanistically, ACAT transfers the fatty acyl moiety of a fatty acyl CoA to the 
hydroxyl group of a sterol which lies embedded in a lipid bilayer (membrane).  ACAT 
activity is present in a variety of tissues including the intestinal mucosa, the liver 
(Kupffer cells and hepatocytes), adrenals, testes, and macrophages (with an increase in 
ACAT activity during plaque formation) (108).  ACAT is stimulated when cellular 
free cholesterol (FC) levels (its substrate) surpass a threshold above normal cell 
cholesterol concentrations (109), and this may be due to an FC-induced rise in ER 
cholesterol.  ACAT plays a role in the storage of cholesterol, by esterifying cholesterol 
to cholesterol esters, which accumulate for example in macrophages to form foam 
cells, or in steoridogenic tissues as a substrate for steoridogenesis. 
There are 2 different ACAT isoforms with different tissue localizations.  The 
ACAT1 isoform has a more ubiquitous expression pattern, and in humans, it is the 
major isoform in liver and macrophage-derived foam cells (108).  ACAT2 is the 
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predominant isoform in human intestine and is present at low levels in human 
hepatocytes.  This is in contrast with other mammals such as mice and non-human 
primates where ACAT2 is the predominant isoform in liver.  Within the cell, most of 
ACAT (isoforms 1 and 2) is located in the ER, with a small portion of 
immunoreactivity in macrophages localizing close to the trans-Golgi network or with 
the plasma membrane fraction (110). 
Hydropathy plots suggest that both ACATs contain multiple transmembrane 
domains, and it is possible that the active site for ACAT1 would locate in the cytosol 
while the active site for ACAT2 would locate to the lumen of the ER (111;112). 
1.2.2.2   Use of ACAT inhibitors 
Current inhibitors of ACAT (fatty acid amides, urea based compounds, 
compounds with increased water solubility) are nonselective for either isoforms since 
they were selected before the existence of two isoforms was known.  Among these, 
two common ACAT inhibitors are CP-113 818 (Pfizer) and 58-035 (Dr. Thomas 
Hughes, Novartis).  58-035 is a 3-[decyldimethylsilyl]-N-[2-(4-methylphenyl)-1-
phenylethyl]propanamide compound also called PFK058-035.  The IC50 of 58-035 
was found to be of 0.38+/-0.12µM in rat liver microsomal ACAT assays (113).  It is 
assumed to be a direct competitive inhibitor of ACAT (114).   
Commonly, during the time frame of a typical cell culture experiment, upon 
cholesterol loading in the absence of ACAT inhibition, cells would mainly have an 
increase in CE.   
In cell culture (both hepatoma Fu5AH cells and cultured arterial SMCs or 
macrophages), when used at concentrations >0.1µg/mL (and up to 10µg/mL) in 
combination with cholesterol-loading agents, 58-035 selectively and effectively 
inhibits the esterification of cholesterol (>95%), and thus it inhibits the accumulation 
of CE (115).  It also leads to a slight increase in cellular FC.  Thus, the presence of an 
ACAT inhibitor speeds up the FC loading, while overall, total cholesterol in the cell 
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decreases (115).  The inhibition of CE formation is dose-dependent and very rapid as 
full inhibition is observed after only 30 minutes of exposure to the cells (115).  Unless 
cholesterol acceptors are present in the medium, ACAT inhibitors can cause 
cholesterol-loaded cells to undergo apoptosis and necrosis.   
1.2.3  Sterol regulatory element binding proteins (SREBPs) 
1.2.3.1   Different SREBPs with different roles in metabolism 
There are two different SREBP genes that express SREBP1 and SREBP2 
respectively.  SREBP1 has two promoters, each encoding an mRNA with a different 
first exon (longer for 1a than for 1c, which has a shorter transactivation domain). 
The combined levels of SREBP1a and 1c within the cell are generally comparable 
to the levels of SREBP2 (116).  SREBP1c is the major isoform of SREBP1 in liver 
and adipose tissue, with approximately 10 times more 1c than 1a in animal liver cells.  
The same trend is found in McA-RH7777 (ATCC#  CRL-1601) or FTO-2B cells lines 
(117), while non hepatic cells and most cancer cells often have more 1a (e.g. mouse 
NIH-3T3, HEK-293, CHO or HepG2) (118).   
In transgenic mice that overexpress truncated, mature forms of SREBP1a, 1c or 2 
in the liver, and in SREBP1 knockout studies, SREBP2 favors the synthesis of 
cholesterol from acetyl CoA, whereas the 1c isoform favors the synthesis of TG and 
PL.  In other words, SREBP1 isoforms are more selective for activating genes 
involved in fatty acid biosynthesis (lipogenic genes) and SREBP2 is more specific for 
controlling genes in cholesterol biosynthesis (119). 
Livers of mice overexpressing SREBP1a were massively enlarged, owing to 
accumulation of TG and cholesterol (119).  Livers of mice overexpressing SREBP1c 
(with comparable SREBP overexpression) were only slightly enlarged, with only a 
moderate increase in TG but not cholesterol (120).  The cholesterol-related mRNAs 
were not elevated, and only slight elevations were seen for mRNAs involved in FA 
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synthesis.  Neither SREBP1a nor 1c transgenic mice displayed an elevation of HL 
mRNA levels (120).   
Luciferase reporter gene assays in HepG2 cells showed that all three SREBP wild 
type isoforms activate the SRE, SRE-like, or E-box sequences in target genes, but with 
different efficiencies.  SREBP1a was found to be a more potent activator for all gene 
targets (121), while the activation potential of SREBP1c was significantly weaker than 
that of 1a (with an extra acidic activation domain at its N-terminal) or of 2 (122).  1a 
and 2 can activate cholesterogenic genes (classic SREs) to almost similar extent, but 
1c is very weak.  1c and 2 (the major isoforms in the liver) displayed similar activities 
in activating lipogenic genes.  1a and 1c can activate E-boxes, but 2 is inactive 
although it can bind. 
 
Table 1-1: Relative transcriptional activities of the SREBP family (121) 
 
 Nuclear SREBP2 Nuclear SREBP1c Nuclear SREBP1a 
SRE +++ ~0 +++ 
SRE-like ++ ++ +++ 
E-box 0 + ++ 
 
Transcriptional activation of genes by SREBP is dependent on the interaction of 
SREBP with additional transcription factors (Sp1, NF-Y) and/or coactivators (CREB), 
especially for genes activated through SRE or SRE-like sequences.  These interactions 
can stabilize the DNA complexes.  NFY or Sp1 may not be crucial for E-box-mediated 
activation by SREBP1, which instead may be modulated by adjacent AP-1 sites. 
1.2.3.2  Regulation of the various SREBPs 
SREBPs are synthesized as ER-bound precursors, where they bind to the sterol-
sensing domain of the SREBP cleavage-activating protein (SCAP).  Cholesterol 
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interacts with the sterol-sensing domain of SCAP and produces a conformational 
change in SCAP, which triggers binding of the Insig protein and prevents the 
SCAP/SREBP/Insig complex from reaching the Golgi (123).  When intracellular 
cholesterol concentrations are low, SCAP escorts SREBP from the ER to the Golgi 
(116), where SREBP undergoes proteolytic cleavage.  Site 1 protease (a membrane-
bound protease) first cleaves within the hydrophilic loop of SREBP.  Then, site 2 
protease (a zinc metalloprotease) cleaves within the membrane-spanning domain of 
SREBP, releasing the N-terminal fragment, which can translocate to the nucleus to 
activate transcription.  25-hydroxy-cholesterol is even more effective than cholesterol 
at downregulating SREBP processing.  Sterols alone can reduce SREBP2 in a 
sustainable manner, but the ability of sterols to suppress SREBP1 (cleavage) is 
dependent on the presence of fatty acids (124). 
A liver X receptor (LXR) binding site was identified within the SREBP1c 
promoter (125) which mediates the LXR-mediated stimulation of the SREBP1c 
isoform (126;127).  Basal transcription and expression of SREBP1c specifically 
requires LXR and its endogenous ligands (117), which are oxysterol intermediates of 
the cholesterol biosynthetic pathway.   
In comparison with the 1a isoform which displays low constitutive expression 
(non-regulated), the 1c isoform is not only regulated at the level of sterol-dependent 
cleavage but is also highly regulated by LXR and insulin.  Thus, SREBP1c is not 
regulated by sterols as tightly as 1a and 2 in hamsters (128) or in liver cell lines (129).  
In the presence of cholesterol, LXR activates SREBP1c transcription, and as a result 
there can be active 1c in the nucleus at high cholesterol levels.  How the SREBP1c 
precursor is processed to a mature transcription factor in the presence of sterols is still 
unknown.   
In mice, SREBP1c (but not 1a or 2) is known to be induced at the transcriptional 
level and at the protein level in lipogenic states (high carbohydrate diet, refeeding) 
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(130).  Lipogenic gene transcription is inhibited by polyunsaturated fatty acids 
(PUFA) through a decrease in nuclear SREBP1 (nSREBP1) without affecting nuclear 
SREBP2 (131;132).  PUFA inhibition of nSREBP1 is effective in the absence of 
sterols whether cells are cultured in LPDS or delipidated serum medium (124).  
Insulin increases 1c mRNA in mice (133) and in isolated hepatocytes.  Stimulation by 
insulin is blocked by PUFA in rat hepatocytes (134).  PUFA decrease the abundance 
of nuclear SREBP1a and 1c by at least three mechanisms.  First, PUFAs inhibit 
SREBP1c gene transcription specifically, with very little effect on 1a and none on 2 
(135-137) in part by antagonizing oxysterol binding to the LXR and thus LXR 
activation (136).  Cholesterol was shown to override this repression in mice fed 
cholesterol and PUFA (138).  Second, PUFAs accelerate SREBP1c mRNA decay in 
vivo or in primary hepatocytes (139).  Third, PUFAs inhibit processing of SREBP1 
precursor to its mature form (135).  This PUFA inhibition overrides the cholesterol-
induced activation of SREBP1 protein maturation (138). 
1.2.3.3  SREBP-activated genes and SREBP-binding sequences 
Many cholesterol biosynthetic genes are activated by SREBPs, including HMG 
CoA synthase, HMG-CoA reductase, farnesyl-diphosphate synthase, squalene 
synthase, SREBP2, and the LDLR.  Cholesterol biosynthetic genes either have the 
classic SRE1 (ATCACCCCAC) (140) or its modified SRE3 (CTCACACGAG), and 
adjacent cofactors (NF-Y, Sp1) in their promoters.  Mutation of nine out of the ten 
nucleotides of the SRE1 in the promoter of the LDLR impairs the response to sterols.  
The SRE is necessary for high transcription of reporter genes in sterol-deprived cells 
but is not required for basal sterol-repressed transcription. 
A number of lipogenic enzyme genes are also under the control of SREBPs, such 
as acetyl CoA carboxylase, fatty acid synthase (FAS), stearoyl CoA desaturase1 and 2, 
glycerol-3-phosphate acyltransferase, and Spot 14.  For these genes, SREBP binding 
and activation sites are more diverse.  Some genes such as Spot 14 (141) and FAS 
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(142) contain E-boxes which are thought to confer sensitivity to PUFA, glucose or 
insulin through SREBPs.  E-boxes or E-box like sequences (5’-CANNTG-3’) bind 
members of the basic helx-loop-helix (bHLH) family such as USF1/2 (methyl 
sensitive transcription factors with consensus sequence 5’CACGTG3’), cmyc, 
inhibitors of DNA binding (Ids), SREBP1, as well as some non-members.  Within the 
SREBP family, SREBP1 has the unique property of binding/activating E-boxes or E-
box like sequences, although binding to a complete CACGTG site does not necessarily 
mediate activation.  Maximal activation of an E-box requires SREBP concentrations 
up to 100 fold higher than for maximal activation of an SRE.  Other genes could 
utilize SRE-like sequences (TCAGGCTAG) such as in ATP Citrate Lyase (143) or 
SRE halves (TCACCC) such as in the malic enzyme promoter (121). 
Finally, other SREBP-activated genes include PPARγ and LPL which expression 
is directly controlled by SREBP through an SRE site, although E-boxes are present in 
the promoter (62;144;145). 
1.2.3.4  Genes known to be downregulated by SREBPs 
More recently, SREBPs were also shown to mediate downregulation of some 
target genes.  In all examples of downregulation by SREBP known to date as 
described below, genes are upregulated by sterols and downregulated by sterol 
depletion.  For an overall view of how SREBPs can activate or inhibit transcription, 
see Figure 1-2. 
Downregulation through binding of SREBP to SREs 
Human microsomal triglyceride transfer protein (MTP) is down-regulated by 
SREBP through an SRE (5’-GCAGCCCAC) located at -124/-116bp.  A truncated 
form of SREBP2 lacking the transcriptional activation domain and normally acting as 
an inhibitor of transcription could also mediate inhibition, indicating that direct 
binding to the promoter itself may be sufficient.  Interaction with cooperative factors 
seems unlikely because of the lack of Sp1 or NFY binding sites in the vicinity of the 
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SRE, and because of the lack of effect of deleting the transcriptional activation 
domain.  SREBP2 could possibly act by competing for binding with AP-1, which has 
an adjacent binding site and is necessary for promoter activity (146). 
SREBP1c downregulates PKA-stimulated (but not basal) phosphoenolpyruvate 
carboxykinase (GTP) (PEPCK/PEPCK-C) in isolated hepatocytes.  SREBP1 or 2 bind 
weakly to both SREs in the promoter (-322/-313 and -590/-581), and an unknown 
factor is necessary for facilitating SREBP1c binding.  Mutation of the -590 element 
only dramatically enhanced basal PEPCK expression, but a mutation of both SREs 
was necessary to fully relieve the promoter of SREBP-mediated inhibition.  Sp1 
(which has a binding site on the opposite strand of the DNA) and SREBP1 compete 
for binding to the -590 SRE, and displacement of Sp1 results in an inhibition of gene 
transcription.  Both Sp1 and SREBP1 bind the promoter in this region in vivo as 
shown by chromatin immunoprecipitation (ChIP).  Replacing the PEPCK SRE 
sequence by that of the LDLR (one nucleotide difference: ATCACCCCTC) at -590 
also mutates the Sp1 binding element and allows for both SREBP1 and Sp1 to bind 
the consensus SRE and stimulate transcription.  Replacing the -322 SRE by the LDLR 
SRE did not have any stimulatory effect (147).   
Downregulation through binding of SREBP to E-boxes 
ApoA5, a protein which associates with HDL and VLDL in plasma, is 
downregulated by SREBP1 in a dose-dependent manner at the promoter activity level.  
Two E-boxes at +10/+15 (5’-CAGGTG) and -76/-81 (5’-CACGTG) in the ApoA5 
promoter bind specifically to SREBP1-c in vitro and are functional as shown by 
mutation analysis.  A construct containing 3 tandem repeats of the more potent 
+10/+15 E-box was downregulated by SREBP1, and mutation of an SP1 site adjacent 
to the +10/+15 site did not affect downregulation.  Overall, downregulation was 
conferred by binding of SREBP-1 to isolated E-boxes, with possible displacement of 
other bHLH-ZIP (148). 
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Mature SREBP2 inhibits ABCA1 promoter activity through binding to an E-box 
between -156 and -116.  The association of SREBP2 to the vicinity of the E-box on 
the ABCA1 promoter was demonstrated in vivo doing chromatin immunoprecipitation 
(ChIP) analysis under sterol starvation.  This E-box was previously shown to bind 
other transcription factors including USF1 and USF2.  In this study, USF1 and 2 were 
shown to activate the hABCA1 promoter.  USF1 levels were unchanged under sterol 
starvation (high SREBP levels) whereas USF2 was downregulated.  SREBPs could 
replace USF by competing for binding to the E-box.  Alternatively, SREBP2 could 
form a complex with other transcription factors or recruit other repressors to the 
promoter (149).   
Downregulation without direct binding of SREBP to DNA 
Sterol 12α-hydroxylase, an enzyme required for cholic acid synthesis, is up-
regulated by SREBP1 but down-regulated by SREBP2.  Whereas activation by 
SREBP1 involves binding to two perfect inverted SREs in the proximal promoter 
(lower strand: 5’-TCACCCCAC at -323/-330 and -306/-315), the inhibition by 
SREBP2 was unaffected by deletion or mutation of these SRE sites. SREBP2 
repressed gene transcription apparently without binding to the promoter, possibly by 
binding to LRH1 (also known as FTF) thereby preventing LRH1-mediated activation 
of gene transcription (note: LRH1 binding may not be affected) (150).   
Promoter activity of human oxysterol 7α-hydroxylase (CYP7B1 – an enzyme 
active in the metabolism of oxysterols) is suppressed by SREBP1.  The SREBP1-
responsive region was mapped to a GC-rich region in the proximal promoter (-86 to 
+176) which was previously shown to bind Sp1.  Three GC-boxes in this region were 
found to be involved in SREBP1 downregulation, and a single GC-box was sufficient 
to mediate inhibition.  Gel-shift assays using extracts from SREBP1 or 2 
overexpressing cells failed to show binding of SREBP to the promoter.  SREBP1c was 
able to completely abolish Sp1 activation in cotransfection experiments, suggesting an 
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indirect mechanism whereby SREBP1 would bind to Sp1 and prevent it from binding 
to the GC boxes (151).   
SREBP1 downregulates HNF4α-stimulated expression of PEPCK.  In this case, 
SREBP1 would not bind to the promoter but would bind through its transactivation 
domain to the ligand binding/AF2 domain of HNF4α (as demonstrated by 
gluthathione-S-transferase pull-down assays and in vivo by coimmunoprecipitation).  
This binding would still allow HNF4α to bind to the glucocorticoid-response unit in 
the promoter but would prevent HNF4α from recruiting the essential PPARγ 
coactivator-1 and from activating transcription.  A similar mechanism was 
hypothesized to explain the SREBP1-mediated down-regulation of glucose 6 
phosphatase, another gluconeogenic HNF4α-activated gene (152). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-2: Known mechanisms for gene transcription regulation by SREBPs 
SREBPs can activate gene transcription (A) through binding to sterol responsive 
elements (SRE), SRE-like elements, and/or E-boxes. SREBPs can also inhibit 
transcription of target genes through binding to an SRE (B), an E-box (C) or without 
binding directly to the promoter (D). Although regulation is isoform-specific for each 
target gene, all mature SREBP isoforms are referred to here as nuclear SREBP 
(nSREBP) for simplicity. 
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1.3  Introduction to the research chapters 
This thesis investigates the regulation of HL by cholesterol and factors which 
affect intracellular cholesterol levels. 
Chapter 2 describes the effects of cholesterol depletion and repletion on hepatic 
lipase protein secretion and enzyme activity levels in our tissue culture model.  These 
data were used as a basis for all further experiments designed to investigate the 
underlying mechanisms for this regulation. 
Chapter 3 describes the effects of sterol manipulations on HL at the level of 
transcription by looking at mRNA steady-state levels, mRNA degradation rate, and 
HL promoter activity levels.  SREBPs are major transcription factors controlling the 
expression of genes involved in cholesterol metabolism.  Thus, we also investigated 
their role in HL regulation using similar methods, alone or in the presence of USF1, 
which is a known activator of HL.  Gel shift assays were performed in order to 
identify transcription factor binding sites within the hHL proximal promoter.  Finally, 
co-immunoprecipitation experiments were performed to investigate a possible 
interaction of SREBP1 with positive effectors of HL transcription such as USF1. 
Finally, Chapter 4 presents the effects of sterol manipulations at the post-
transcriptional level by looking at HL protein synthesis, protein degradation, and 
translation efficiency.
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Chapter 2 – Effects of sterol manipulations on HL 
protein and enzymatic activity in rat hepatoma cells 
 
2.1 Introduction 
Because of the role of HL in enhancing lipoprotein uptake and cholesterol loading, it 
has been speculated that HL expression could be regulated by intracellular cholesterol as 
an additional means to ensure feedback regulation of cell cholesterol levels (74).  To date 
however, despite numerous studies, not much has been elucidated regarding the 
regulation of hepatic lipase.  In particular, the regulation of hepatic lipase by cholesterol 
is still subject to some debate, and no underlying mechanism has been offered.  Because 
of the apparent discrepancies between different groups regarding the effect of cholesterol 
treatment on HL secretion, our first goal was to clearly define the effects of cholesterol 
on HL protein secretion and activity levels in our cell culture model. 
2.2 Methods 
2.2.1 Tissue culture 
Fu5AH and McA-RH7777 cells were maintained at 37°C in a 5% or 10% CO2 
atmosphere respectively in their individual growth medium.  McA-RH7777 cells were 
grown on collagen-coated dishes in medium consisting of 20% horse serum, 5% fetal 
bovine serum, 2mM L-glutamine, 9.8g/L NaHCO3, 10.6g/L N-2-hydroxyethylpiperazine-
N'-2-ethanesulfonic acid (HEPES), 42.3g/L GIBCO Dulbecco’s modified Eagle’s 
medium #61100-103 (DMEM); pH 7.2.  Fu5AH medium consisted of 10% FBS, 2mM L-
glutamine, 11.7g/L NaHCO3, 12.7g/L HEPES, 50.9g/L GIBCO #61100-103 Eagle’s 
minimal essential medium (MEM); pH 7.2. 
The cells were split upon reaching confluency using standard procedures.  Briefly, the 
medium was aspirated and the cells were washed with phosphate-buffered saline.  PBS 
was then aspirated and replaced by 0.25% trypsin +/- 0.1% ethylenediaminetetraacetic 
acid (EDTA) in phosphate-buffered saline (PBS), which was removed after 30 seconds.  
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The cells were resuspended in medium and part of this solution was used to start a flask 
with new growth medium.  
2.2.2 Reagents 
Cholesterol (cell culture tested, Sigma C3045) and 25-OH-cholesterol (Sigma H1015) 
were made fresh every few days as a 500X stock (5mg/mL cholesterol, 0.5mg/mL 25-
OH-cholesterol) in ethanol.  Sodium mevalonate (mevalonolactone, Sigma M4667) was 
prepared as a 50mM stock in PBS and was stored at 4C.  β-sitosterol (Sigma #S-9889) 
was kept at -20C as a 0.5mg/mL chloroform stock.  The ACAT inhibitor 58-035 was 
obtained from Dr.  Thomas Hughes at Novartis.  It was reconstituted as a 10mg/mL stock 
in dimethyl sulfoxide (DMSO) and stored at -20C in aliquots.  Recommended 58-035 
final concentrations in cell culture range from 0.1µg/mL to 10µg/mL.  Methyl-β- 
cyclodextrins solutions (Sigma C-4555) were prepared as described in 2.2.5. 
2.2.3 Preparation of delipoproteinated serum by ultracentrifugation 
Lipoprotein-deficient serum (LPDS) was made according to a protocol adapted from 
Busch et al. (74).  FBS (of original density 1.006g/mL) was adjusted to a final density of 
1.21g/mL using a 1.478g/mL solution (made with NaBr, NaCl) (153).  The serum was 
spun for over 40 hours at 55,000 revolutions per minute (rpm), at 15C in Quick-Seal 
tubes (Beckman #342414) using a 60Ti rotor (Beckman ultracentrifuge), with no brake.  
Tubes were cut 5.1cm from the bottom, and the lower compartments were recovered on a 
glass cylinder on ice, making sure to rinse the sides of the tubes to resuspend and recover 
any aggregated protein.  The delipoproteinated serum was then dialyzed overnight at 4C 
against 10mM potassium phosphate, 120mM NaCl, 2.7mM KCl, pH 7.4.  The dialysis 
buffer was changed in the morning and again after a few hours.  The dialyzed LPDS was 
recovered, adjusted to the original volume of serum using dialysis buffer, and filter-
sterilized in a hood for tissue culture use.  Occasionally, the osmolarity of the LPDS was 
checked and was consistently around 300mosm. 
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2.2.4 Preparation of defatted serum 
In the following procedure, FBS was first treated with Cab-O-Sil to remove all 
lipoproteins from the plasma (154) and the remaining free fatty acids were extracted with 
n-butanol and isopropyl ether according to the Cham and Knowles protocol (155).   
Briefly, 2% Cab-O-Sil (2g/100mL) was added to the FBS, and the serum was 
incubated at 4C for 4 hours with occasional gentle shaking.  The serum was then 
centrifuged for 30 minutes at 20,000rpm using a Sorvall SS-34 rotor and the supernatant 
was filter-sterilized in a tissue culture hood. 
To one volume serum, 1.2 and 0.8 volumes of isopropyl ether and n-butanol were 
added, respectively, and the mixture was incubated in a hood for 20 minutes at room 
temperature, followed by 20 minutes on ice, swirling regularly to ensure good mixing of 
the aqueous and organic phases.  The mixture was then centrifuged for 10 minutes at low 
speed (1000rpm) in 50mL Pyrex tubes using a 921 rotor.  Three phases separated, an 
upper organic phase, an intermediate foamy phase (which should be minimized as much 
as possible by spinning harder), and a lower water-soluble phase.  Both upper and middle 
phases were aspirated out and the lower phase was submitted to centrifugation again to 
rid of the remaining organic phase.  To ensure that there was no residual n-butanol in the 
water-soluble phase, 0.4 volume isopropyl ether was added to the lower phase mixture 
and the same protocol was followed as for the previous extraction.  The final mix was 
flushed for 2 hours with a stream of N2 allowing for recovery of around 1 volume of 
defatted serum at this step.  This serum was frozen in layers by swirling the flask in a 
mixture of ethanol and dry ice, the shell-frozen serum was freeze-dried, resuspended in 
0.2 volume with distilled water, dialyzed against PBS, adjusted back to one volume with 
PBS, and spun at 10,000rpm for 30 minutes in an SS-34 rotor (Sorvall) to pellet insoluble 
protein.  Finally, the supernatant was filter-sterilized and stored at -20C in multiple 
aliquots.  Note that this procedure affects neither ionic strength nor pH. 
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2.2.5 Methyl-beta-cyclodextrin (mβ-CD) solutions 
Methyl-beta-cyclodextrin (Sigma C-4555, MW 1317-59, average: 1338) solutions 
were prepared according a protocol derived from Christian et al. (103).   
10mM mβ-CD stock solutions in MEM were made by stirring at room temperature 
for 30 minutes and filter-sterilizing through a 0.2µm filter, and were stored at 4C up to 
several months in glass containers.  The stock solution was diluted 5 or 2 fold 
respectively with LPDS, L-glutamine (2mM final) and MEM to reach 2mM or 5mM mβ-
CD final in the tissue culture media.  The pH was checked with pH paper, and adjusted to 
7.4 if necessary, although it was usually not required.   
50mg/mL (129.3mM) stock solutions of cholesterol (MW: 386.67) in 1:1 
chloroform:methanol were made in glass scintillation vials, sealed with Teflon lining, and 
flushed with N2 after each use for up to 2-4 weeks. 
To make the 5mM mβ-CD 8:1 mβ-CD:cholesterol molar ratio medium, cholesterol 
from the stock solution was pipeted into a glass round bottom flask (of adequate volume 
to accommodate the final medium) in such amount as to reach 625µM in the final 
medium.  The cholesterol was dried under N2 while swirling the vial to achieve maximal 
dispersion on the glass surface in contact with the medium.  The 5mM mβ-CD tissue 
culture medium was added to the dried cholesterol, vortexed to help resuspension, 
sonicated for 3 minutes in a 37C waterbath, and rotated overnight in a 37C waterbath 
under constant low flow of N2.  The pH was then adjusted to 7.4, and the solution was 
filter-sterilized through a 0.2µm filter (with prefilter).  Note that even though the 
concentration of cholesterol used for making the complexes is 625µM, in practice, the 
final cholesterol concentration is unknown because the solution is saturated in cholesterol 
and the excess is filtered out. 
2.2.6 Rat hepatic lipase (rHL) ELISA 
The level of rHL enzyme in sonicated cell lysate or in medium was determined by 
ELISA using the method described by Cisar and Bensadoun (156) with the following 
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specifications: the plate was incubated overnight at 4C after coating (1µg/well of goat 
anti-rHL) to decrease background, and after sample addition to increase the signal due to 
specific binding.  After addition of the blocking solution and of the conjugate, the plate 
was incubated for 2 hours at 37C since longer incubation times were found to increase 
the background noise.  The plate was washed 3 times after each step except after the 
conjugate step where 6 washes were found to be more optimal.  Note that this assay does 
not cross-react with human HL, human LPL, or chicken LPL.  The sensitivity of the rHL 
ELISA (0.05ng) enables quantitative analysis of the secreted rHL for comparison with 
controls even for short-term treatments.  Most secretion levels are normalized to cellular 
DNA concentrations and expressed as ng secreted rHL/mg cell DNA. 
2.2.7 Determination of cell DNA concentration 
Upon collection, cells were rinsed with PBS, the PBS was carefully aspirated, and the 
cells were scraped and collected in 750-1000µL per 35mm dish of 4mM 3-(3-
cholamidopropyl)diethyl-ammonio-1 propanesulfonate (CHAPS) lysis buffer (4mM 
CHAPS, 50mM NH4OH, 3U/mL heparin, pH 8.1, with freshly added 1µg/mL leupeptin, 
1µg/mL antipain, 10µg/mL benzamidine, 10KIU/mL trasylol from 1000X stock in 
trasylol solvent, and 1µg/mL chymostatin, 1µg/mL pepstatin from 1000X stock in 
DMSO).  The cell lysates were frozen at -20C until analysis.  Before the DNA assay, cell 
lysates were sonicated twice at 100W for either 20 or 30 seconds each time, with a 
minimum of 30 seconds on ice in between.  DNA concentration was assayed using a 
protocol adapted from Labarca and Paigen (157). 
2.2.8 Extraction of free and total cholesterol from cell lysates for gas 
chromatography 
Cell lysates (600µL in 4mM CHAPS lysis buffer as previously described) were 
sonicated twice for 20 seconds each with a ≥30 second interval on ice in between and 
transferred to acid-washed glass screw-cap tubes.  Each lysate was extracted with 10mL 
(1 volume) chloroform: methanol 2:1 along with 25µg β-sitosterol (a soybean sterol 
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absent in mammals) as an internal standard.  After 30 minutes on ice, 0.2 volume of 
water was added, and the mixture was vortexed and spun at 1000rpm for 5 minutes (at 
room temperature (RT) or at 4°C). 
Three quarters of the ~6mL lower chloroform phase were dried and resuspended in 
50µL chloroform for analysis of free cholesterol (FC).   
A 1.5mL aliquot of lower phase was transferred to a new acid-washed screw-capped 
flat-bottom glass tube, dried under nitrogen in a ~40-60°C sand bath, saponified by 
incubating for one hour at 60°C in 2mL (1 volume) of 2% KOH in 95% ethanol, allowed 
to cool to room temperature, extracted with 1 volume hexanes and 1 volume water, and 
centrifuged for 5 minutes at 1000rpm at RT.  The upper hexane phase containing the 
saponified lipids was transferred to new tubes, dried under nitrogen and resuspended in 
50µL chloroform for analysis of total cholesterol (TC). 
2.2.9 Gas chromatography 
2µL aliquots of either FC or TC were analyzed by gas chromatography (158) using a 
hydrophobic RTX5 capillary column crossbonded SE-54 (Restek #10221, Lot# 1649A, 
15m x 0.32mm inner diameter), and H2 as a carrier gas.  The column was set at 220ºC in 
a 5890A gas chromatograph (Hewlett Packard) equipped with a flame ionization detector.  
The injector port and detector were maintained at 260ºC and the hydrogen flow rate 
through the column was 34.5mL/min. 
To determine the initial amounts of cell cholesterol, the Rf (response factor) value for 
β-sitosterol (S), the internal standard, was set at 1, and the Rf value for cholesterol (C) 
was determined to be equal to 1.01.  Knowing that Ccount/Cmass= Scount/Smass x Rf, for each 
sample the amount of cell free or total cholesterol (µg FC or TC/µg DNA) was 
determined using the following calculation:  
[(FC/TCcount x 25µg)/(RF x Scount)]/µgDNA.   
The DNA mass for this calculation was determined in 600µl lysate. 
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2.2.10 Hepatic lipase activity assay 
HL activity was determined using a protocol adapted from Bensadoun et al. (159).  
Briefly, tritiated triolein (in chloroform supplemented with 50µg/mL butylated hydroxyl-
toluene) was weighed along with cold triolein to the desired specific activity.  The 
chloroform was evaporated under a flow of nitrogen, and the vial was placed on ice.  
Gum Arabic was then added to 0.5% final in the 0.5mL final reaction and the mixture 
was emulsified by sonicating 3 times for 30 seconds each at 100W, with 30 seconds on 
ice in between each pulse.  NaCl, BSA, and Tris-base were added to final concentrations 
of 1M NaCl, 1% BSA, and 0.2M Tris, pH 8.6.  The final volume was adjusted with water 
to 0.5mL/reaction taking into account the volume of sample (≤0.2mL) to analyze.  This 
mix was used on the same day for quantitative analysis, but could be stored at –20C for 
several months for semi-quantitative results.  Each aliquot was placed on ice up to several 
hours until the enzyme sample was added.  The reaction was vortexed and incubated in a 
30C waterbath for 1 hour.  The reaction was stopped by addition of 6.5 volumes of 
Belfrage solution (methanol 30.8% w/w, heptane 50% w/w, chloroform 18.7% w/w, oleic 
acid 0.1g/L) and 1.5 volume of borate buffer (0.25M potassium tetraborate, 0.25M 
potassium carbonate, pH 9.5).  The tubes were vortexed and centrifuged (10 minutes, 
~800g, RT).  1.9mL of upper aqueous phase containing the liberated 3H-labeled FFA 
were counted in scintillation liquid. 
Calculation of catalytic activity: 
µEq FA / hour / mL sample = net cpm x 2 / (Volume x Time x 0.38 x SSA x 1.9) 
where: cpm represents the number of counts per minute, 
Volume is the volume of the reaction mixture expressed in mL,  
Time is the reaction time in hours, 
SSA is the specific activity of the substrate in cpm/µEq FA. 
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2.3 Results 
2.3.1 Linearity of rHL secretion over 24 hours 
First, an assay was designed in order to verify that rHL secretion from cultured cells 
was linear over 24 hours in the conditions used for secretion assays throughout this 
thesis.  Cells were treated with complete or LPDS medium supplemented with heparin 
and the medium was collected after 2, 4, 12 or 24 hours for anaysis of secreted rHL by 
ELISA. rHL secretion was found to be linear in both complete (y= 1.56x -2.40, 
R2=0.995) and LPDS (y= 1.10x -0.32, R2=0.999) medium in the presence of 100U/mL 
heparin from 2 to 24 hours (Figure 2-1). 
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Figure 2-1 Linearity of rHL secretion over 24 hours in complete or LPDS media in 
the presence of 100U/mL heparin.   
Fu5AH cells were split into 35 mm dishes.  On the next day, at t=-2hr, cells were 
placed on LPDS medium (10% LPDS, 2mM L-Glutamine in MEM) for 2 hours.  At 
t=0hr, cells were rinsed with PBS containing 100U/mL heparin for 3 minutes, and this 
rinse was carefully aspirated before 2mL/well fresh complete or LPDS medium was 
added, each supplemented with 100U/mL heparin.  Medium was collected at the 
indicated times, and analyzed for secreted rHL mass by ELISA. 
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2.3.2 Dual effects of depletion of cell cholesterol on rHL secretion 
Depletion of intracellular cholesterol is reported to be a relatively slow process, 
taking about 12 hours.  Thus, rHL secretion from cultured hepatoma cells was evaluated 
over the course of 24 hours, using increasing amounts of methyl-β-cyclodextrins, which 
can efficiently stimulate efflux of cholesterol from the cells (Figure 2-2).  rHL secretion 
was found to increase to 173% of basal level over the first 4 hours on defatted medium.  
Over the next 4 hours, rHL secretion was further increased to 185 or 193% of basal level 
in defatted medium with no or small amounts (0.5mM) of methyl-β-cyclodextrins 
respectively, and this increased secretion level was maintained over the next 20 hours.  
On the other hand, in defatted medium containing 1mM or more of methyl β 
cyclodextrins, rHL secretion was found to be decreased compared to defatted medium 
only, down to 90.9% of basal level on 5mM for 20 hours.  Microscopic observation of the 
cells under those conditions showed gross changes in cell morphology (data not shown), 
presumably due to a depletion of membrane cholesterol.  Overall, the first effect of 
cholesterol depletion was to increase rHL secretion.  On the other hand, over periods of 
depletion longer than 4-8 hours, the more stringent the cholesterol depletion, the faster 
rHL secretion levels decreased back to basal levels. 
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Figure 2-2 rHL secretion upon cholesterol depletion 
McA-RH7777 cells were split into collagen-coated 35mm dishes.  Upon confluency, 
at t=-4hr, cells were placed on 2mL/dish fresh complete McA medium.  At t=0hr, the 
medium was aspirated and the cells were placed on 2mL/dish defatted medium (5% 
defatted FBS, 2mM L-glutamine in DMEM).  At t=4hr, the defatted medium was 
aspirated and the cells were placed on fresh defatted medium supplemented with 
increasing amounts of methyl-β-cyclodextrin as indicated.  Sets of 3 dishes were 
collected at times 0hr, 4hr, 8hr and 24hr.  In each case, four hours prior to collection, the 
cells were rinsed with 100U/mL heparin-containing PBS for 3 minutes, this wash was 
carefully aspirated, and the cells were incubated for 4 hours with 1mL/dish of the 
indicated treatment medium supplemented with 100U/mL heparin.  After the four-hour 
incubation, the medium was collected and spun at 14,000rpm for 10 minutes at 4C.  The 
supernatant was transferred to new tubes and frozen at -20C before being analyzed by 
ELISA.  The cells were rinsed with PBS and collected in 0.75mL of 4mM CHAPS lysis 
buffer for storage at -20C.  The cells were thawed and sonicated before the DNA was 
analyzed.  rHL secretion levels are presented as ng medium rHL/mg DNA over the four 
hour secretion period.   
100 
150 
200 
250 
300 
350 
400 
-4 0 4 8 12 16 20 24
Time of collection (hours)
Se
cr
et
ed
 rH
L 
(n
g/
m
gD
N
A
/4
hr
) 
 
0mM mbCD
0.5mM mbCD
1mM mbCD
2.5mM mbCD
5mM mbCD
0mM
0.5mM
1mM
2.5mM
5mM
Complete 
medium 
Defatted 
medium 
Methyl-β-
CD in 
defatted 
medium 
Methyl-β-
CD in 
defatted 
medium 
 44 
2.3.3 Decreased rHL secretion upon repletion of cell cholesterol 
Based on the previous result, in order to ensure a high level of basal rHL secretion, 
cells were incubated for 4 hours in defatted medium supplemented with 2mM methyl-β-
CD.  After this preliminary cholesterol depletion phase, rHL secretion levels were 
monitored upon repletion with cholesterol (5mM methyl-β -CD 8:1 cholesterol) in 25% 
defatted medium (Figure 2-3).  Cholesterol repletion led to a rapid decrease in secreted 
rHL down to 56.6% and 17.5% of time 0 by 4 and 48 hours respectively.   
In the same experiment, free and total cholesterol levels were assessed by gas 
chromatography (Figure 2-4).  As expected, total and free cholesterol levels were low at 
time 0 (after cells had been depleted of cholesterol for 4 hours), and the methyl β 
cyclodextrin:cholesterol complexes increased cell cholesterol levels throughout the 
course of the experiment.  Free cholesterol levels increased by 5.6 fold by 4 hours and 
remained at that high level thereafter.  Presumably, free cholesterol levels are maintained 
within a narrow range of concentrations within the cells, and all excess cholesterol is 
stored in the cells as cholesterol esters.  Accordingly, total cholesterol increased by 7.0 
fold by 4 hours and kept increasing over the course of the experiment up to 25.9 fold of 
original levels at 24 hours.   
In order to confirm these results and verify that the downregulation of secreted rHL 
was not merely due to prolonged exposure to defatted serum-containing medium, parallel 
experiments were carried out with cells in medium containing either 5% defatted FBS, or 
25% lipoprotein-deficient serum (LPDS, 20% from horse serum and 5% from FBS).  
During the cholesterol repletion phase, rHL secretion dropped down to 17.5% (Figure 
2-4) or 16.1% (Figure 2-5) of basal levels with 5mM methyl-β-cyclodextrins in 25% or 
5% defatted medium respectively.  However, 5% defatted serum medium or 25% LPDS 
medium alone (without cholesterol addition) were also found to decrease rHL secretion 
following the 4 hour depletion phase, albeit to a lesser degree, to 50.9% and 63.0% of 
basal levels respectively.  This result was not unexpected given the dual effects of 
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cholesterol depletion on rHL secretion (Figure 2-2).  The fact that the LPDS medium had 
a very similar effect to the defatted medium suggests that the observed effect is not just 
due to the mode of preparation of either defatted serum (by Cab-O-Sil treatment and n-
butanol/isopropyl ether extractions) or lipoprotein deficient serum (by potassium bromide 
ultracentrifugation).  Overall, cholesterol significantly decreases rHL secretion to 36.8% 
and 31.7% of control 5% defatted medium at 24 and 48 hours respectively.  Thus, 
cholesterol repletion decreased rHL secretion, at least at 24 and 48 hours within the 
repletion phase.  Whether the decrease at 4 hours within the repletion phase is due to 
cholesterol or to the secondary effects of the original cholesterol depletion is not clear. 
In order to further confirm that the observed effects are indeed due to the 
manipulation of sterol content within the cells, cholesterol was presented to the cells 
under different forms.  Whether presented in the form of lipoproteins (in complete 
medium), a mix of sterols (10µg/mL cholesterol and 1µg/mL 25-hydroxy-cholesterol 
from an alcohol concentrated stock) or as a complex with methyl-β-cyclodextrins, 
cholesterol was found to decrease rHL secretion slightly after 24 hours compared with 
control LPDS medium (data not shown).  Similar results of the sterol mix were observed 
in an enriched basal medium (OPTI-MEM), but because secretion levels were overall 
lower than in the traditional MEM basal medium, this medium was not used in further 
experiments.   
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Figure 2-3 rHL secretion upon cholesterol repletion 
McA-RH7777 cells were split into collagen-coated 35mm dishes.  At t=-4hr, to 
deplete the cells of cholesterol, the cells were placed on 2mM methyl-β-CD in defatted 
medium.  This medium was refreshed at t=-2hr.  At t=0hr, the medium was aspirated and 
replaced by 5mM methyl-β-CD 8:1 cholesterol (molar ratio) in 25% defatted medium.  
This medium was refreshed at t=24hr.  For each secretion time point, the medium was 
aspirated on 3 dishes, and the dishes were rinsed with PBS containing 100U/mL heparin, 
then 0.75mL of the respective treatment medium containing 100U/mL heparin was 
added.  Medium and cells from these dishes were collected 2 hours later at the indicated 
time point.  The medium was analyzed for rHL mass by ELISA, and the cell lysates were 
analyzed for DNA.  Averages +/-SD, n=3. 
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Figure 2-4 Total and free cholesterol levels upon cholesterol repletion 
Cell lysates from McA-RH7777 cells (as described in Figure 2-3) were sonicated and 
extracted with chloroform:methanol 2:1 along with β-sitosterol as an internal standard.  
Most of the lower phase was dried and resuspended in chloroform for analysis of free 
cholesterol.  The remaining lower phase was dried under nitrogen, saponified, and 
extracted with hexanes and water.  The upper hexane phase was dried under nitrogen and 
resuspended in chloroform for analysis of total cholesterol.  Both free (FC) and total (TC) 
cholesterol analyses were done by gas chromatography. Average ±SD, n=3. 
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Figure 2-5 rHL secretion upon cholesterol repletion or upon prolonged cholesterol 
depletion 
At t=-4hr, McA-RH7777 cells in 35mm dishes were placed on 2mM methyl-β-CD 
either in delipoproteinated or defatted serum medium (as in subsequent treatment) in 
order to deplete the cells of cholesterol.  This medium was refreshed at t=-2hr only in the 
experiment with cholesterol in 25% defatted serum medium.  At t=0hr, the medium was 
aspirated and replaced by either 25% LPDS serum (20% from horse serum and 5% from 
FBS) medium, 5% FBS defatted serum medium, 5% FBS defatted medium supplemented 
with 5mM methyl-β-CD 8:1 cholesterol (molar ratio), or 25% defatted serum (20% from 
horse serum and 5% from FBS) supplemented with 5mM methyl-β -CD 8:1 cholesterol.  
All treatment media were refreshed at t=24hr.  For each secretion time point, the medium 
was aspirated on 3 dishes, the dishes were rinsed with PBS containing 100U/mL heparin, 
and 0.75mL of the respective treatment medium containing 100U/mL heparin was added.  
Medium and cells from these dishes were collected at the indicated time point after a 
two-hour incubation.  The medium was analyzed for rHL mass by ELISA, and secretion 
was normalized for DNA.  Each bar corresponds to the average secreted rHL mass as a 
percent of secretion at time 0 for each series, +/-SD (n=3). 
This graph is a compilation of data from different experiments, where the experiment 
with cholesterol in 25% defatted serum medium is the same as the one presented in 
Figure 2-3 in absolute secretion values. 
 49 
 
2.3.4 Increases in intracellular free cholesterol can mimic the effects 
of cholesterol treatment 
Free cholesterol concentration is more critical than total cholesterol concentration to 
exert sterol-mediated regulatory effects.  Thus, we sought to determine whether an 
increase in intracellular free cholesterol could mimic and/or amplify the effects of 
cholesterol treatment.  The Acyl Coenzyme A: Cholesterol Acyltransferase (ACAT) 
inhibitor 58-035 at concentrations >0.1µg/mL in combination with cholesterol-loading 
agents is known to selectively and effectively inhibit the esterification of cholesterol 
(>95% within 30 minutes in Fu5AH cells), leading to a slight increase in cellular FC, but 
overall decreasing total cell cholesterol (115).   
As expected, increasing concentrations of 58-035 for 24 hours decreased rHL 
secretion (Figure 2-6).  Because high amounts of 58-035 can lead to cell apoptosis over 
long incubation times, the smallest amounts of 58-035 to achieve full effect on rHL 
secretion (2 or 5µg/mL) were used in later experiments. 
Next, cells were treated either with sterols, 58-035, or a mixture of both to see 
whether the combination of sterols and an inhibitor of cholesterol esterification could 
amplify the decrease in rHL secretion.  There appeared to be no additive effect of sterols 
and 58-035 on rHL secretion (Figure 2-7) suggesting that they may act at least partly 
through the same pathway, and that “full” inhibition of rHL secretion through this 
pathway is achieved under all treatment conditions. 
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Figure 2-6 ACAT inhibitor 58-035 decreases rHL secretion in a dose-dependent 
fashion 
Fu5AH cells were spit into 35mm dishes.  Upon confluency, at t=0hr, the medium 
was aspirated and the cells were placed on 2mL/well treatment medium, which consisted 
of Fu5AH LPDS medium (10% LPDS, 2mM L-Glutamine in MEM) supplemented with 
the indicated concentration of ACAT inhibitor or 0.1% DMSO as a carrier.  At 
t=20hours, the medium was carefully aspirated and replaced by 1mL/well of an identical 
treatment medium supplemented with 100U/mL heparin.  After a 4 hour incubation, at 
t=24hours, the medium was collected and centrifuged for 10 minutes at 15,000rpm, then 
the supernatant was transferred and frozen at -20C until the rHL ELISA was performed.  
The cells were rinsed with PBS, scraped in 1mL/well of 4mM CHAPS lysis buffer, 
frozen at -20C, and sonicated twice for 20-seconds at 100W before DNA was analyzed 
for normalization. Average ±SD, n=3. 
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Figure 2-7 The decrease in rHL secretion upon 58-035 and sterol treatment is not 
additive  
Fu5AH cells were split into 35 mm dishes.  Upon confluency, at t=0hr, cells were 
placed on 1.5mL/dish LPDS medium (10% LPDS, 2mM L-Glutamine in MEM) alone 
(LPDS), or LPDS medium supplemented with 5µg/mL 58-035 (ACAT inhibitor), with 
10µg/mL cholesterol and 1µg/mL 25-OH-cholesterol (Sterols), or with a combination of 
both (ACAT inhibitor + sterols).  Ethanol or DMSO were added as carrier controls as 
appropriate.  Four hours prior to each collection, the medium was aspirated from the cells 
to be collected and replaced by 1mL/dish fresh treatment medium supplemented with 
100U/mL heparin.  Medium and cells were collected at the indicated times.  The medium 
was analyzed for secreted rHL mass by ELISA, and the cells were analyzed for DNA 
content. Average ±SD, n=3. 
 
2.3.5 Cholesterol does not affect cell HL specific activity 
Hepatic lipase is an enzyme which catalytic activity can potentially be regulated; 
therefore, we sought to determine whether sterol regulation of HL also involved 
regulation at the activity level.  Cell-associated rHL specific activity was not significantly 
decreased by cholesterol administered in the form of 5mM methyl-β-cyclodextrins 
complexed at an 8:1 molar ratio cyclodextrin:cholesterol for 17 hours (Figure 2-8).  
Further, cell-associated rHL specific activity was not significantly changed by sterols 
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addition, 58-035 treatment, or a combination of both 58-035 and sterols (Figure 2-9), 
while the ACAT inhibitor did decrease secreted rHL mass down to 52% in this 
experiment (data not shown).  Overall, cell sterol content manipulation was found to have 
no significant effect on cell-associated HL specific activity. 
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Figure 2-8 Cholesterol does not affect the specific activity of intracellular and cell-
associated hepatic lipase 
McA-RH7777 cells were split into collagen-coated 100mm dishes and placed on Cab-
O-Sil-treated LPDS medium at confluency.  After 4 hours on LPDS medium, at t=0hr, 
cells were placed on LPDS medium with or without supplementation with 5mM methyl-
β-cyclodextrin complexed at an 8:1 molar ratio cyclodextrin:cholesterol.  At t=17hr, the 
cells were collected on ice and sonicated before being immediately analyzed for lipase 
activity.  The remainder of the samples was frozen at -20C and later analyzed for rHL 
mass (by ELISA).  The bars correspond to the average specific activity of triplicates +/- 
standard deviation.  p=0.28, two-tailed unpaired t-test. 
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Figure 2-9 Intracellular and cell-associated hepatic lipase specific activity is not 
affected by sterol or 58-035 treatments 
Fu5AH cells were split into 100mm dishes.  Upon confluency, at t=0hr, the medium 
was aspirated and the cells were placed on 7mL/dish LPDS medium (MEM, 2mM L-
glutamine, 10% LPDS) supplemented with either 2µg/mL ACAT inhibitor (using DMSO 
as a carrier) or 10µg/mL cholesterol +1µg/mL 25-OH-cholesterol (using ethanol as a 
carrier at 1:500 dilution in cell media) or both.  Carrier controls were added as 
appropriate.  At t=24hours, the medium was collected and pooled per sets of 3 dishes, 
then frozen at -20C before being assayed for secreted rHL mass by ELISA.  The cells 
were rinsed with PBS and each set of 3 dishes was collected into 1mL of 4mM CHAPS 
lysis buffer.  The lysate pools were sonicated twice for 30 seconds at 100W, and then 
spun down for 10 minutes at 14,000 rpm at 4C.  The supernatants were transferred and 
immediately assayed for lipase activity.  The remaining lysates were frozen at -20C 
before being assayed for rHL mass by ELISA.  The data is expressed as nanoequivalent 
(neq) fatty acids released/hour/ng cell (intracellular and cell-associated) rHL.  No 
significant difference was found (p>0.09) using Student's two-tailed unpaired t test. 
 
2.4 Discussion 
Previous reports from the literature have shown that cholesterol decreases HL levels 
in human hepatoma HepG2 cells (74).  After confirming this result in HepG2 cells (data 
not shown), we turned to rat hepatoma cells for further studies.  This switch was 
motivated by a practical reason : the ELISA for rat HL is a much more rapid, and more 
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importantly much more sensitive assay than the currently available “biotinylated” human 
ELISA.  Nonetheless, cholesterol was expected to lead to a similar decrease in HL 
synthesis in rat cells than in human cells since cholesterol feeding in rats has consistently 
been found to lead to decreased HL synthesis in the literature (70-72). 
In order to study the down-regulation of hepatic lipase by cholesterol, we first sought 
to find baseline conditions where the enzyme would be secreted at high levels.  Hepatic 
lipase (activity and sometimes mRNA) has been reported to be upregulated in some 
conditions by insulin (160), triiodothyronine/T3 (161;162) and glucose (163), but these 
had no effect on HL secretion levels in our system (data not shown).  Therefore, to find 
optimal conditions to study the effect of a cholesterol loading, we investigated the effect 
of a preliminary depletion of cellular cholesterol with LPDS, which also had previously 
been reported to increase HL activity secretion after 24 (74) or 48 hours (75) by up to 
50%.  Unexpectedly, in our model, a long-term (24-hour) incubation in LPDS medium as 
compared with complete medium decreased HL secretion (Figure 2-1).  Of note, in this 
experiment, the medium was not changed over the 24-hour incubation, raising the 
possibility that unknown elements of the LPDS medium could have become limiting, 
therefore decreasing HL secretion independently of cholesterol levels.  In contrast, as 
shown in Figure 2-2, we found that depleting cells of cholesterol in our model did 
enhance HL secretion under slightly different conditions.  This time, in order to minimize 
the potential for factors other than cholesterol to become limiting in LPDS medium and 
affect secretion levels; secretion was measured only over the last four hours after addition 
of fresh treatment medium.  When depletion was achieved in relatively mild conditions 
(i.e. defatted medium alone or supplemented with only 0.5mM methyl-β-cyclodextrins), 
cholesterol depletion yielded an increase in secreted HL within the first 4 hours of 
treatment, and these high levels of HL secretion were maintained over the course of the 
24-hour treatment.  However, when more stringent conditions were used for cholesterol 
depletion (i.e. defatted medium containing 1mM or more of methyl-β-cyclodextrins) rHL 
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secretion was found to be decreased again (compared to defatted medium alone) starting 
after 8 hours.  As mentioned before, microscopic observation of the cells under those 
conditions showed gross changes in cell morphology.  Because of this observation, it is 
likely that in these extreme conditions, membrane cholesterol is depleted.  Indeed, stable 
levels of cholesterol within the cells are known to be essential for membrane integrity.  In 
tissue culture, where rapidly dividing cells require active membrane synthesis, the 
cellular demand in cholesterol is high.  Yet, instead of cholesterol flowing into the cells, 
at high levels of methyl-β-cyclodextrins cholesterol would be expected to shuttle from the 
cells to the medium, which could lead to severe consequences for cell membrane 
integrity.  Alternatively, we cannot rule out that the delayed decrease in HL secretion 
under conditions of severe cholesterol deprivation could be due, at least partly, to the 
activation of SREBP, which in turn would lead to a decrease in HL synthesis (see chapter 
3).  Overall, depletion of cell cholesterol in hepatoma cells increased HL secretion in 
conditions where membrane integrity was maintained.  A similar mild technique for 
cholesterol depletion was frequently used in subsequent experiments in order to increase 
HL baseline secretion levels. 
Whether using rat hepatoma cells (Fu5AH or McA-RH7777 cell lines) or human 
hepatoma cells (HepG2 cells – data not shown) as a model, cholesterol repletion was 
uniformly found to decrease HL secretion, and this effect was consistently seen early on, 
starting at 4 hours after addition of cholesterol.  Furthermore, intracellular cholesterol 
was modulated using different means: by culturing cells in the presence of lipoprotein-
containing medium versus delipoproteinated medium; by adding cholesterol directly to 
the medium as a complex to methyl-β-cyclodextrin or as a mixture of 10µg/mL 
cholesterol and 1µg/mL 25-OH-cholesterol (a mixture commonly used for the study of 
sterol-regulated genes such as the LDL receptor or HMG-CoA-reductase); by adding a 
mixture of sterols and the ACAT inhibitor 58-035 simultaneously to the medium (which 
increases cell free cholesterol levels while slightly decreasing total cholesterol levels 
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(115); or finally by adding the ACAT inhibitor alone.  Either of these means of increasing 
cellular total or free cholesterol levels led to a decrease in secreted HL.  Further, the fact 
that HL secretion levels decreased in response to an ACAT inhibitor strongly suggested 
that it is an increase in intracellular free cholesterol specifically, and not an increase in 
total cholesterol, which mediates the decrease in HL secretion. 
Overall, the results presented here are consistent with previous results in the 
literature.  After a 48 hour pretreatment in LPDS medium, treatment with 1mM 
mevalonic acid (an intermediate in the cholesterol biosynthesis pathway) for 48 hours 
increased cell cholesterol by 26% and resulted in a 53% decrease in secreted HL activity 
(compared with LPDS medium control) (74).  However, in contrast to our study where a 
mixture of cholesterol and 25-OH-cholesterol decreased HL secretion, after a 48 hour 
pretreatment in LPDS medium, exposure of cells to 25-hydroxycholesterol (an oxidized 
metabolite of cholesterol) for 24 hours produced a small but reproducible induction of 
secreted lipolytic activity (74).  The reasons for these discrepancies are unknown. 
We sought to determine whether cholesterol also had an effect on HL specific 
activity.   While decreasing secreted HL mass, we found that cholesterol did not affect 
cell-associated and intracellular HL specific activity.  The reason why the activity assay 
was done on cell lysates as opposed to medium is due to the lower sensitivity of the 
lipase activity assay compared to that of the ELISA.  The concentration of HL in medium 
incubated with cells for a period of 4 hours did not allow for a reliable quantification of 
medium enzyme activity.  On the other hand, the instability of HL enzyme activity at 37C 
precluded the use of longer incubation times in order to allow for HL medium 
concentration to increase sufficiently.   
The roles of hepatic lipase in lipoprotein metabolism stem from both its enzymatic 
role as a phospholipase and a triglyceride hydrolase and from its “bridging” role to 
increase the residency time of lipoproteins in close proximity to their cellular receptors 
(23).  Its combined role as a lipolytic enzyme and as a ligand increases both the hepatic 
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clearance of chylomicron remnants and other apo-B containing lipoproteins 
(23;25;26;164;165), as well as the selective uptake of HDL-CE in the liver (28;166-170).  
As a consequence, high levels of extra-cellular HL have been shown to increase 
cholesterol internalization from circulating lipoproteins in liver and steroidogenic cells.  
The effects of cholesterol depletion or repletion on HL levels are amplified by its 
catalytic role in lipid metabolism, such as a small decrease in secreted HL could lead to a 
substantial decrease in its propensity to increase cellular internalization of cholesterol.  
This hypothesis suggests that hepatic lipase could play a role in maintaining cellular 
cholesterol homeostasis.  Under conditions of low free intracellular cholesterol levels, HL 
secretion levels would increase, which would favor cholesterol influx from the circulation 
into the cells.  However, when intracellular free cholesterol levels are high, HL secretion 
would be down-regulated, which would limit the amount of cellular cholesterol uptake.  
Overall, the down-regulation of HL by cholesterol would be beneficial in the liver, and 
potentially in other cell types where HL has been shown to be expressed, albeit to a lesser 
extent, such as the adrenals, ovaries and macrophages.  If these results could be 
extrapolated to macrophages, this would have special significance in the context of the 
atherosclerotic plaque.  As opposed to HL, LPL is activated by high levels of cholesterol 
through activation of LXR (171), and macrophage expression of LPL has been shown to 
contribute to foam cell formation and atherosclerosis in vivo (172).  In the case of HL, the 
down-regulation of HL by sterols would tend to attenuate this feed-forward lipid-loading 
mechanism. 
In the next two chapters, we sought to further investigate the mechanisms by which 
cholesterol down-regulates hepatic lipase secretion.  In Chapter 3, we examined the effect 
of cholesterol on HL transcriptional levels, and in Chapter 4, we examined the effect of 
cholesterol on HL at the post-transcriptional level. 
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Chapter 3 - SREBP as a major mediator of HL 
transcription 
 
3.1 Introduction 
In the previous chapter, we defined the effect of cholesterol on HL protein and 
activity levels.  In this chapter, we examined the effects of sterols on HL at the 
transcriptional level.  We provide evidence that cholesterol decreases HL mRNA steady-
state levels without affecting the mRNA degradation rate.  Regulation of HL promoter 
activity was investigated through luciferase activity assays.  Cholesterol as such failed to 
alter the activity of a proximal hHL promoter construct.   
Within liver cells, intracellular cholesterol homeostasis is tightly maintained.  Sterol 
Regulatory Element Binding Proteins (SREBPs) are the major transcription factors 
mediating the feedback regulation of cholesterol levels by controlling the expression of 
genes involved in cholesterol biosynthesis (e.g. HMG-CoA reductase), lipoprotein uptake 
(LDL Receptor), or (62) lipoprotein hydrolysis and uptake (lipoprotein lipase (LPL)).  
HL is known to enhance lipoprotein uptake and cholesterol loading in cell culture 
(23;25;28).  Therefore, it became apparent that SREBPs may also play a significant role 
in the cholesterol regulation of HL expression.   
Evidence is presented in this chapter that nuclear SREBPs (nSREBPs) inhibit the 
transcription of the HL gene and could be mediating the downregulation of HL under 
conditions where cholesterol is elevated and/or cholesterol synthesis is inhibited.  
Cholesterol feeding in mice results in decreased concentrations of nSREBP2 and 
nSREBP1a but in a marked increase in nSREBP1c (126).  What is more, nSREBP 
transfection could reverse the activation of HL by USF1 in promoter activity assays.  
Several activator binding sites within the hHL proximal promoter were identified through 
gel shift assays, but these assays failed to show direct binding of nSREBP to the HL 
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promoter.  Co-immunoprecipitation experiments suggest that inhibition of transcription 
may occur through interaction of SREBP1 with positive effectors of HL transcription 
such as USF1. 
3.2 Methods 
3.2.1 Reagents 
Please refer to the previous chapter for commonly used reagents.  Actinomycin D 
(Sigma A9415) was prepared as a 1.25mg/mL (2,500X) stock in ethanol and stored at 4C.  
The final contribution of ethanol due to actinomycin D in the treatment medium was 
0.04%.  N-acetyl-leucyl-leucyl-norleucinal (ALLN) was obtained from Sigma (A-6185) 
and was stored at –20C as a 10mg/mL stock in DMSO.  Mevastatin/compactin (Sigma 
M2537) or lovastatin (Fisher NC9702522) were made as a 500 or 1000X stock in ethanol 
and were stored at –20C. 
3.2.2 Plasmids 
The pCMV-SREBP1a-460 vector was purchased from the ATCC (#99637).  pCMV-
SREBP1c-436 was obtained from Dr. M-J Latasa in Dr. Sul’s laboratory (U.C.  Berkeley) 
and could be obtained from the ATCC (#99636).  Both vectors originated from the 
laboratory of Drs. Joseph Goldstein and Michael Brown (University of Texas 
Southwestern, Dallas, TX) (120). 
pSRE-luc (pSynSRE) was received from Tilla Worgall, and originated from Tim 
Osborne’s group (173).  This construct contains a pGL2-basic backbone with a TATA 
box and transcription start from a SalII-HindIII fragment (-28/+39) of Synthase mut P 
inserted into XhoI/HindIII of the multiple cloning site.  Just upstream is a -324/-225 
fragment of hamster HMG-CoA synthase in between Sac1 and Nhe1, which contains two 
sterol responsive elements (SREs) required for sterol regulation, binding sites for the 
ATF/AP1 family of transcription factor, and a consensus binding site for CBF/NFY.  
Thus this vector is specifically activated by SREBPs and it is suited for monitoring the 
transcriptional activity of the mature nuclear form of SREBP (nSREBP). 
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pcDNA3-USF1and pcDNA3-USF2, mammalian expression vectors for human USF1 
and mouse USF2 respectively, were obtained from Dr Sul’s laboratory (U.C. Berkeley) 
and originated from Dr. M. Sawadago (M.D. Anderson Medical Center, University of 
Texas Southwestern, Dallas).  The pFlag-dominant negative USF1 construct was a gift 
from Dr. Sul’s laboratory (U.C. Berkeley).  This vector is a pcDNA3.0 construct driving 
the expression of an N-terminus flagged human USF1 with an internal deletion of the 
basic region of USF1 from amino acid 193 to 211 (174).  Without this DNA binding 
sequence, the mutated USF1 can dimerize but cannot bind DNA and activate 
transcription. 
pRc/CMV and pcDNA3 were purchased form Invitrogen. 
pEGFP-N1, a mammalian expression vector for the green fluorescent protein, was 
obtained from Clontech (#6085-1). 
3.2.3 Tissue culture 
Fu5AH and McA-RH7777 cells were handled as described in the previous chapter.  
Human hepatoma HepG2 cells were obtained from the Children’s Memorial hospital in 
Boston and were grown in the same medium as Fu5AH medium (10% FBS, 2mM L-
glutamine, 11.7g/L NaHCO3, 12.7g/L HEPES, 50.9g/L GIBCO #61100-103 MEM, pH 
7.2).  A 1:2 splitting ratio was generally used for confluency to be reached again within 
2-3 days. 
3.2.4 Isolation of RNA  
RNA was isolated with Trizol (Invitrogen) using a protocol adapted from the 
manufacturer’s instructions.  Using this protocol, the yield was generally ~100-300µg 
RNA/100mm dish or ~30-45µg RNA/35mm dish for confluent McA-RH7777 cells. 
Briefly, cells grown in 35mm dishes were harvested in 1.25mL Trizol™.  The lysates 
were transferred to ribonuclease (RNase)-free eppendorfs and incubated at RT for 5 
minutes.  Optionally, the lysates were stored at –80°C at this step.  For phase separation, 
0.25mL chloroform was added to each tube, the tubes were shaken vigorously for 15 
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seconds, incubated at RT for 3 minutes, and spun at 11,300rpm (12,000g) for 15 minutes 
at 4°C.  The upper aqueous phase was transferred to clean RNase-free eppendorfs and the 
RNA was precipitated with 0.625mL/tube isopropyl alcohol.  The samples were mixed by 
pipeting up and down, incubated for 10 minutes at RT, and centrifuged at 11,300rpm for 
10 minutes at 4°C.  The RNA-gel like pellet was washed with at least 1.25 mL/tube of 
75% ethanol.  The samples were spun at 9,000 rpm (7,500g) for 5 minutes at 4°C, the 
supernatants were removed and the samples were air-dried until the RNA became 
transparent.  Each RNA sample was resuspended in 100µl RNase-free water. 
Optionally, the RNA was further purified using RNeasy columns (QIAGEN).  In this 
case, 100µg/sample (the maximum capacity of the columns) was purified according to 
the manufacturer’s instructions, consistently with almost 100% recovery. 
3.2.5 mRNA quantification by real-time reverse transcription – 
polymerase chain reaction (RT-PCR) using a TaqMan probe assay 
Basic principle:  
TheTaqMan assays use a fluorogenic probe that anneals within the complementary 
DNA (cDNA) target sequence during polymerase chain reaction (PCR).  Because the 
probe is designed to have a lower annealing temperature, it anneals prior to annealing of 
the primers.  A reporter dye (FAM) is attached to the 5’ end of the probe, and a quencher 
dye is attached to its 3’end.  During PCR, the 5’nuclease activity of the DNA polymerase 
cleaves the probe, which releases the reporter dye from the quencher and increases the 
fluorescence intensity. 
Reverse transcription reaction: 
1µg RNA/sample was reverse transcribed in a 50µl reaction in the presence of 2.5µM 
oligo dT (AB # N808-0128) as primers, 1.25U/µl MultiScribe™ Reverse Transcriptase 
(Applied Biosystems #4311235, a recombinant Moloney murine leukemia virus 
(rMoMuLV) reverse transcriptase), 1X TaqMan RT buffer, 5.5mM MgCl2, 500µM/dNTP 
(AB # N808-0260), and 0.4U/µl RNase inhibitor (Applied Biosystems).  A no template 
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control (NTC) containing no RNA was always included as a negative control.  The 
reactions were set up in 0.3mL thin-walled PCR tubes for the robocycler, mixed well, and 
spun down.  Primers were annealed by incubating for 10 minutes at room temperature.  
The reverse transcriptase reaction was achieved by incubating at 48°C for 30 minutes, 
and the enzyme was then inactivated by a 5-minute incubation at 95°C.  The obtained 
cDNA was frozen down at -20°C until real-time PCR was performed. 
Real time polymerase chain reaction: 
Real-time PCR using cDNA as a template was performed utilizing a custom-designed 
TaqMan probe assay (Assays-by-Design (SM) Service, Gene Expression, Assay ID 
4331348) with two unlabeled PCR primers (RHL-E2E3F: CCA TCC ACT TGT CAT 
GAT CAT CCA and RHL-E2E3R: CTT CCA GAT CCA GGT TTC TAG CAA, 18µM 
each) and a FAM™ dye-labeled TaqMan® MGB probe annealing on the same strand as 
the reverse primer (FAM CAT CCA CCG ACC ACC C, 5µM).  The probe was designed 
based on the corrected cDNA sequence from Sendak.  The exon/intron junctions are not 
known for rat, but only those exon/exon junctions that bore 100% homology with the 
human sequence were sent as options for the design of a probe.  The designed probe 
overlaps the putative junction of exon2 and exon3. 
The assay and cycling conditions were set according to the manufacturer’s 
instructions.  Briefly, the 20µL final PCR reaction consisted of 1X TaqMan PCR Master 
Mix (AB #4324018 1), 1X assay mix (1:20 dilution of appropriate 20X probe and 
primers assay mix), and for the hepatic lipase detection samples 4µL/sample of either 
cDNA sample, standard, or NTC.  When results were normalized to a negative control as 
opposed to being calculated from a standard curve, the ribosomal phosphoprotein P0 
(36B4) (175) was used.  Beta actin was found to respond to treatments and therefore 
could not be used as an internal control.  For the 36B4 internal standard PCR reactions, 
the cDNA was first diluted 1:9 in water, and 9µL of this diluted cDNA was used in the 
20µL reaction.  The 384 well plate was covered with an optical adhesive cover and spun 
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down before the PCR.  The AB1 Prism 7900HT at the Biotechnology Resource Center 
facility was used for the runs.  Real time thermal profile consisted of 2 steps, the first step 
being a one-time 10 minute incubation at 95C, and the second step consisting of 40x 
{(95C, 15 seconds), (60C, 1minute)}.  ROX fluorescence was used as a passive reference 
for background.   
Calculations for standard (when applicable): 
The rHL cDNA used as a standard was inserted in pCDNA3.1(-) (Invitrogen).  The 
number of rHL transcripts was calculated using the following formula:  
rHL transcript number = rHL standard mass (pg) x 10-12 x (6.022E+23copies/mole) / MW 
where the molecular weight of vector and insert is equal to 3641739. 
Note that Applied Biosystems now has a hepatic lipase (LIPC) TaqMan Assay On 
Demand available (Rn00561474_m1). 
3.2.6 Cloning of the human HL promoter constructs 
Constructs containing deletions of the human HL (hHL) promoter (up to –1480nt) 
driving the expression of a firefly luciferase reporter gene were created by cloning into 
the pGL3 basic vector using a PCR-based approach.  At the time when cloning was 
initiated, the available sequences were that of Chang et al. (Genbank X58779) (58) and 
Ameis et al. (M35425) (56) which overlapped and together covered 3446 base pairs (bp) 
of the hHL promoter upstream of the translation start codon.  Note that the complete 
sequence of the (60-150kb) human hHL gene (promoter and introns) is now available 
from the chromosome 15 genomic contigs NT_010194 and NT_086827. 
A 3411bp promoter sequence was amplified with Herculase polymerase (Stratagene) 
from human female genomic DNA using ATC GAT GAG CT/C AAA TAA AAT TCA 
CTT GCC CTA AGG TCC as forward and ATC GAT CTC GA/G TCC AAG GGC ACT 
TGA TTG GAT as reverse primers, where the Sac1 and XhoI restrictions sites are 
underlined respectively.   
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The conditions for the PCR reaction were as follows (50µL reaction): 3% DMSO, 
2.5U Herculase polymerase in buffer, 0.4µM of each primer, 100ng genomic DNA 
(Novagen), 0.2mM each dNTP.  The robocyler cycle was: 
1x (94C, 3minutes) for initial denaturation;  
35x {(94C, 45sec); (66C, 45sec); (72C, 4min30)} for amplification ; 
1x (72C, 10min) for final elongation. 
The -3297/+113hHL amplified fragment was directly subcloned into the pCR-
BluntII-TOPO (Zero-Blunt TOPO PCR cloning kit from Invitrogen) and the amplified 
fragment was cut out by Sac1 and Xho1 double digestion (Nco1, which does not cut the 
insert but cuts the vector twice, was also added to distinguish the insert from the vector), 
ran on a gel and gel extracted using the QIAquick gel extraction kit.  The pGL3 basic was 
also digested with Sac1 and XhoI and dephosphorylated before it was run on a gel and 
gel extracted.  The insert was then cloned into the MCS of the pGL3basic using sticky 
end ligation between the Sac1 and XhoI sites.   
The sequence analysis described is in near complete agreement with the sequence of 
Oka et al. (59) with the exception of an additional T insertion at -140 (5T in a row in the 
sequence described here, versus 4 only reported in the Oka sequence).  This T deletion in 
the Oka sequence also does not exist in the Ameis sequence.  The numbering of the hHL 
promoter refers to the nomenclature of Oka et al (59) adjusted to the -140 insertion.  The 
current sequence represents the “wild-type” haplotype at each of the 5 base pairs defining 
the common -514C/T polymorphism.  The sequence differs from other reported 
sequences (accession numbers X58779 and M35425) (57) by the following point 
mutations: -708A→C, -709A→C, G insertion at –785, -1038 G→C, -1186 T deletion,     
-1330G→C.  This -3297/+113hHL promoter vector was used as a template to amplify all 
further constructs for similar cloning in between the Sac1 and XhoI sites of the MCS of 
the pGL3basic.  All primer pairs used the same reverse primer containing the XhoI 
restriction site: CGATCTCGA/GCTTGGTAATTTCTGAAGCC and the following 
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forward primers: CGATGAGCT/CGCAGTTGGGGGCAGTAA (-117/+14), 
CGATGAGCT/CTTGATTAATTTGGAACTCTGAC (-249/+14), 
CGATGAGCT/CAACACCACTTTCCTGAGC (-373/+14), 
CGATGAGCT/CCCTCTCAATGGGTCACTT (-572/+14), 
CGATGAGCT/CTGGTCGCCTTTTCCCTACC (-684/+14), 
CGATGAGCT/CGAACTCCTGACCTCGTGAT (-965/+14), 
CGATGAGCT/CTGTGTCAATGCATAAAAGTCA (-1480/+14).   
All deletion inserts and junctions were fully sequenced. 
For PCR conditions, see Table 3-1.   
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Table 3-1: PCR conditions for the cloning of hHL promoter constructs 
 
 
 Denaturation (1) 
1x 
Amplification (2) 
30x unless specified 
Elongation (3) 
1x 
-117/+14 94C, 3min 40x {(94C, 45sec),  
(59C, 45sec),  
(72C, 1min)} 
72C, 10min 
-373/+14 94C, 3min (94C, 45sec), 
 (61C±2, 45sec), 
 (72C, 1min) 
72C, 10min 
-572/+14 94C, 3min (94C, 45sec),  
(61C±2, 45sec), 
(72C, 1min) 
72C, 10min 
-684/+14 94C, 3min (94C, 45sec),  
(61C±2, 45sec),  
(72C, 1min) 
72C, 10min 
The conditions for the above PCR reactions were as follows (50µL reaction): 2% 
DMSO, 5U Taq DNA polymerase (Gibco), 2.5mM MgCl2, 0.4µM of each primer, 0.5ng 
of -3297/+113hHL promoter vector as template, 0.2mM each dNTP, 1X buffer (Gibco). 
-249/+14 95C, 1min (95C, 1min),  
(54C±4, 1min),  
(72C, 1min) 
72C, 10min 
-965/+14 95C, 1min (95C, 1min),  
(55C, 1min),  
(72C, 4min) 
72C, 10min 
-1480/+14 95C, 1min (95C, 1min),  
(55C, 1min),  
(72C, 4min) 
72C, 10min 
The conditions for the above PCR reactions were as follows (50µL reaction): 2% 
DMSO, 2.5U Pfu Turbo DNA polymerase (Stratagene), 0.4µM of each primer, 1ng of -
3297/+113hHL promoter vector as template, 0.2mM each dNTP, 1X buffer including 
2mM MgCl2 (Stratagene). 
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3.2.7 hHL promoter activity analysis  
Principle of the assay 
In the Dual-Luciferase® Reporter Assay, the activities of firefly (Photinus pyralis) 
and Renilla (Renilla reniformis, also known as sea pansy) luciferases are measured 
sequentially from a single sample.  Firefly and Renilla luciferases have dissimilar enzyme 
structures and substrate requirements.  Photon emission from the firefly luciferase 
reporter is measured first through oxidation of beetle luciferin in the presence of ATP, 
Mg2+ and O2.  Immediately after quantifying the firefly luminescence, the luminescent 
signal from the firefly reaction is quenched by at least a factor of 105 and simultaneously, 
the Renilla luciferase reaction utilizing O2 and coelenterateluciferin (coelenterazine) is 
activated.  The amount of light integrated over a certain period of time is proportional to 
the amount of luciferase reporter activity in the sample, which in turn reflects the activity 
of the promoter driving its expression. 
Assay in 24-well plate format 
The empty pGL3 basic (negative control) or each construct were transfected alone or 
cotransfected with the pRL-TK vector (internal control containing the Renilla luciferase 
gene and used for normalization of cell density and transfection efficiency) into hepatoma 
cells.  Typically, cells were transfected in 24 well plates with 80-200ng/well total DNA, 
with a 10:1 molar ratio of experimental luciferase reporter to pRL-TK control vector 
respectively.  Transfection was done in a total volume of 250µL serum-free DMEM or 
MEM in the presence of lipofectamine and Plus reagent (Gibco) according to the 
manufacturer’s instructions.  Three hours after transfection, the medium was replaced and 
the appropriate maintenance or treatment medium was added to the cells.  The cells were 
then treated for the time indicated in each experiment until collection.  Both firefly and 
Renilla luciferase activities from 24-well plate lysates were measured using the Dual 
luciferase system (Promega) according to the manufacturer’s instructions.   Briefly, cells 
were rinsed with phosphate-buffered saline, and the PBS was aspirated completely.  
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100µl of 1X passive lysis buffer (PLB - provided) was dispensed in each well and the 
plates were shaken at RT on a rocking platform for 15 minutes, then frozen at -80C for 
anywhere from a few minutes up to a couple days.  Lysis buffer was indifferently 
transferred to eppendorf tubes and spun down or pipeted directly from the wells of the 
culture plate into the assay tube.  For each sample, the assays for firefly luciferase 
activity and Renilla luciferase activity were performed sequentially using 10 seconds 
integration times for each reading.  First, a blank reading was obtained with 100µl of 
LAR II in a 12x75mm borosilicate glass tube.  A second firefly reading was obtained 
after addition of 20µl of cell lysate into the luminometer tube and pipetting up and down.  
When applicable, a third and last reading for renilla luciferase was obtained after addition 
of 100µl of Stop & Glo® Reagent and vortexing.   
Assay in 96-well plate format 
White-sided, clear bottom, tissue-culture-treated, polysterene 96 well plates (Costar 
3610) were collagen-coated (50µl/well at 25µg/µl), and exposed to UV light overnight.   
This step was critical to prevent cells (especially McA-RH7777) from peeling off upon 
multiple changes of medium and thus to ensure obtaining a nice monolayer culture at 
time of collection.  McA-RH7777 or Fu5AH cells were plated in 100µl medium at 
40,000 cells/well one day before transfection.  When the medium was changed, care was 
taken to pipet on the side of the wells such as not to disturb the cell monolayer.  
Typically, McA/Fu5AH cells were transfected in 96 well plates with 25ng/well total 
DNA, with a 50:1 molar ratio of experimental luciferase reporter to phRL-TK control 
vectors respectively.  No luminescence signal was detected in 96 well plates when the 
pRL-TK vector was used, such as transfection experiments in 96 well-plates required to 
switch to the phRL-TK vector (Promega) with much enhanced promoter activity over the 
pRL-TK, thereby enabling to get solid renilla values with the 96 well plate luminometer.  
Transfection was done in a total volume of 70µL MEM (no serum) in the presence of 
0.5µl lipofectamine and 1µl Plus reagent (Gibco life technologies) according to the 
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manufacturer’s instructions.  Three hours after transfection, the medium was replaced and 
100µl of the appropriate maintenance or treatment medium was added to the cells.  The 
luciferase assay was performed 24 to 48 hours after transfection.  Both firefly and Renilla 
luciferase activities from 96-well plate lysates were measured using the Dual-Glo™ 
Luciferase Assay System (Promega #E2920 / E2940) according to the manufacturer’s 
instructions.  Briefly, plates were removed from the incubator, the medium was aspirated, 
50µl MEM was added back to each well, and the plates were equilibrated to room 
temperature.  50µl of Dual-Glo™ Luciferase Reagent was added to each well and mixed 
in by gentle shaking of the plate.  After 10-30 minutes waiting time, a white polyester 
sealing-tape (Nunc 235305) was taped to the bottom of the plate, such as the white-
bottomed plate now had lower cross-talk interference upon reading in the luminometer 
(emission slide out).  Firefly luminescence was measured over an integration time set at 5 
seconds per well, reading from the top.  50µl of Dual-Glo™ Stop & Glo ® Reagent was 
then added to each well, mixed, and Renilla luminescence was measured after 10-30 
minutes. 
Calculations: 
Results  were expressed relative to the Renil la luciferase internal  
control .    
Fireflynet. = Fireflygross –  (average of ~3 firefly readings from untransfected wells)  
or because firefly reading from untransfected wells is about 0 above background: 
Fireflynet. = Fireflygross –  (background count (LARII reading) for same tube) 
Renillanet= Renillagross – (average of ~3 Renilla readings from untransfected wells) 
Firefly/Renilla ratio= Fireflynet.  average/ Renillanet.  Average 
3.2.8 Lowry-Bensadoun Protein Assay  
Total protein concentration in samples was assayed using an adaptation by 
Bensadoun and Weinstein (176) of the original Lowry et al. procedure (177) to assay 
protein in the presence of interfering materials such as lipids.   
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3.2.9 Preparation of nuclear extracts 
Nuclear extracts from HepG2 cells in 100mm dishes were prepared using the NE-
PER Nuclear and Cytoplasmic Extraction Reagents (Pierce 78833) according to the 
manufacturer’s instructions.  The protein content of the crude nuclear extracts was 
assessed by Lowry after a preliminary deoxycholate-trichloroacetic acid (TCA) 
precipitation. 
3.2.10 Gel shift and supershift assays 
Tissue culture 
HepG2 cells were split into 100mm dishes.  Upon 90% confluency, cells were treated 
with LPDS medium with or without a mix of 10µg/mL cholesterol, 1µg/mL 25-OH-
cholesterol and 5µg/mL 58-035 or 37.5µM compactin/mevastatin.  DMSO and ethanol 
were added as carrier controls as appropriate.  The treatment medium was refreshed after 
24 hours.  After 48 hours of treatment, nuclear extracts were prepared as described above 
(3.2.9). 
DNA probe preparation 
Reverse phase cartridge purified complementary oligos (with 5’OH ends) were 
ordered to use as probes.   
 
Table 3-2: Probes used in gel shift and supershift assays 
 
Probe 
# 
Probe location in hHL 
promoter 
Forward primer sequence mer 
1 -14/+14 ggtctctttggcttcagaaattaccaag 28 
2 -70/-48 gagaggttaattattaatgggca  23 
3 -110/-95 ggggcagtaaagaaag 16 
4 -252/-218 aagttgattaatttggaactctgaccttggcccca 35 
5 -317/-298 gcagccacgtggaagccacc 20 
6 -520/-509 ttgacacggggg 12 
7 -566/-546 aatgggtcacttggcaagggc 21 
8 -595/-578 gaagtgtgtttactctag 18 
9 -929/-906 ccaaagtgctgtgattacaggagt 24 
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5 pmoles single-stranded oligos were end-labeled with 20 pmoles [γ-32P]-ATP 
(3000Ci/mmole, 10mCi/mL) and 10U T4 polynucleotide kinase (NEB) for 1 hour at 37C, 
and the reaction was stopped by addition of 50mM EDTA.  Double-stranded probes were 
annealed by mixing equimolar amounts of complementary forward and reverse primers in 
water, and incubating at 95C for 2 minutes, followed by 30 minutes at 37C.  Double-
stranded probes were purified on a 10% nondenaturing polyacrylamide gel (1X TBE: 
0.089M Tris base, 0.089M boric acid, 2mM EDTA, pH 8.0), which had been previously 
prerun for 30 min at 5V/cm.  The band was localized by exposure to film, excised from 
the gel, and transferred to a microfuge tube.  To elute the DNA from the gel, the band (1 
volume) was crushed with a p1000 tip, and incubated with 2 volumes of elution buffer 
(10mM Tris, 50mM NaCl, 1mM EDTA) for 4 hours at 37C.  The elution buffer was 
recovered and the DNA was submitted to an ethanol precipitation using Glycoblue 
(Ambion) as a carrier.  Probes were resuspended in 250µL TE, pH 8.0 and stored at 4C 
for up to 3 weeks. 
Binding reactions for mobility shift assays 
Frozen nuclear extracts were thawed on ice.  Binding reactions for 
regular/competition gel shift assays were assembled in the presence of gel shift binding 
buffer (50mM KCl, 10mM HEPES, pH 7.9, 0.1mM EDTA, 2.5mM 
phenylmethylsulfonyl fluoride (PMSF), 2µg poly(dI-dC)⋅poly(dI-dC) (Amersham#27-
7880-01), 10% glycerol, 0.3µg/µL BSA), with 20,000 to 30,000cpm probe and with or 
without 10µg crude nuclear extract (diluted more than 10 fold), and/or 1pmole cold 
unlabelled double-stranded probe competitor as appropriate.  The sequence of the non-
specific competitor used was GAGCCCAGCATTTTTTGTCGCA.  The 20µL reaction 
mixes were incubated at 10-15C for 20 minutes in a constant-temperature water bath 
before being run for about 70 minutes at 35mA on a 4% nondenaturing gel with 2.5% 
glycerol, using 0.5X TBE as a running buffer.  Binding reactions for supershift assays 
were assembled in the presence of supershift binding buffer (0.1M NaCl, 10mM HEPES, 
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pH 7.9, 0.1mM EDTA, 2.5mM PMSF, 3mM MgCl2, 2µg poly(dI-dC)⋅poly(dI-dC), 10% 
glycerol, 0.1µg/µL BSA) with or without 10µg crude nuclear extract (diluted more than 
10 fold) and/or 2µg antibody as appropriate in a total volume of 18µL.  Reactions were 
preincubated at 4C for 2 hours to allow antibody to antigen binding, after which 20,000 
to 30,000cpm probe was added to a final volume of 20µL.  Binding reactions were then 
incubated for an additional 20 minutes at 10-15C before being run on a gel.  All gels were 
prerun for 30 to 60 min at 100V immediately prior to loading.  Loading dye was not 
added to binding reactions in order to prevent potential denaturing of complexes.  Gels 
were exposed to a phosphorimager screen at room temperature (~1-24 hours in general) 
for analysis. 
Antibodies 
The following polyclonal immunoglobulin G (IgG) antibodies were purchased from 
Santa Cruz:  
rabbit xUSF1 (H-86), sc-8983; rabbit xSREBP1a/c (H-160), sc-8984X; goat 
xSREBP2 (N-19), sc-8151X; rabbit xHNF1α (H-140), sc-10791; rabbit xTFIID/TBP, 
(SI-1), sc-273X; rabbit HNF4α, (H-171), sc-8987X; rabbit xCOUP-TFI, (H-60), sc-
28611X; rabbit xRXRα, (D-20), sc-553; rabbit xRXRα, (∆N 197), sc-774; rabbit xSp1, 
(H-225), sc-14027; rabbit xSp3 (D-20), sc-644; goat xSF1 (E-18), sc-10976X; rabbit  xc-
Jun (H-79), sc-1694X.   
Antibodies obtained from other sources were mouse IgG2b xPPARα, (Affinity 
BioReagents, MA1-822), as well as house-raised rabbit antisera from Dr. L. Kraus 
laboratory (Cornell University) against c-jun (JunNT, PROD 1/2/03) or c-fos (3rd bleed, 
280-335).  Rabbit IgG (Sigma I-5006), goat IgG (Sigma I-5256), and mouse IgG (Sigma 
I-5381) were all stored in PBS, 0.02% azide. 
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3.2.11  Co- immunoprecipitation 
Co- immunoprecipitation of transcription factors from non-transfected cells  
800µg nuclear extract (see 3.2.9) from treated cells (see 3.2.10) was diluted 1:10 in 
gel shift binding buffer (50mM KCl, 10mM HEPES, pH 7.9, 0.1mM EDTA, freshly 
added 2.5mM PMSF) with 0.3µg/µL BSA and incubated for 1 hour at 4C with 8µg of 
either xUSF1 antibody (sc-8983), xHNF1α (sc-10791), xHNF4α (sc-8987), or rabbit IgG 
(Sigma I-5006).  50µL protein G- Sepharose 50% slurry (pre-equilibrated in binding 
buffer) was added to each tube for incubation overnight at 4C with constant gentle 
shaking.  On day 2, the tubes were spun down at 5000rpm for 3 minutes at 4C to pellet 
the protein G complexes, and the beads were washed 4 times for 5-10 minutes each at 4C 
with 1mL of fresh chilled 0.1% Nonidet-P-40 in PBS.  The protein complexes were 
released with 60µL elution buffer (50mM Tris-base, 100mM NaCl , 1% Triton X-100, 
0.3% CHAPS, 1% sodium deoxycholate, 10mM EDTA, pH 9.0) for 30 minutes at 37C, 
the tubes were spun down, and the supernatants were collected.  This elution step was 
repeated once.  The eluate pools were concentrated down to <50µL with Microcon YM-
30 (Millipore #42409) concentrators, which was achieved in a few minutes.  Laemmli 
buffer (with β-mercaptoethanol) was added to 1X final, the samples were boiled for 3-5 
minutes, and ran on a 10% SDS-PAGE.  The MagicMark XP Western Protein Standard 
(Invitrogen) was used as a standard.  The proteins were transferred to PVDF Immobilon 
P membrane using semi dry transfer, and the membranes were blocked overnight at 4C in 
PBS-tween with 5% non-fat dry milk.  On day 3, the membranes were incubated 
overnight at 4C in blocking buffer supplemented with 1µg/mL xSREBP1 (sc-8984X).  
On day 4, the membranes were rinsed and washed six times for 10 minutes with PBS-
tween (at 4-25C), then were incubated for 2 hours at RT in blocking buffer supplemented 
with anti rabbit-horseradish peroxidase (HRP) conjugate (Sigma A-9169) at 1:50,000 
(Pierce).  The membranes were rinsed and washed 6 times for 6-10 minutes with PBS-
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tween at 4-25C, and revelation was achieved with the West Pico Reagents (Pierce) 
according to the manufacturer’s instructions. 
Co- immunoprecipitation of transcription factors from nSREBP1a or nSREBP1a and 
USF1 transfected cells 
HepG2 cells in 100mm dishes were transfected with 5µg/dish of pCMV-SREBP1a-
460 or pEGFP-N1 (Clontech 6085-1), or 2.5µg/dish of each pcDNA3-USF1 and pCMV-
SREBP1a-460 in MEM using the Lipofectamine Plus reagent (Gibco/Life technologies).  
After 4 hours, the medium was aspirated and replaced by fresh serum-containing 
medium.  The growth medium was replaced after 24 hours.  43 hours after transfection, 
the neutral cysteine protease and proteasome inhibitor N-acetyl-leucyl-leucyl-norleucinal 
(ALLN) was pipeted into the growth medium at 15µg/mL (39µM) final.  After an 
additional 5-hour incubation, the medium was aspirated and nuclear extracts were 
prepared from cells transfected with nSREBP1a only or nSREBP1a and USF1 as 
described in 3.2.9.  5mg nuclear extracts were pre-cleared by centrifuging at 14,000rpm 
for 10 minute at 4C.  The supernatants were diluted 1:5 in binding buffer (10mM Tris, pH 
7.4, 150mM NaCl, 0.1% Triton X-100, 2.5mM PMSF) with 0.3µg/µL BSA and 
incubated for 1 hour at 4C with 4µg antibody or IgG as described above.  The overall 
procedure for co-immunoprecipitation was the same as described above with the 
following specifications: 80µL protein G Sepharose 50% slurry was added to each tube, 
the proteins were released with 80µL elution buffer twice, and after transfer the 
membranes were blocked for 2 hours at room temperature. 
3.3 Results 
3.3.1 Decreased rHL mRNA levels upon cholesterol repletion 
To determine whether the decrease in synthesized rHL upon cholesterol treatment 
could be at least partially explained by a decrease in transcription of the HL gene, the 
levels of rHL mRNA levels after cholesterol treatment were assessed.  In these 
experiments, quantification of rHL mRNA levels by real-time reverse-transcription 
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polymerase chain reaction was done either by using a standard curve (data not shown) or 
by normalizing to P0 as presented, yielding virtually identical results.  After a 24-hour 
treatment with sterols, an ACAT inhibitor or a combination of both, rHL mRNA levels 
(relative to P0) were 94.4%, 75.0%, and 77.5% of control cells (on LPDS medium) 
respectively (Figure 3-1).  Overall, these data show that rHL mRNA levels are modestly 
decreased upon sterol treatment for 24 hours, and remain low over the second day of 
treatment (Figure 3-1). 
To determine when the decrease in rHL mRNA is first detectable, a time course of 
rHL mRNA levels during cholesterol repletion was performed.  rHL mRNA levels were 
analyzed by real time PCR and transcript numbers were calculated from a standard curve.  
rHL mRNA levels were found not to be changed over the first four hours of cholesterol 
repletion, but decreased thereafter, to 80.1% and 49.0% of control levels at 24 and 48 
hours respectively (Figure 3-2).   
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Figure 3-1 rHL mRNA levels are decreased upon sterol or 58-035 treatment 
Fu5AH cells were split into 35 mm dishes.  After 2 days, upon confluency, at t=0hr, 
triplicate wells were placed on 2mL/dish of either LPDS medium (10% LPDS, 2mM L-
Glutamine in MEM) (LPDS), LPDS medium supplemented with 5µg/mL ACAT 
inhibitor 58-035 (ACAT inhibitor), LPDS medium supplemented with 10µg/mL 
cholesterol and 1µg/mL 25-OH-cholesterol (Sterols), or a combination of both (ACAT 
inhibitor + sterols).  Ethanol and/or DMSO were added as carrier controls as appropriate.  
At t=24hr, the medium was refreshed on one subset of cells.  For collection, cells were 
rinsed with PBS and collected in Trizol at t=24hr or 48hr as indicated.  The Total RNA 
was extracted with Trizol (Invitrogen) according to the instructions of the manufacturer.  
mRNA was used as a template for real-time RT-PCR using TaqMan probes for rHL 
(custom-made Assay-by-design, Applied Biosystems) or ribosomal P0 (Assay-on-
demand Rn00821065_g1 from Applied Biosystems).  rHL mRNA levels were 
normalized to P0, and data were processed using the ∆∆Ct calculation method.  Data are 
presented as percent change relative to control wells.  Data for the 24 hour time point 
correspond to an average of two independent experiments. 
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Figure 3-2 rHL mRNA levels upon cholesterol repletion 
McA-RH7777 cells were split into collagen-coated 35mm dishes.  At t=-4hr, to 
deplete the cells of cholesterol, the cells were placed on 2mM methyl-β-CD in defatted 
medium.  At t=0hr, the medium was aspirated and replaced by 5mM methyl-β-CD 8:1 
cholesterol (molar ratio) in defatted medium.  This medium was refreshed at t=24hr.  At 
each collection time point, cells were rinsed with PBS and collected in Trizol.  Total 
RNA was extracted with Trizol (Invitrogen) and further purified using RNeasy columns 
(Qiagen) according to the instructions of the manufacturers.  mRNA was used as a 
template for real-time RT-PCR using a custom-made TaqMan assay for rHL (Assay-by-
design, Applied Biosystems).  Quantification of rHL mRNA levels was done using a 
standard curve and is expressed as percent change relative to time 0, when repletion of 
cholesterol began. 
 
3.3.2 rHL mRNA degradation rate is not affected by sterol treatment 
The observed decrease in rHL protein synthesis and decrease in steady-state mRNA 
levels could be due to either a decrease in the transcription of the HL gene and/or to an 
increase in the degradation rate of the HL mRNA.  Figure 3-3 shows that the degradation 
rate of rHL mRNA appears to be unchanged by either sterol treatment or by 58-035 
treatment over the first 24 hours of treatment, suggesting that the decrease in rHL steady-
state mRNA levels in sterol-treated cells at 24 hours (Figure 3-1) is not due to a change in 
rHL mRNA stability.  Again in this experiment, quantification of rHL mRNA levels was 
done either by using a standard curve (data not shown) or by normalizing to P0 as 
presented, yielding virtually identical results. 
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Figure 3-3 rHL mRNA degradation rate is unchanged upon sterol treatment 
Two hours prior to the experiment, confluent Fu5AH cells in 35mm dishes were pre-
incubated with LPDS medium (10% LPDS, 2mM L-Glutamine in MEM).  At time t=0 
hour, one set of cells was collected in Trizol for rHL mRNA baseline quantification, 
while other cells were placed on LPDS medium supplemented with 0.5µg/mL 
actinomycin D without (LPDS) or with 10µg/mL cholesterol and 1µg/mL 25-OH-
cholesterol (sterols) or 2µg/mL 58-035 (ACAT inhibitor).  Ethanol and DMSO were used 
as carrier controls as appropriate.  Subsets of cells were collected in Trizol at the 
indicated time points (2, 5, 10 and 24 hours).  Total mRNA was extracted and used as a 
template for real-time RT-PCR using TaqMan probes for rHL (custom-made Assay-by-
design, Applied Biosystems) or ribosomal P0 (Assay-on-demand Rn00821065_g1 from 
Applied Biosystems).  rHL mRNA levels were normalized to P0, and data were 
processed using the ∆∆Ct calculation method.  Data are presented as fold change 
(average (n=3) +/- SD) relative to control wells at time 0. 
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3.3.3 The activity of a -1480/+14 human HL promoter fragment is 
unchanged by sterol or 58-035 treatment 
Next, we examined transcriptional activity of the HL gene under sterol treatment.  
Whereas rat HL was studied in previous experiments involving analysis of protein levels 
(because the available rat HL ELISA is much more sensitive than for the human protein), 
the following studies on promoter regulation were performed using the human HL gene 
sequence available from NCBI. 
In order to delineate the promoter sequence responsible for a decrease in the 
transcription of the HL gene, a series of hHL promoter deletion constructs were cloned 
upstream of a luciferase reporter gene.  The deletion constructs spanned the hHL 
promoter from -1480bp to +14.  None of the constructs was found to be responsive to 
sterol or 58-035 treatments under conditions where rHL mRNA is known to be repressed 
(Figure 3-4).  Therefore, the effect of sterols or free cholesterol on the hHL promoter is 
not obvious, a result which was confirmed in multiple experiments in rat or human cells.  
Despite the lack of effect on the hHL promoter, these sterol treatments were effective at 
downregulating mature nSREBP transcriptional activity as shown by a decrease in the 
promoter activity of the pSRE-luc vector, where activity is driven by two sterol 
responsive elements (SREs) (see Figure 3-5).  Because nuclear SREBP1c is very 
inefficient at activating an SRE, the activity of the pSRE-luc reflects the combined levels 
of mature SREBP1a and 2 isoforms in the nucleus (Table 1-1). Thus, sterol treatments 
resulted in a decrease in combined levels of nuclear SREBP1a and 2.  Meanwhile, 
nuclear SREBP1c levels should have increased (73;126). 
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Figure 3-4 The activity of a -1480/+14 human HL promoter fragment is unchanged 
upon sterol or 58-035 treatment 
Fu5AH cells were split into collagen-coated 96 well plates at a density of 40,000 
cells/well.  Two days later, at 95% confluency, at t=0hr, each well was cotransfected in 
MEM with 2 vectors amounting a total of 25ng/well DNA using the Lipofectamine Plus 
Reagent (Gibco).  phRL-TK (used for normalization of cell number and transfection 
efficiency) and pGL3 basic constructs (each containing the firefly luciferase gene under 
the control of different lengths of the hHL promoter) were added at a molar ratio of 
1(phRL-TK):50(construct).  At t=3hr, the transfection medium was aspirated and 
replaced by 0.1mL fresh LPDS medium without (control) or with 5µg/mL 58-035 
(ACAT inhibitor), or a mix of 10µg/mL cholesterol and 1µg/mL 25-OH-cholesterol 
(sterols), or a combination of both (sterols + ACAT inhibitor).  Ethanol or DMSO were 
added as carrier controls as appropriate.  At t=24hr, the medium was aspirated and 
50µL/well MEM was added.  The luciferase assay was then performed according to the 
instructions of the manufacturer (Dual-Glo luciferase assay system, Promega).  All values 
correspond to the ratio of the firefly luciferase activity to the renilla luciferase activity 
(both corrected for untransfected cells background) relative to the ratio obtained for the 
pGL3 basic empty vector in the absence of treatment (arbitrarily set at 1).  Means +/- SD 
of 5-6 wells are shown.  This experiment was representative of four similar experiments. 
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Figure 3-5: SREBP transcriptional activity is decreased in HepG2 cells treated with 
sterols or an ACAT inhibitor 
At t=0hr, HepG2 cells at 90% confluency in 24 well plates were cotransfected in 
MEM using the Lipofectamine Plus Reagent (Gibco).  Cells received 100ng/well pSRE-
luc.  At t=3hr, the transfection medium was replaced by 0.75mL LPDS medium with or 
without a mix of 10µg/mL cholesterol and 1µg/mL 25-OH-cholesterol (sterols) or 
5µg/mL 58-035 (ACAT inhibitor), or complete medium as indicated.  The medium was 
refreshed at 24 hours, and at t=48 hours cells were rinsed with PBS and lysed in 
100µl/sample of 1X passive lysis buffer.  The plates were shaken for 15 minutes and 
frozen down at -80C for enhanced lysis.  The luciferase assay was performed according 
to the instructions of the manufacturer (Promega).  Averages +/- SD, n=4.   
 
3.3.4 nSREBP transfection decreases rHL mRNA levels 
Because HL is known to increase the flux of cholesterol into liver cells and other HL-
expressing cells (in the ovaries and adrenals), we sought to find out whether SREBP was 
involved in HL regulation as a part of its overall role in maintaining cholesterol cell 
homeostasis.   
We first tried to see whether secreted HL levels would be altered upon nSREBP 
transfection.  In McA-RH7777 cells maintained in complete medium such as endogenous 
nSREBP levels were maintained at a minimum, no change in HL secretion could be 
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detected 24 hours after transfection (data not shown).  In the same experiment, USF 
transfection, a known activator of HL (80) also failed to upregulate HL secretion.  In 
order to bypass any potential post-transcriptional regulation at the protein synthesis and 
secretion steps, we next examined mRNA and hHL promoter activity levels.  Because the 
lack of an effect may be due to poor transfection efficiency, looking at hHL promoter 
activity levels where only transfected cells give a luminescence signal has the added 
advantage of increasing sensitivity.   
nSREBP1a transfection in McA-RH7777 decreased levels of rHL mRNA compared 
to mock-transfected control cells after 15 hours (Figure 3-6).  Because the experiment 
was conducted in defatted medium, endogenous mature nSREBP levels in control cells 
should have been high, which possibly could mask an effect of even greater amplitude.  
We reasoned that nSREBP could either affect rHL transcription directly or indirectly 
through another transcription factor.  Alternatively, nSREBP could act by increasing 
cholesterol biosynthesis in the cells (upregulation of HMG-CoA reductase), which would 
lead to increased cell cholesterol levels, which in turn could downregulate HL, as was 
described previously.  To test the latter hypothesis, we included a treatment with 50µM 
compactin in the same experiment.  At this concentration, cholesterol biosynthesis should 
be efficiently suppressed, and although increased nSREBP levels would be expected to 
upregulate the expression of the LDLR, the cells could not take up cholesterol from the 
defatted medium, which does not provide a source of lipoproteins.  50µM mevalonate 
was also added in the treatment media, enough to provide for synthesis of non-sterol 
isoprenoids but not for sterol synthesis.  nSREBP was found to downregulate rHL mRNA 
in the presence of compactin, and thus the effect of nSREBP appeared to be independent 
of cholesterol synthesis.  The cholesterol effects, however, could be mediated by changes 
in nSREBP levels. Compactin alone was found to decrease HL mRNA levels, which 
could be explained by the fact that compactin itself is known to upregulate nSREBP (see 
Figure 3-10).   
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Figure 3-6 nSREBP1a and compactin decrease rHL mRNA levels 
McA-RH7777 cells were split into collagen-coated 35mm dishes.  At t=0hr, each well 
was transfected using the Lipofectamine Plus Reagent (Gibco) in DMEM with 
0.8µg/well pCMV-SREBP1a-460 (ATCC) or pRc/CMV as a control.  At t=3hr, the 
transfection medium was aspirated and replaced by 2mL defatted medium (containing 
5% defatted FBS) with 50µM mevalonate and with or without 50µM compactin.  At 
t=15hr, the cells were scraped and collected in the medium, transferred to eppendorf 
tubes and spun down.  The medium was aspirated and the cells were rinsed with PBS.  
RNA was extracted using Trizol (Invitrogen) and further purified through RNeasy 
columns (Qiagen).  rHL mRNA was quantified by real-time RT-PCR using a custom-
designed TaqMan probe assay.  **: statistical significance was assessed by 2-tailed 
unpaired Student’s t-test (p<0.002). 
 
3.3.5 The proximal human HL promoter fragment is activated by 
USF and inhibited by SREPB1a 
Next we tried to see if the hHL promoter deletion constructs would be responsive to 
nSREBP1a transfection.  Although we could not detect an effect of cholesterol on hHL 
promoter activity (Figure 3-4), if cholesterol could modify rHL transcription through 
SREBP, the direct overexpression of this transcription factor would magnify that effect. 
** 
** 
** 
** 
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In the presence of serum-containing medium in which endogenous nSREBP levels 
are expected to be low, overexpression of mature nSREBP1a was found to strongly 
inhibit all deletion constructs in McA-RH7777 cells, including the shortest -117/+14 
fragment (Figure 3-7).  Thus, a basal sequence necessary for inhibition appeared to be 
located within the -117/+14 sequence.  Additionally, because the longer constructs 
appeared to have even stronger inhibition than the shorter ones, sequences further 
upstream in the promoter may cooperate in inhibiting transcription.  Similarly, 
nSREBP1a transfection was found to downregulate hHL promoter activity in a human 
hepatoma HepG2 cell line (data not shown). 
There are only a few examples of gene downregulation by SREBPs.  In these cases, 
SREBP-induced downregulation of gene targets was proposed to be mediated either 
through binding to an SRE (146) or E-box (148) DNA sequence, or indirectly through 
binding to transcription factors such as Sp1(151) or LRH1(150) and inhibiting 
transactivation.  In the case of HL, analysis of the proximal promoter failed to reveal the 
presence of an SRE.  Conversely, sequence analysis revealed the presence of a few E-
boxes in the HL promoter.  One of these E-boxes is located at the common –514 
polymorphism of the hHL promoter.  The common C-514T mutation disrupts a 
CACGGG USF functional binding site by lowering the affinity of USF to the element by 
2-4 fold (80).  Functionally, there is a positive association between the CC patients with 
an intact USF binding site and higher HL activity levels (86).  Interestingly, wild-type CC 
patients are also more responsive to statin therapy than TT patients or CT heterozygotes 
(44).  Both nSREBPs and USFs are known to bind E-boxes.  What’s more, USF is known 
to induce HL promoter activity (80).   
Together, this suggested that SREBP could inhibit HL promoter activity by 
competing with USF for binding to the HL promoter.  In order to investigate the 
interaction between SREBPs and USFs in hepatoma cells, we tried to see whether 
nSREBP1a could reverse the USF-induced activation of HL by co-transfecting USF1 
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with increasing amounts of nSREBP1a.  We found that both USF1 and USF2 could 
activate human HL promoter activity, and that this activation was effective with the 
shortest -117/+14 HL promoter construct available (Figure 3-8).  Further, at stable levels 
of USF1, increasing levels of nSREBP1a decreased HL promoter activity of HL promoter 
constructs, which was obvious for the –373/+14 vector but also seemed true for the 
shorter –117/+14 construct.  Similar experiments showed that the effect on the –249/+14 
construct is the same as for the –373/+14 vector (data not shown).  At high levels of 
nSREBP1 (a or c), HL promoter activity levels were low.  This experiment was 
conducted in LPDS medium, where endogenous nSREBP levels should originally be 
high.  In these conditions, a dominant negative USF1 construct lacking the DNA binding 
domain could also activate HL promoter activity.  We repeated this experiment in HepG2 
cells grown in complete medium, where endogenous nSREBP levels are expected to be 
low (Figure 3-9).  Under these conditions, again, USFs could activate hHL promoter 
activity and this effect was repressed by co-transfection with increasing levels of 
nSREBP.  Again, the effects were more marked for the longer –373/+14 vector than for 
the shorter –117/+14 vector.  However, in these conditions, the dominant negative USF1 
construct lacking the DNA binding domain could not activate HL promoter activity. 
In this experiment, we also monitored the activity of the pSRE-luc vector to test for 
nSREBP transcriptional activity.  As expected the SRE element was strongly activated 
upon transfection of nSREBP, such as the activity of the promoter was saturated even at 
the lowest levels of nSREBP tested.  USF transfection did not affect pSRE-luc activity.  
Overall, these experiments showed that downregulation of HL promoter activity by 
SREBP is mediated through an element within the –249 to +14 region.  Because the -
117/+14 vector yielded inconsistent data, we could not conclude whether some or all 
elements necessary for regulation lie within this region. 
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Figure 3-7 nSREBP1a decreases hHL promoter activity in McA-RH7777 cells 
McA RH7777 cells were split into 24 well plates.  At 90% confluency, at=0hr, each 
well was cotransfected in DMEM with 3 vectors amounting a total of 120ng/well DNA 
using the Lipofectamine Plus Reagent (Gibco).  pRL-TK (used for normalization of cell 
number and transfection efficiency) and pGL3 basic constructs (each construct containing 
the firefly luciferase gene under the control of different lengths of the hHL promoter) 
were added at a total of 80ng/well at a molar ratio of 1(TK):10(construct).  In addition, 
cells received 40ng/well pCMV-SREBP1a-460 (ATCC) or pcDNA3 as a control.  At 
t=3hr, the transfection medium was aspirated and replaced by 0.75mL fresh McA 
complete (serum-containing) medium.  At t=24hr, the cells were scraped and collected in 
the medium, transferred to eppendorf tubes and spun down.  The medium was aspirated 
and the cells were rinsed with PBS and spun down.  The PBS was aspirated and the cells 
were resuspended in 100µl/sample of 1X passive lysis buffer (Promega) before being 
frozen down.  The luciferase assay was performed according to the instructions of the 
manufacturer (Dual-luciferase reporter assay kit, Promega).  All values correspond to the 
ratio of the firefly luciferase activity to the renilla luciferase activity (both corrected for 
background) relative to the ratio of the pGL3 basic empty vector in the absence of 
nSREBP1a transfection (normalized to 1).  The data is an average +/- SD of 6-12 wells in 
2 different experiments. 
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Figure 3-8: Wild-type and dominant negative USFs activate, and SREPB1 represses 
hHL promoter activity in LPDS medium 
Fu5AH cells were split into 24 well plates.  At 90% confluency, at=0hr, each well 
was cotransfected in MEM with a total of 190ng/well DNA using the Lipofectamine Plus 
Reagent (Gibco).  pGL3 basic constructs (each construct containing the firefly luciferase 
gene under the control of different lengths of the human hepatic lipase promoter) were 
added at a total of 150ng/well.  In addition, cells received up to 20ng/well of pCMV-
SREBP1a-460 (ATCC), pCMV-SREBP1c, pcDNA3-USF1, pcDNA3-USF2, pcDNA3-
dominant negative USF1, as indicated in the legend.  The amount of DNA was adjusted 
to 190ng with pcDNA3 or pRc-CMV as appropriate.  At t=3hr, the transfection medium 
was aspirated and replaced by 0.75mL fresh LPDS medium.  Note that in such 
conditions, endogenous nSREBP levels would be expected to be high.  At t=24hr, the 
medium was replaced, and at t=48 hours, cells were rinsed with PBS.  The PBS was 
aspirated entirely, 100µl/sample of 1X passive lysis buffer (Promega) was added to each 
well, after which the plates were shaken at room temperature for 15 minutes and frozen 
down at -80C for enhanced lysis.  The luciferase assay was performed according to the 
instructions of the manufacturer (Dual-luciferase reporter assay kit, Promega).  All values 
correspond to the firefly luciferase activity corrected for background relative to the 
activity of the pGL3 basic empty vector in the absence of transcription factor 
transfection.  Average +/- SD, n=3. 
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Figure 3-9: Wild-type USFs activate, and SREPB1 represses hHL promoter activity 
in complete medium 
At t=0hr, HepG2 cells at 90% confluency in 24 well plates were cotransfected in 
MEM using the Lipofectamine Plus Reagent (Gibco).  Cells received 150ng/well pGL3 
hHL promoter constructs (top panel) or pSRE-luc (bottom panel) and up to 20ng/well 
each of pCMV-SREBP1a-460, pCMV-SREBP1c, pcDNA3-USF1, pcDNA3-USF2, or 
pFlag-dominant negative USF1, as indicated.  The total amount of DNA was adjusted to 
190ng/well with pcDNA3 or pRc-CMV as appropriate.  At t=3hr, the transfection 
medium was replaced by 0.75mL fresh complete (10% FBS) medium, except for one set 
of cells which was treated with LPDS medium for comparison.  The medium was 
refreshed at 24hrs, and at t=48 hours cells were rinsed with PBS and lysed in 
100µl/sample of 1X passive lysis buffer.  The plates were shaken for 15 minutes and 
frozen down at -80C for enhanced lysis.  The luciferase assay was performed according 
to the instructions of the manufacturer (Promega).  For HL promoter activity, values 
correspond to luciferase activity corrected for background (Average +/- SD, n=5).  For 
pSRE-luc, values correspond to the ratio of luciferase activity for the indicated treatment 
to that in complete medium (Average +/- SD, n=4). 
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3.3.6 Compactin decreases hHL promoter activity while increasing 
nSREBP levels 
As a further confirmation that increasing mature nSREBP levels yields a decrease in 
HL promoter activity, we treated cells with compactin, an inhibitor of HMG-CoA 
reductase.  Compactin is known to increase nuclear SREBP2 levels (128).  In HepG2 
cells grown in LPDS medium, we confirmed that the 50µM compactin treatment 
increased pSRE-luc activity by 4.7 fold.  In these conditions, there was a decrease in hHL 
promoter activity, at least for the shorter –117/+14 and –249/14 luciferase constructs (but 
apparently not the –373/+14 construct).  These data are consistent with the nSREBP1a 
transfection data and suggest the presence of a responsive element within the –117/+14 
region. 
The trend for 20µM lovastatin to decrease HL levels was confirmed at the protein 
secretion level in McA-RH7777 cells, which were first cultured in defatted medium for 
48 hours, and then treated for 48 hours in defatted medium with or without lovastatin 
(data not shown). 
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Figure 3-10: Compactin increases nSREBP transcriptional activity and decreases 
HL promoter activity in HepG2 cells cultured in LPDS medium 
At t=0hr, HepG2 cells at 90% confluency in 24 well plates were cotransfected in 
MEM using the Lipofectamine Plus Reagent (Gibco).  Cells received 100ng/well pGL3 
hHL promoter constructs (top panel) or pSRE-luc (bottom panel).  At t=3hr, the 
transfection medium was replaced by 0.75mL LPDS medium with or without 50µM 
compactin as indicated.  The medium was refreshed at 24 hours, and at t=48 hours cells 
were rinsed with PBS and lysed in 100µl/sample of 1X passive lysis buffer.  The plates 
were shaken for 15 minutes and frozen down at -80C for enhanced lysis.  The luciferase 
assay was performed according to the instructions of the manufacturer (Promega).  
Averages +/- SD, n=4.   
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3.3.7 Gel shift analysis of the proximal hHL promoter 
Having identified the proximal promoter (-249/+14) of hHL to be the minimal 
sequence required for regulation by USF and SREBP, we next turned to gel shift assays 
to try and identify factors that could mediate the response to USF and nSREBP 
transfection.   
Within the –117/+14 hHL promoter fragment, we chose three probes (probes 1-3) 
covering the putative transcription factor binding sites within each of the three known 
DNase1 protected sites (see Appendix Q map).  Within the –249/-117 region, we chose 
one probe (probe 4) using the same criteria as above.  We also selected a few probes 
upstream of the critical –249/+14 region.  Within the –373/-249 region, where there was 
no known DNase 1 protected sites, we chose one probe covering a putative site for USF, 
which also resembles an SREBP half-site (probe 5).  For a similar reason, probe 9, which 
lies within a region where no DNase1 protection study was conducted, was selected 
because it covers a site which E-box sequence resembles SREBP binding sites.  Thus, 
each of these two sites covers a putative binding sequence for sterol responsive 
transcription factors.   Probe 6 was selected because it covers the –514 HL promoter 
polymorphism with its proposed functional USF site.  Finally, probes 7 and 8 were 
selected because they cover known protected sites with putative binding sites for 
USF/steroidogenic factor/AP1 and AP1/forkhead related activator respectively.  
Altogether, within the proximal promoter, the selected set of probes covered putative 
binding sites within all known protected sites from both the Oka and the Hadzopoulou-
Cladaras studies (59;60), with the exception of site C from the Hadzopoulou-Cladaras 
study at –158/-118, which we excluded because it was further upstream of the critical –
117/+14 region, and because no known putative binding sites were identified using 
Matinspector (178), which would have made the identification of a binding factor even 
more difficult. 
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Probe 1, spanning the –14/+14 region of the hHL promoter, covered a protected site 
encompassing the minor and major transcription start sites.  In this region, in gel shifts 
using nuclear extracts from control, compactin, or sterol-treated cells, we found no 
specific binding to the probe despite the presence of two non specific very faint bands 
(data not shown).  Similarly, we found no binding to probe 3, spanning the –110/-95 
region of the hHL promoter (data not shown).  Probe 2, spanning the –70/-48 region of 
the hHL promoter, covered a known site for HNF1 binding (58).  We were able to 
confirm that HNF1 could bind to this region in supershift assays (Figure 3-11).  The 
intensity of the shifts using nuclear extracts from treated cells was decreased to 80.2% 
±4.7 (sterols) and 69.3% ±11.6 (compactin) compared to shifts using extracts from 
control cells (p<0.02 using Student’s 2-tailed unpaired t-test) (Figure 3-11), suggesting 
that both treatments inhibit binding of HNF1α to its response element. 
Further upstream, probe 4, spanning the –252/-218 region of the hHL promoter, 
contained putative binding sites for a number of transcription factors.  Incubating this 
probe with nuclear extract resulted in the appearance of two to three shifted bands (Figure 
3-12).  Of these, the 2 upper bands were not always distinguishable, and we therefore 
quantified them together, even though they may or may not be due to binding of the same 
factor(s).  Antibodies against HNF1, COUP, Sp1, PPAR/RXR or Steroidogenic factor 1 
could not supershift the lower band.  We also found no evidence that they could 
supershift one of the upper bands, even though we could not rule out that possibility 
because of the presence of a single upper band in some of the supershift assays.  An 
antibody against HNF4α supershifted the single upper band.  Additionally, in gel shifts 
using nuclear extracts from control or treated cells, we found that the intensity of the 
lower band and the upper band doublet was 84.2% ±6.2 and 80.7% ±4.8 (sterols) and 
61.5% ±10.5 and 74.5% ±10.3 (compactin) respectively compared to control cells 
(p<0.01 using Student’s 2-tailed unpaired t-test).  Therefore, both treatments inhibit 
binding of factors, in particular of HNF4α, to this region.   
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Probe 5, spanning the –317/-298 region of the hHL promoter, covered a putative site 
for USF.  This probe yielded one shifted band when incubated with nuclear extract from 
control or treated cells (Figure 3-13).  The shifted band was completely supershifted with 
an antibody against USF1.  Neither SREBP1 nor SREBP2 were found to directly bind to 
the probe, despite the presence of an SREBP1 half-site within the probe sequence.  Gel 
shifts using nuclear extracts from control or treated cells showed that the intensity of the 
shift was 61.2% ±20.1 (sterols) and 70.5% ±16.1 (compactin) compared to control cells 
(p<0.01 using Student’s 2-tailed unpaired t-test) (Figure 3-13), suggesting that again, 
both treatments inhibit binding of USF1 to its response element.   
Probe 6, spanning the -520/-509 region of the hHL promoter, was selected because it 
covers the –514 HL promoter polymorphism with its proposed functional USF site.  This 
probe was not shifted using nuclear extracts from either control or treated cells.   
Probe 7, spanning the –566/-546 region of the hHL promoter, was selected because it 
encompasses a known protected site with putative binding sites for USF/steroidogenic 
factor/AP1.  Incubating this probe with nuclear extract resulted in the appearance of three 
shifted bands in gel shift assays (Figure 3-14).  Of these, the 2 upper bands were 
quantified together for simplicity, yielding similar results as if they were quantified alone, 
while increasing the power.  When using nuclear extracts from control or treated cells, we 
found that neither the intensity of the lower band nor of the upper band doublet were 
significantly changed 83.6% ±11.1 and 92.4% ±23.8  (sterols) and 84.2% ±7.5 and 
100.3% ±11.1 (compactin) respectively compared to control cells (p>0.05, using 
Student’s 2-tailed unpaired t-test).  Therefore, both treatments did not alter binding of 
factors to this region, and it appears unlikely that this region is involved in sterol 
regulation of HL (Figure 3-14).  In a supershift assay using control crude extract in 
supershift binding buffer, surprisingly, only a single band was shifted.  No evidence of 
binding was found using antibodies against HNF1α, Sp1, Sp3, SREBP1, SREBP2 (data 
not shown), HNF4α, COUP, AP1 (c-jun/c-fos) or Steroidogenic factor 1 (SF1) (Figure 
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3-14).  An antibody against USF1 completely supershifted the single band (Figure 3-14), 
but it remains unclear which of the original three bands observed in gel shift assays was 
shifted with xUSF1. 
Probe 8, spanning the –595/-578 region of the hHL promoter, was selected because it 
encompasses a known protected site with putative binding sites for AP1 and forkhead 
related activator 2.  Incubating this probe with nuclear extract resulted in the appearance 
of two shifted bands in gel shift assays, which we quantified together for simplicity 
without a change in results (Figure 3-15).  When using nuclear extracts from control or 
treated cells, we found that the intensity of band was not significantly changed 90.9% 
±29.8 (sterols) and 130.7% ±25.4  (compactin) compared to control cells (p>0.05, using 
Student’s 2-tailed unpaired t-test) (Figure 3-15).  In a supershift assay using control crude 
extract in supershift binding buffer, no evidence of binding was found using antibodies 
against HNF1α, TBP, USF1, Sp1, Sp3, SREBP1, SREBP2, HNF4α, COUP, or AP1 (c-
jun/c-fos) (Figure 3-15).  An obvious candidate for binding would be the forkhead related 
activator 2, but since this region does not appear to mediate the effects of sterols or 
compactin, we did not investigate this further. 
Probe 9, spanning the –929/-906 region of the hHL promoter, lies within a region 
where no DNase1 protection study was conducted, but was selected because it covers a 
site which E-box sequence resembles SREBP binding sites.  Incubating this probe with 
nuclear extract resulted in the appearance of two shifted bands in gel shift assays (Figure 
3-16).  When using nuclear extracts from control or treated cells, we found that the 
intensity of the lower and upper bands were 88.4% ±3.8 and 98.6% ±7.3 (sterols) and 
104.8% ±20.9 and 109.4% ±14.6 (compactin) respectively compared to control cells.  
None of these changes were significant except for the lower band in the sterol treatment 
(p<0.01, using Student’s 2-tailed unpaired t-test).  In a supershift assay using control 
crude extract in supershift binding buffer, no evidence of binding was found using 
antibodies against HNF1α, USF1, Sp1, Sp3, SREBP1, SREBP2 (Figure 3-16). 
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Overall, we were able to confirm HNF1 binding within the hHL promoter at -70/-48, 
and further identified binding sites for HNF4 and USF1 at -252/-218, and -317/-298 
respectively.  Binding of these factors was diminished using nuclear extracts from sterol 
or compactin treated cells.  Further, we found that USF1 could bind to the -566/-546 
region of the hHL promoter but that this binding was unresponsive to sterol or compactin 
treatment. 
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Figure 3-11 HNF1α binds the –70/-48 region of the hHL promoter and this binding 
is decreased with extracts from sterol mix- or compactin-treated cells 
Nuclear extracts were prepared from HepG2 cells treated for 48 hours in LPDS 
medium without (L) or with a mix of 10µg/mL cholesterol, 1µg/mL 25-OH-cholesterol 
and 5µg/mL 58-035 (S) or 37.5µM compactin (C).  (A) Nuclear extracts were incubated 
for 20 minutes at 10-15C in gel shift binding buffer with 20,000cpm probe 2 (spanning 
the –70/-48 region of the hHL promoter) in the presence or absence of excess unlabelled 
specific (probe 2) competitor.  The 20µL binding reactions were analyzed on a 5% 
nondenaturing gel in 0.5X TBE and the gel was exposed to a phosphorimager screen.  (B) 
To allow antibody to antigen binding, nuclear extracts were pre-incubated for 2 hours at 
4C in supershift binding buffer in the presence or absence of 2µg specific antibodies as 
indicated.  After this preincubation, 20,000cpm probe 2 was added and the mix was 
incubated for an additional 20 minutes at 10-15C.  The 20µL binding reactions were 
analyzed on a 4% nondenaturing gel in 0.5X TBE.  (C and D) A similar gel-shift assay as 
in panel A was conducted in the presence or absence of excess unlabelled specific (probe 
2) or non-specific (NS) competitor.  Quadruplicate reactions were run from nuclear 
extracts from treated or non-treated cells and the density of the shifts was quantified in 
panel D. 
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Figure 3-12 HNF4α binds the –252/-218 region of the hHL promoter and this 
binding is decreased with extracts from sterol mix- or compactin-treated cells 
Nuclear extracts were prepared from HepG2 cells treated for 48 hours in LPDS 
medium without (L) or with a mix of 10µg/mL cholesterol, 1µg/mL 25-OH-cholesterol 
and 5µg/mL 58-035 (S) or 37.5µM compactin (C).  (A) Nuclear extracts were incubated 
for 20 minutes at 10-15C in gel shift binding buffer with 20,000cpm probe 4 (spanning 
the –252/-218 region of the hHL promoter) in the presence or absence of excess 
unlabelled specific (probe 4) or non-specific (NS) competitor.  The 20µL binding 
reactions were analyzed on a 4% nondenaturing gel in 0.5X TBE and the gel was exposed 
to a phosphorimager screen.  (B) Quadruplicate reactions from nuclear extracts from 
treated or non-treated cells were run in a similar gel-shift assay as in panel A and the 
density of the shifts was quantified.  (C-E) To allow antibody to antigen binding, nuclear 
extracts were pre-incubated for 2 hours at 4C in supershift binding buffer (C and D) or in 
gel shift binding buffer (E) in the presence or absence of 2µg specific antibodies as 
indicated.  After this preincubation, 20,000-30,000cpm probe 4 was added and the mix 
was incubated for an additional 20 minutes at 10-15C.  The 20µL binding reactions were 
analyzed on 4% nondenaturing gels in 0.5X TBE. 
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Figure 3-13 USF1 binds the –317/-298 region of the hHL promoter and this binding 
is decreased with extracts from sterol mix- or compactin-treated cells 
Nuclear extracts were prepared from HepG2 cells treated for 48 hours in LPDS 
medium without (L) or with a mix of 10µg/mL cholesterol, 1µg/mL 25-OH-cholesterol 
and 5µg/mL 58-035 (S) or 37.5µM compactin (C).  (A and B) Nuclear extracts were 
incubated for 20 minutes at 10-15C in gel shift binding buffer with 30,000cpm probe 5 
(spanning the –317/-298 region of the hHL promoter) in the presence or absence of 
excess unlabelled specific (probe 5) or non-specific (NS) competitor.  The 20µL binding 
reactions were analyzed on a 4% nondenaturing gel in 0.5X TBE and the gel was exposed 
to a phosphorimager screen.  Quadruplicate reactions were run from nuclear extracts 
from treated or non-treated cells and the density of the shifts was quantified in panel B.  
(C) To allow antibody to antigen binding, nuclear extracts were pre-incubated for 3 hours 
at 4C in supershift binding buffer in the presence or absence of 2µg specific antibodies as 
indicated.  After this preincubation, 20,000cpm probe 5 was added and the mix was 
incubated for an additional 20 minutes at 10-15C.  The 20µL binding reactions were 
analyzed on a 4% nondenaturing gel in 0.5X TBE. 
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Figure 3-14: USF1 binds the –566/-546 region of the hHL promoter and this binding 
is unresponsive to sterol or compactin treatment 
Nuclear extracts were prepared from HepG2 cells treated for 48 hours in LPDS 
medium without (L) or with a mix of 10µg/mL cholesterol, 1µg/mL 25-OH-cholesterol 
and 5µg/mL 58-035 (S) or 37.5µM compactin (C).  (A and B) Nuclear extracts were 
incubated for 20 minutes at 10-15C in gel shift binding buffer with 30,000cpm probe 7 
(spanning the –566/-546 region of the hHL promoter) in the presence or absence of 
excess unlabelled specific (probe 7) or non-specific (NS) competitor.  The 20µL binding 
reactions were analyzed on a 4% nondenaturing gel in 0.5X TBE and the gel was exposed 
to a phosphorimager screen.  Quadruplicate reactions were run from nuclear extracts 
from treated or non-treated cells and the density of the shifts was quantified in panel B.   
(C and D) To allow antibody to antigen binding, nuclear extracts were pre-incubated for 
2 hours at 4C in supershift binding buffer (C) or in gel-shift binding buffer (D) in the 
presence or absence of 2µg specific antibodies as indicated.  After this preincubation, 
30,000cpm probe 7 was added and the mix was incubated for an additional 20 minutes at 
10-15C.  The 20µL binding reactions were analyzed on a 4% nondenaturing gel in 0.5X 
TBE.   
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Figure 3-15: Unidentified factor(s) bind the –595/-578 region of the hHL promoter 
Nuclear extracts were prepared from HepG2 cells treated for 48 hours in LPDS 
medium without (L) or with a mix of 10µg/mL cholesterol, 1µg/mL 25-OH-cholesterol 
and 5µg/mL 58-035 (S) or 37.5µM compactin (C).  (A and B): Nuclear extracts were 
incubated for 20 minutes at 10-15C in gel shift binding buffer with 20,000cpm probe 8 
(spanning the –595/-578 region of the hHL promoter) in the presence or absence of 
excess unlabelled specific (probe 8) or non-specific (NS) competitor.  The 20µL binding 
reactions were analyzed on a 4% nondenaturing gel in 0.5X TBE and the gel was exposed 
to a phosphorimager screen.  Quadruplicate reactions were run from nuclear extracts 
from treated or non-treated cells and the density of the shifts was quantified in panel B.  
(C, D and E): To  
allow antibody to antigen binding, nuclear extracts were pre-incubated for 2 hours at 4C 
in supershift binding buffer (C and D) or in gel-shift binding buffer (E) in the presence or 
absence of 2µg specific antibodies as indicated.  After this preincubation, 20,000-
30,000cpm probe 8 was added and the mix was incubated for an additional 20 minutes at 
10-15C.  The 20µL binding reactions were analyzed on a 4% nondenaturing gel in 0.5X 
TBE.   
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Figure 3-16 Unidentified factor(s) bind the –929/-906 region of the hHL promoter 
independently of sterol or compactin treatment 
Nuclear extracts were prepared from HepG2 cells treated for 48 hours in LPDS 
medium without (L) or with a mix of 10µg/mL cholesterol, 1µg/mL 25-OH-cholesterol 
and 5µg/mL 58-035 (S) or 37.5µM compactin (C).  (A and B) Nuclear extracts were 
incubated for 20 minutes at 10-15C in gel shift binding buffer with 30,000cpm probe 9 
(spanning the –929/-906 region of the hHL promoter) in the presence or absence of 
excess unlabelled specific (probe 9) or non-specific (NS) competitor.  The 20µL binding 
reactions were analyzed on a 4% nondenaturing gel in 0.5X TBE and the gel was exposed 
to a phosphorimager screen.  Quadruplicate reactions were run from nuclear extracts 
from treated or non-treated cells and the density of the shifts was quantified in panel B.  
(C) To allow antibody to antigen binding, nuclear extracts were pre-incubated for 3 hours 
at 4C in supershift binding buffer in the presence or absence of 2µg specific antibodies as 
indicated.  After this preincubation, 20,000cpm probe 9 was added and the mix was 
incubated for an additional 20 minutes at 10-15C.  The 20µL binding reactions were 
analyzed on a 4% nondenaturing gel in 0.5X TBE.  
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3.3.8 SREBP1 co-immunoprecipitation experiments 
In the absence of binding of SREBP to the HL promoter, we sought to determine 
whether SREBP could inhibit HL through binding to known (USF1, HNF1α) or putative 
(HNF4α) HL activators.   
We first attempted co-immunoprecipitation experiments using nuclear extracts 
prepared from HepG2 cells treated for 48 hours in LPDS medium without or with a mix 
of 10µg/mL cholesterol, 1µg/mL 25-OH-cholesterol and 5µg/mL 58-035 or 37.5µM 
compactin.  800µg nuclear extract were incubated for 1 hour at 4C in gel shift binding 
buffer (50mM KCl, 10mM HEPES, pH 7.9, 0.1mM EDTA, 2.5mM PMSF) with 
0.3µg/µL BSA and 8µg of rabbit IgG or of an antibody against USF1, HNF1α, or 
HNF4α.  50µL protein G- Sepharose 50% slurry was added for an overnight incubation at 
4C.  The next day, the beads were washed with 0.1% Nonidet-P-40 in PBS and the 
protein complexes were released in elution buffer (50mM Tris-base, 100mM NaCl, 1% 
Triton X-100, 0.3% CHAPS, 1% sodium deoxycholate, 10mM EDTA, pH 9.0) for 30 
minutes at 37C.  The eluates were concentrated on Microcon YM-30 concentrators, run 
on a 10% SDS-PAGE along with MagicMark XP Western Protein Standard, and 
transferred to PVDF Immobilon P membrane using semi dry transfer, before a western 
blot for SREBP1 was performed.  In these conditions (data not shown), with low 
endogenous levels of transcription factors, we were unable to detect an increase in co-
immunoprecipitated SREBP1 in nuclear extracts first immunoprecipitated with xUSF1, 
xHNF1α, or xHNF4α compared to nuclear extracts mock immunoprecipitated with rabbit 
IgG. 
Next, we decided to artificially increase the levels of transcription factors through 
transfection of either nSREBP1a alone, or nSREBP1a and USF1.  In this experiment, in 
order to monitor transfection efficiency, we transfected one set of cells in the same 
conditions as for transcription factors with pEGFP-N1, a mammalian expression vector 
for the green fluorescent protein (GFP).  Transfection efficiency with GFP vector was 
 108 
very low, with far less than 2% of cells expressing GFP.  Using nuclear extracts from 
cells transfected with nSREBP1a only, there was a high amount of noise on SREBP1 
Western blots after a mock immunoprecipitation with rabbit IgG.  This background noise 
prevented a conclusion to be drawn whether SREBP1 co-immunoprecipitated with USF1, 
HNF1α, or HNF4α (Figure 3-17).  However, when using nuclear extracts from cells co-
transfected with both nSREBP1a and USF1, it was clear that SREBP1a co-
immunoprecipitated with USF1 (Figure 3-17).  Thus, in overexpression experiments, we 
were able to show that SREBP1a can bind USF1, and possibly also HNF1α and HNF4α. 
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Figure 3-17 SREBP1 co-immunoprecipitates with USF1 in nSREBP1a and USF1 
transfected cells 
HepG2 cells were transfected with expression vectors for mature nSREBP1a (S) 
alone or in combination with USF1 (U), then were grown for 43 hours in complete 
medium before 15µg/mL N-acetyl-leucyl-leucyl-norleucinal (ALLN) was added to the 
growth medium for an additional 5-hour incubation.  Nuclear extracts were prepared, and 
for each immunoprecipitation, 5mg nuclear extract was incubated for 1 hour at 4C in 
binding buffer (10mM Tris, pH 7.4, 150mM NaCl, 0.1% Triton X-100, 2.5mM PMSF) 
with 0.3µg/µL BSA and 4µg antibody (either xUSF1, xHNF1α, or xHNF4α) or rabbit 
IgG.  80µL protein G- Sepharose 50% slurry was added for an overnight incubation at 
4C.  The next day, the beads were washed with 0.1% Nonidet-P-40 in PBS and the 
protein complexes were released in elution buffer (50mM Tris-base, 100mM NaCl, 1% 
Triton X-100, 0.3% CHAPS, 1% sodium deoxycholate, 10mM EDTA, pH 9.0) for 30 
minutes at 37C.  The eluates were concentrated on Microcon YM-30 concentrators, run 
on a 10% SDS-PAGE along with MagicMark XP Western Protein Standard, and 
transferred to PVDF Immobilon P membrane using semi dry transfer before a western 
blot for SREBP1 was performed.  Briefly, the membranes were blocked for 2 hours at RT 
in PBS-tween with 5% non-fat dry milk, incubated overnight at 4C in blocking buffer 
supplemented with 1µg/mL xSREBP1, rinsed and washed with PBS-tween, incubated for 
2 hours at RT in blocking buffer supplemented with anti rabbit-HRP conjugate, rinsed 
and washed with PBS-tween at 4-25C.  West Pico Reagents (Pierce) were used for 
revelation of the SREBP1 Western. 
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3.4 Discussion 
The data presented in this chapter showed that nSREBPs inhibit the transcription of 
the HL gene and could be mediating the downregulation of HL under conditions where 
cholesterol is elevated and/or cholesterol synthesis is inhibited.  Several activator binding 
sites within the hHL proximal promoter were identified through gel shift assays, but none 
for nSREBPs.  Co-immunoprecipitation experiments suggest that inhibition of 
transcription may occur through interaction of SREBP with positive effectors of HL 
transcription such as USF1. 
In parallel with the decrease in HL secreted protein mass and activity, rHL mRNA 
levels were decreased upon sterol treatment for 24 hours, and remained low over the 
second day of treatment (Figure 3-1).  In the case of mRNA levels however, rHL mRNA 
levels were found not to be changed over the first four hours of cholesterol repletion, but 
only decreased thereafter, to 80.1% and 49.0% of control levels at 24 and 48 hours 
respectively (Figure 3-2).  This timing difference suggests that the observed decrease in 
secreted HL reflects both an alteration of mRNA levels and regulation at the translational 
or post-translational level.  The cause for the decrease in mRNA levels was further 
investigated in this chapter.  The mechanism by which secretion of HL protein was 
decreased at stable mRNA levels was investigated in chapter 4. 
The decrease in steady-state HL mRNA levels after 24 or 48 hours of treatment could 
be due to a decrease in transcription and/or an increase in mRNA degradation.  Using 
actinomycin D to inhibit general transcription, we found that HL mRNA degradation rate 
was not changed (Figure 3-3), suggesting that the change in mRNA steady-state levels is 
instead due to a decrease in the transcription of the HL gene.  In order to try and delineate 
the promoter sequence responsible for a decrease in the transcription of the HL gene, we 
created a series of hHL promoter deletion constructs spanning the hHL promoter from -
1480bp to +14 and driving the expression of a luciferase reporter gene.  Under conditions 
where rHL mRNA is known to be repressed, we consistently found that sterols or 58-035, 
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an ACAT inhibitor, had no effects on the activity of any of the promoter constructs 
(Figure 3-4).  These sterol treatments were effective at downregulating mature nSREBP 
transcriptional activity as shown by a decrease in the promoter activity of the p-SRE-luc 
vector, which activity is driven by two SRE elements (Figure 3-5).  All the data presented 
thus far showed a downregulation of rat HL while we used a human HL sequence for 
promoter experiments.  Yet, this species variation was not expected to make a difference 
since hHL was previously reported to be repressed by mevalonic acid in HepG2 cells 
(74).  The reason why sterols had no effect on hHL promoter activity in our assay 
remains unclear.  Because direct transfection of nSREBP could decrease HL promoter 
activity, it is unlikely that our assay failed because of the lack of some HL promoter 
chromatin structure essential for repression.  It is possible that sterols indeed have no 
effect on this portion of the promoter.  However, this same portion of the promoter was 
found to be sensitive to nSREBP transfection in promoter activity assays, and using 
nuclear extracts from control or sterol treated cells in gel shift assays, we found that 
sterols affect the binding of some activators to probes within this region.  We know that 
total nSREBP activity was decreased in our assay, but we could not quantify the activity 
or levels of each isoform specifically.  nSREBP1a and 2 were both expected to decrease 
upon sterol addition, but the nSREBP1c isoform specifically should have increased (126).  
To which extent a decrease in 1a was balanced by an increase in 1c is unknown.  If such 
compensation could have blunted the effect on HL promoter activity levels, it is unclear 
why sterols could nonetheless decrease HL mRNA and secretion levels under the same 
treatment conditions. 
The pGL3 basic vector (without an inserted promoter) was previously found to have 
an E-box (5’-CGCGTG-3’) in between the MluI and NheI restriction sites (179) that 
binds to SREBP1a and 1c.  However, this problem was avoided in this study by cloning 
the hHL promoter fragments in between the Sac1 and XhoI sites, thereby deleting this E-
box in the series of constructs used for the study of promoter regulation.  Original 
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promoter activity assays with sterols (Figure 3-4) or nSREBP1a (Figure 3-7) treatments 
were done by normalizing firefly luciferase activity to renilla activity.  The pRL-TK 
vector expresses Renilla luciferase under the control of the herpes simplex virus 
thymidine kinase promoter.  This vector has been shown to vary upon treatment with 
adenoviral 12S E1A oncoprotein in Saos-2 cells (180) or dihydrotestosterone and 
dexamethasone in CV-1 cells (181), making it an inappropriate control for the study of 
these transcriptional regulators.  Because this internal control was sometimes markedly 
responsive to sterol treatments, we tried to switch to pHβAPr-1-βGal (a β galactosidase 
expression vector driven by the human β actin promoter (182), gift from Dr. E. Keller, 
data not shown), which also showed to be responsive to sterol treatment.  In the absence 
of an internal control which expression was not affected by the treatment, the promoter 
activity data was drawn from statistical analyses of un-normalized replicates in multiple 
experiments, yielding more reliable results.  After confirming the previous results in this 
manner, we performed later assays with nSREBP1a and USF (Figure 3-8 and Figure 3-9) 
or compactin (Figure 3-10) using firefly constructs only.   
Cholesterol is known to downregulate processing of SREBP1a and 2, which when 
mature activate genes involved in lipid metabolism by binding to SREs or SRE-like 
elements.  Unlike lipoprotein lipase (62), HL has never been shown to date to be under 
the direct control of SREBPs.  Yet, because HL expression is known to influence cell 
cholesterol levels, we sought to find out whether SREBP was involved in HL regulation 
as a part of its overall role in maintaining cholesterol cell homeostasis.  If cholesterol 
could modify rHL transcription through SREBP, the direct overexpression of this 
transcription factor would magnify that effect.  We failed to see a change in HL protein 
secretion 24 hours after nSREBP1a transfection in McA-RH7777 cells maintained in 
complete medium (data not shown).  In the same experiment, USF transfection, a known 
activator of HL (80)(76) also failed to upregulate HL secretion, which suggested that the 
sensitivity in this assay may be too low to detect a change even if present.  This is not a 
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surprising finding since transfection efficiency in hepatoma cells is very low (see 3.3.8) 
and most cells do not express the exogenous DNA.  In order to bypass potential post-
transcriptional regulation, we next examined mRNA and hHL promoter activity levels.  
Promoter activity assays in particular provide increased sensitivity since only transfected 
cells give a luminescence signal.  nSREBP1a transfection in McA-RH7777 decreased 
levels of rHL mRNA compared to mock-transfected control cells after 15 hours (Figure 
3-6).  Additionally, nSREBP was found to downregulate rHL mRNA in defatted medium 
with compactin, conditions where the nSREBP-induced increase in cholesterol 
biosynthesis and lipoprotein uptake was blocked.  Thus, the inhibitory effect of SREBP 
appeared to be independent of total cholesterol levels.  Overexpression of mature 
nSREBP1a in complete medium was found to strongly inhibit all deletion constructs in 
rat (Figure 3-7) or human hepatoma cells, including the shortest -117/+14 fragment.  
Sequences further upstream in the promoter may cooperate to potentiate the inhibition of 
transcription.  Compactin, which increased pSRE-luc activity by 4.7 fold in our 
experiments (Figure 3-10), also led to a decrease in HL mRNA and in the activity of the –
117/+14 hHL promoter fragment.  Further, statins also lead to a decrease in the secretion 
of HL mass.  Taken together, we found a consistent inverse relationship in between 
nSREBP levels and HL mRNA levels:  
• transfection of nSREBP1a was found to decrease HL RNA and promoter activity;  
• compactin, which increased nSREBP transcriptional activity, presumably through 
the SREBP1a and 2 isoforms, led to a decrease in HL RNA and promoter activity.  Of 
note, depletion of cholesterol in vivo with a bile acid resin and an HMG-CoA reductase 
inhibitor increased nSREBP2 but decreased nSREBP1 in the liver of mice and hamsters 
(128;183).  However, in McA cells, compactin only slightly decreased mature nSREBP1c 
levels (117) despite a selective decrease in SREBP1c mRNA and membrane protein due 
to the inhibition of oxysterol (LXR ligands) synthesis. 
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• treating cells with sterols, which strongly decreased total nSREBP transcriptional 
activity (Figure 3-5), is known to lead to a decrease in HL mRNA levels, but to an 
increase in nSREBP1c activity specifically.  Dietary cholesterol in mice led to a marked 
increase of hepatic SREBP1c expression through activation by oxysterol-activated 
LXR/RXR heterodimers without affecting SREBP1a or 2.  The increase in SREBP1c 
mRNA resulted in a similar increase in mature nSREBP1c and activation of its lipogenic 
gene targets (73;126).  SREBP1c transcription is induced by cholesterol and repressed by 
PUFAs.  Cholesterol could override the PUFA-induced decrease in SREBP1 mRNA, 
while PUFA could oppose the maturation of SREBP1c by cholesterol (184).  In our 
experiments, it is likely that PUFAs are absent (defatted medium) or highly limiting 
(LPDS medium), and as a consequence that nSREBP1c levels would have increased 
again after 12 hours of treatment (135).  Under this hypothesis, the decrease in nSREBP 
transcriptional activity may have mostly reflected a decrease in nSREBP1a and 2 which 
are the most active isoforms (121), and may have concealed an increase in total nSREBP 
mass due to increased nSREBP1c.  In this regard, it is of interest that primary hepatocytes 
as well as McA cells (but not HepG2 cells), have more endogenous SREBP1c than 1a 
(117;118). 
The results presented in this study differ sharply from the results of Busch et al. (74), 
who found that treating HepG2 cells for 48 hours with mevinolin in LPDS increased HL 
secreted activity and mRNA by 4.9 and 1.8 fold respectively.  Further, whereas a mix of 
cholesterol and 25-OH-cholesterol was found to inhibit HL expression in our studies, 
Busch et al. (74) found that 25-OH-cholesterol further increased HL expression when 
added together with mevinolin.  Thus, our studies do not concur with their hypothesis that 
sterols such as 25-OH-cholesterol regulate HL differentially than HMG CoA reductase.  
However, in accordance with our studies, statins (compactin or atorvastatin) have been 
shown to decrease HL secreted activity and mRNA levels in some studies (12;76).  
During the course of our studies, atorvastatin was found to abolish the oleate-induced 
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stimulation of HL in cultured hepatoma cells.  Oleate resulted in a 50% decrease in 
nSREBP activity while atorvastatin increased total nSREBP activity by 2.3 fold.  
nSREBP2 transfection was found to decrease HL promoter activity.  Both nSREBP2 
transfection and atorvastatin treatment were found to prevent the USF1-induced increase 
in HL activity of the shortest –305/+13 vector, in a similar way as presented here.  The 
authors suggested that SREBP might mediate the effects of atorvastatin and oleate on HL, 
possibly through interactions with USF1 (76).  Our studies directly confirm these results 
and further show that: 1) nSREBP-induced downregulation is not isoform dependent 
since nSREBP1a also decreased HL, 2) the USF1-mediated upregulation, and nSREBP-
mediated downregulation of HL promoter activity is effective on a hHL –117/+14 
promoter fragment, 3) nSREBP1 and USF1 can interact as shown by co-
immunoprecipitation experiments.  Together, our results also suggest that nSREBP-
mediated down-regulation might act through inhibition of USF1 or other HL activators. 
Currently, the few examples of gene downregulation by SREBPs to our knowledge 
involve either direct binding of SREBP to DNA (146-149), or indirect inhibition through 
binding to/ antagonizing other transcription factors such as Sp1, HNF4 or LRH1 (150-
152).  Analysis of the hHL proximal promoter failed to reveal the presence of an SRE.  
Conversely, several E-boxes are present in the HL promoter, which could potentially bind 
to either or both nSREBPs or USFs.  Because USF is a known activator of HL promoter 
activity (76;80), this suggested that SREBP could inhibit HL promoter activity by 
competing with USF for binding to the HL promoter.  Here, we found that transfection of 
USF1 or USF2 could activate human HL promoter activity through the shortest -117/+14 
HL promoter construct available (Figure 3-9), and that co-transfection of USF1 with 
increasing levels of nSREBP1a could reverse this activation in a dose-responsive fashion 
in rat or human hepatoma cells cultured in LPDS or complete medium (Figure 3-8, 
Figure 3-9).  This nSREBP-induced downregulation was mediated through an element 
within the –249 to +14 region, and possibly through the shorter -117/+14 sequence.   
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A dominant negative USF1 construct lacking the DNA binding domain could also 
activate HL promoter activity in LPDS medium, but not in complete medium.  This raises 
the possibility that the USF activation effect could partly result from the release of a low-
level SREBP inhibition of the HL promoter in cells at baseline in LPDS medium. 
Using gel-shift assays, we tried to identify factors that could mediate the response to 
USF and nSREBP transfection.  The choice of probes for gel-shift assays was guided by 
the presence of known DNase1 protected sites and/or the presence of putative binding 
sequences for known lipid/sterol responsive transcription factors (e.g. USF, nSREBP…). 
In gel shifts using nuclear extracts from control, compactin, or sterol-treated cells, we 
found no specific binding to the –14/+14 and –110/-95 regions of the hHL promoter, 
despite the fact that those regions covered known protected sites.  Therefore, we found no 
evidence that these regions were involved in sterol regulation.  We were able to confirm 
that HNF1α could bind to the –70/-48 region of the hHL promoter in supershift assays 
(Figure 3-11), and found that binding was inhibited by both sterols and compactin 
treatments.  Because binding of HNF1 to this proximal binding site is known to activate 
HL, inhibition of HNF1 binding could result in inhibition of transcription in both 
treatments, and this would explain the inhibition of –117/+14 hHL promoter activity in 
response to compactin treatment (Figure 3-10).  This suggests that sterol regulation of the 
hHL promoter within the –117/+14 region is mediated at least partially through the –66/-
52 HNF1 site, whereby sterol treatments could modulate the ability of HNF1 to bind and 
activate transcription of the HL gene. 
HNF4α was found to bind to the –252/-218 region of the hHL promoter, along with 
unidentified transcription factors.  Again, sterols and compactin treatments inhibited the 
binding of factors to this region, in particular that of HNF4α.  At the minimum one factor 
is known to bind this region since the area was covered in DNase1 protection assays.  
Assuming that binding of HNF4α and possibly other transcription factors in this region 
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could further activate HL transcription, inhibition of binding in response to both 
treatments could potentiate the inhibition of HL transcription. 
A single factor, identified as USF1, was found to bind to the –317/-298 region of the 
hHL promoter (Figure 3-13).  Gel shifts using nuclear extracts from control or treated 
cells showed both sterol and compactin treatments inhibit binding of USF1 to its response 
element.  USF1 is an activator of transcription, and absence of binding of USF1 to its 
response element would be expected to result in decreased transcription.  Of note, this 
region of the HL promoter was not identified as a protected site in neither of the two 
existing DNase1 protection studies (59;60). 
The –520/-509 region of the hHL promoter covers the –514 HL promoter 
polymorphism with its proposed functional USF site.  The common C-514T mutation 
disrupts a CACGGG USF functional binding site by lowering the affinity of USF to the 
element by 4 fold (80).  This region was not shifted in gel-shifts using nuclear extracts 
from either control or treated cells.  This does not support the proposed role of USF1 
binding in this region to modulate HL activity levels in human populations.  Functionally, 
there is a positive association between the CC patients (with an intact USF binding site) 
and higher HL activity levels (86).  However, the absence of a shift fits in with the fact 
that this region of the HL promoter was not identified as a protected site in neither of the 
two existing DNase1 protection studies (59;60). 
We identified one factor binding to the –566/-546 region of the hHL promoter as 
USF1.  Binding of factors to the –566/-546, –595/-578 or –929/-906 regions of the hHL 
promoter was not significantly changed upon sterols or compactin treatment compared to 
control cells (Figure 3-14, Figure 3-15, Figure 3-16).   
Of note, nSREBP1 had putative binding sites within probes 5 and 9, and Sp1 within 
probe 4, but neither SREBP1, SREBP2, nor Sp1 or Sp3 were found to bind to any of their 
putative binding sites within the hHL promoter.  The absence of direct binding of Sp1, 
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which commonly interacts with SREBP, further suggests that SREBP regulates the hHL 
promoter by a mechanism other than DNA binding to a response element.   
Without binding directly to the HL promoter, we sought to determine whether 
SREBP could inhibit HL through binding to known (USF1, HNF1α) or putative (HNF4α) 
HL activators.  Binding of SREBP1 to HNF4α has recently been shown to interfere with 
the HNF4α recruitment of peroxisome proliferator-activated receptor-γ coactivator 1 
(PGC-1), leading to a decrease in phosphoenolpyruvate carboxykinase (PEPCK) 
transcription (152).  In this case, HNF4α was shown to bind through its ligand 
binding/AF2 domain to the transactivation domain of SREBP1.  Similarly, direct 
interaction between SREBP2 and HNF4 was demonstrated by in vitro pull-down and in 
vivo co-immunoprecipitation experiments (185).  The mechanism for SREBP inhibition 
of HL could resemble this model, whereby SREBP binding to USF1, HNF1α and/or 
HNF4α would compete for recruitment of a coactivator, leading to a decrease in HL gene 
transcription.  In co-immunoprecipitation experiments using nuclear extracts prepared 
from control or sterol-treated HepG2 cells, we failed to detect a specific co-
immunoprecipitation of SREBP1 with either USF1, HNF1α, or HNF4α.  We reasoned 
that this may be due to lack of binding of these factors, or to low sensitivity in our assay 
where endogenous levels of transcription factors are extremely low.  When artificially 
increasing the levels of transcription factors through transfection of nSREBP1a alone or 
in combination with USF1, we were able to show that SREBP1a can bind to USF1 and 
possibly also to HNF1α and HNF4α (Figure 3-17).  Altogether, this suggests that the 
SREBP-induced decrease in the transcription of the HL gene could be due to interactions 
with these or other positive effectors of HL transcription. 
These studies provide evidence for a novel aspect of the function of SREBPs in the 
crosstalk between cholesterol and fatty acid/triglyceride metabolism (Figure 3-18).  
 
 119 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-18: Proposed model for the regulation of HL by SREBP in the presence or 
absence of cholesterol 
In the presence of cholesterol (upper panel), nuclear SREBP1a and 2 are repressed 
and sterol responsive element (SRE)-driven genes (shown on the left) are not activated.  
Oxysterol synthesis is activated, and as a result the LXR is activated by its oxysterol 
ligands.  Expression of the SREBP1c isoform, which requires LXR activation, is 
increased.  The maturation of SREBP1c can proceed in the absence of polyunsaturated 
fatty acids, resulting in increased levels of nSREBP1c.  nSREBP1c has a very low 
transcriptional activity on an SRE and therefore can not activate SRE-driven genes.  
However, the high levels of nSREBP1c in the liver can effectively repress HL expression 
by inhibiting some of its positive regulators (as shown on the right). 
In the absence of cholesterol (lower panel), SRE-driven genes (left) are activated by 
nSREBP1a and 2. SREBP1c transcription is repressed in the absence of LXR activation, 
and as a result nSREBP1c levels are low.  At low levels of total nSREBPs, HL is 
activated (right). 
While the proposed mechanisms are different, the end effects of the SREBP-mediated 
regulation of SRE-driven genes and HL would all be part of a feedback mechanism to 
maintain stable levels of cholesterol within the cell.  
Of note, other genes can be upregulated or downregulated by SREBPs through 
different mechanisms but are not shown on this simplified diagram. 
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Chapter 4 - Post-transcriptional regulation of HL by 
cholesterol 
 
4.1 Introduction 
As described in chapter 2, cholesterol decreases the secretion of hepatic lipase by 
cultured hepatoma cells.  Measured secreted rHL protein corresponds to enzyme that has 
been synthesized and secreted, minus the amount of enzyme that has been degraded post-
secretion.  Thus, an observed decrease in rHL secretion could be due either to decreased 
synthesis, increased pre-secretion degradation, decreased secretion, and/or increased 
post-secretion degradation.  All of the assays described above were done in the presence 
of 100U/mL heparin, a known inhibitor of rHL internalization from the cell surface and 
subsequent degradation (9), suggesting that post-secretion degradation was not involved 
in the observed down-regulation of rHL secretion.  In this chapter, we further 
investigated the role of cholesterol on the regulation of HL protein synthesis, protein 
degradation, and translation efficiency. 
4.2 Methods 
4.2.1 Reagents 
Please refer to chapters 2 and 3 for a list of commonly used reagents as well as tissue 
culture procedures.  Enlightning solution (Dupont NEN- #NEF-974) was used for 
fluorography to improve detection of 35S since fluor enhances the emission of the label.  
Cycloheximide (VWR CSPS1002) was prepared fresh as a 5mg/mL stock in water.   
4.2.2 Synthesis pulse protocol and immunoprecipitation with protein 
G for cholesterol experiment 
Confluent McA-RH7777 in 100mm collagen-coated dishes (one dish/sample) were 
preincubated for 4 hours with LPDS McA medium (Cab-O-Sil-treated serum) and then 
treated for 4 or 24 hours with LPDS McA medium with or without 5mM methyl-β-
cyclodextrin complexed at an 8:1 molar ratio with cholesterol.  The treatment medium 
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was aspirated and the cells were rinsed twice with methionine- and cysteine-free DMEM.  
The cells were then fed 5mL/dish methionine-, cysteine-free DMEM supplemented with 
100 (4 hours) or 87.5µCi/mL (24 hours) respectively of Tran-35S-label (70% L-Met, 15% 
L-Cys, and various non-labeled amino acids, ICN Biomedicals), and incubated at 37C for 
a 20-minute pulse.  During this short period, degradation was assumed to be insignificant.  
After 20 minutes the medium was aspirated and the cells were rinsed twice with ice-cold 
PBS before being harvested on ice in RIPA lysis buffer (50mM Tris-HCl, 1% NP-40, 
0.5% sodium deoxycholate, 0.1% SDS, 0.15M NaCl, 10U/mL heparin, 1mM methionine, 
pH 8.0, supplemented with freshly added protease inhibitors: 1µg/mL leupeptin, 1µg/mL 
antipain, 10µg/mL benzamidine, 10KIU/mL trasylol from 1000X stock in trasylol 
solvent, and 1µg/mL chymostatin, 1µg/mL pepstatin from 1000X stock in DMSO).  The 
lysates were sonicated at 100W for 20 seconds twice, aliquots were removed for TCA-
precipitable counts determination (see 4.2.3), and the remaining lysate was centrifuged 
for 30 minutes at 25,000rpm in a 40.3 rotor at 4C.  The supernatant was used to 
immunoprecipitate rHL using a protocol modified from Doolittle et al.(2).  To each 
supernatant, concentrated BSA was added to a final concentration of 0.1%, and 10µg 
polyclonal anti-rHL antibody was added to cell lysate from a 100mm dish.  The 
immunoprecipitation mixtures were incubated overnight at 4C.  40µL or 100µL of a 50% 
suspension of protein G-Sepharose was added to lysate from a 100mm dish starting 
material and the lysate was incubated for 2 hours.  The beads were centrifuged at 8,200g 
for 5 minutes.  The supernatant was discarded and the beads were transferred 
quantitatively to new tubes, then washed once with RIPA buffer and around 9 times with 
fresh 0.1% N-lauroyl-sarcosine-sodium salt in PBS.  After the last wash, the beads were 
resuspended in 2X Laemmli buffer and boiled to release the immunoprecipitated rHL.  
An equal amount of TCA-precipitable counts was loaded and ran on the 10% SDS gel.  
The gel was fixed in 30% methanol, 10% acetic acid for 1 hour or more, was incubated 
for 20 minutes in Enlightning for fluorography, and was dried for 2 hours using a slow-
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temperature-increase (up to 80C) cycle on a BioRad gel dryer.  The intensity of the rHL 
band was quantitated using a phosphorimager and/or determined by scintillation counting 
after the band was excised from the gel and dissolved in H2O2. 
4.2.3 Determination of 35S incorporation in TCA precipitable fraction 
This procedure consists of precipitating proteins with trichloro-acetic acid (TCA) as a 
means to monitor the incorporation of radioactivity into total cellular proteins.  It was 
adapted from Miller and Carrino (186).  5µL/tube aliquots of each cell lysate (after 
sonication but before centrifugation) or blank lysis buffer were aliquoted into tubes 
containing 0.9mL of 0.11mg/mL ELISA-grade BSA (used as a carrier protein) and 
1.1mM L-methionine.  100% TCA (0.1mL/tube) was added to reach a final TCA 
concentration of 10%, and the tubes were chilled on ice anywhere from 30 minutes to 
overnight.  Following a 10-15 minutes centrifugation at 13,000 rpm, at 4C, the 
supernatant was removed and the pellet was redissolved in 75µL 0.1M NaOH.  1mL of 
10% TCA was then added for a second round of precipitation, and the mixture was 
chilled and spun again.  The supernatant was carefully removed.  A second pulse-spin 
helped removing any remaining acid that would neutralize the base in the next step.  The 
pellet was then redissolved in 200-300µL 0.1M NaOH (as little as possible to avoid 
quenching).  Following these two precipitations the solubilized protein was quantitatively 
transferred to scintillation vials filled with 10mL scintillation fluid rinsing the tubes three 
times with 150µL dH2O, and counted. 
4.2.4 Synthesis experiment and immunoprecipitation with xrHL 
immunobeads for ACAT inhibitor experiment 
In an attempt to improve immunoprecipitation conditions and decrease the amount of 
bands after immunoprecipitation with an anti-rHL polyclonal antibody, a different 
protocol was used when the synthesis assay was repeated with an ACAT inhibitor 
treatment, as described here. 
 124 
4.2.4.1 Conjugation of xrHL to immunobeads 
5mg of anti-rHL polyclonal antibody was used with activated Immunobead matrix 
(Irvine Scientific) to prepare anti rHL-conjugated immunobeads according to the 
manufacturer’s instructions.  Briefly, the antibody was dialyzed overnight at 4C against 
0.003M phosphate, pH 6.3 (coupling buffer).  The next day, the Immunobead matrix was 
rehydrated with dH2O to reach a 10mg/mL suspension in 0.003M phosphate, 0.01%NaN3, 
pH 6.3.  For conjugation, 10mL matrix was transferred to a 50mL Falcon tube, to which 
40mL of coupling buffer was mixed in.  The beads were spun down at 1,500g for 10 
minutes at 4C, and the supernatant was decanted immediately after the end of the spin.  
This wash was repeated once by adding a few milliliters of buffer at first, vortexing to 
resuspend the beads, and then filling the tubes up to maximum capacity.  The beads were 
finally resuspended in around 3mL coupling buffer.  The dialyzed antibody was then 
added to the beads and the volume was adjusted to 10mL with coupling buffer.  This 
mixture was incubated for 1 hour at 4C before 20mg EDAC (1-ethyl-3-[3-
dimethylaminopropyl] carbodilmide-HCl) was added and thoroughly mixed in.  The 
mixture was then incubated for 3 hours at 4C.  The material was divided into two 50mL 
Falcons and submitted to a series of washes with ice-cold buffers in a similar fashion as 
described above, first with PBS, then with 1.4M NaCl-PBS twice, then again with PBS 
twice.  Finally, the beads were resuspended in PBS and incubated for 3.5 hours at 4C to 
renature the antibody.  The beads were then spun down and resuspended in 0.005M 
phosphate, pH 7.2, pooled, and washed twice with this buffer before being resuspended 
in 10mL final volume 0.005M phosphate, pH 7.2, 1% BSA.  NaN3 was added to a final 
concentration of 0.02% for storage at 4C. 
4.2.4.2 Synthesis pulse protocol for ACAT inhibitor experiment 
The overall procedure was taken from Cisar et al. (21), with a modification in lysis 
buffer (13).  The cell culture medium from 100mm dishes of Fu5AH cells (pools of 2 
dishes per sample) was aspirated at timed intervals, and the cells were rinsed twice with 
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warm methionine- and cysteine-free DMEM (M,C-free DMEM).  The cells were then 
incubated for 10 minutes at 37C, 10% CO2 in M,C-free DMEM before this medium was 
aspirated off carefully.  5mL/dish of warm M,C-free DMEM supplemented with 
75µCi/mL Tran-35S-label (70% L-Met, 15% L-Cys, and various non-labeled amino acids 
-ICN Biomedicals) was added and the dishes were placed at 37C in the incubator for 15 
minutes.  Note that normally under these labeling conditions cell lysate rHL can be 
immunoprecipitated and detected after a pulse of 5 minutes only.  Following the pulse, 
the medium was aspirated, the dishes were rinsed twice with ice-cold PBS and were 
placed on ice from now on.  Each pool of 2 dishes was harvested with a plastic disposable 
rubber policeman in 2.5mL (1+1.5mL) lysis buffer (1% Triton X-100, 1% deoxycholate, 
10mM Tris-HCl, pH 7.4, supplemented with freshly added 1µg/mL leupeptin, 1µg/mL 
antipain, 10µg/mL benzamidine, 10KIU/mL trasylol, 1µg/mL chymostatin, 1µg/mL 
pepstatin, 1µM PMSF).  The lysates were transferred to 6mL tubes for the 40.3 Beckman 
rotor and sonicated at 100W for 20 seconds twice (using a Braun-sonic 1510 probe 
sonicator equipped with a 4mm diameter microprobe).  At this point, 35µl and 5µl 
aliquots were removed and stored at 4C or -20C for DNA assay or TCA precipitation (see 
4.2.3) respectively.  Lysates were centrifuged for 30 minutes to one hour at 30,000 rpm, 
4C, in the Beckman L8-80 ultracentrifuge (40.3 rotor).  The supernatants, including the 
diffuse fat layers, were transferred to 15mL Falcon tubes for immunoprecipitation.   
4.2.4.3 Immunoprecipitation of rHL with immunobeads 
rHL from cell extracts was immunoprecipitated using 2 successive incubations with 
the anti-rHL-conjugated immunobeads (21) as described below.  Immediately after the 
spin following the pulse experiment, 1µg/mL leupeptin, 1µg/mL antipain, 10µg/mL 
benzamidine, 10KIU/mL trasylol, 1µg/mL chymostatin, 1µg/mL pepstatin from 1000X 
stocks were added to the cell lysate dilution buffer (1% Triton X-100, 0.15M NaCl, 5mM 
EDTA, 15U/mL heparin, 50mM Tris-HCl, pH7.5), and the cell extract were diluted with 
2 volumes of cell lysate dilution buffer.  rHL antibody-conjugated immunobeads were 
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equilibrated with PBS to eliminate any remnant azide, then 150µL of immunobeads was 
added to each lysate tube, and the immunoprecipitation mixtures were incubated 
overnight on a rotating shaker at 4C.  Tubes were spun at 16,100g for 3 minutes and set 
on ice.  The supernatant was pipeted out.  The beads were then transferred to new 1.5mL 
screw cap tubes (using a P1000 without allowing air bubbles) with 0.8mL buffer A (1M 
NaCl, 0.2% Triton X-100, 10mM Tris-HCl, pH 7.4).  The original tubes were rinsed with 
500µL wash buffer A to finish washing the tubes and transfer the beads quantitatively.  
From now on, tubes were placed on ice.  Tubes were spun down 3 minutes to pellet, then 
the beads were washed with 1mL buffer B (0.15M NaCl, 10mM Tris-HCl, pH 7.4), 
vortexed briefly and incubated with gentle mixing for 5 minutes.  For elution, the 
antibody complexes were released from the beads by heating at 54C in 75µL of 2% SDS 
for 1 hour, and then again in 25µL of 2% SDS for 10 minutes.  The tubes were spun 
down each time and the supernatants containing the released lipase were pooled.  The 
beads were then washed with 1mL cell lysate dilution buffer and the supernatants were 
again combined with that of the SDS releases.  Final SDS concentration in the samples 
was adjusted to ~0.06% (or lower) using cell lysate dilution buffer before a fresh 150µL 
of rHL antibody-conjugated immunobeads was added to each tube.  The 
immunoprecipitation mixtures were incubated overnight at 4C with gentle shaking.  The 
beads were pelleted by centrigugation, the supernatants were aspirated off and the beads 
were transferred to new tubes in 1.3mL buffer A.  The beads were then incubated in 
buffer A for 1 hour at 4C.  Without interruption the beads were successively washed with 
1mL buffer A, 1mL buffer C (1M NaCl, 10mM Tris-HCl, pH 7.4), 1mL buffer B, twice 
with 1mL buffer D (1% Triton X-100, 0.15M NaCl, 1% sodium deoxycholate, 10mM 
Tris-HCl, pH 7.4), 1mL buffer B, 1mL buffer E (1M NaCl, 0.1% BSA, 10mM Tris-HCl, 
pH 7.4), and 1mL buffer B.  For elution, 85µL 2X-Laemmli buffer was added (20% 
glycerol, 4% w/v SDS, 125mM Tris, 0.0025% w/v bromophenol blue, supplemented with 
fresh 10% v/v β-mercaptoethanol).  The immunoprecipitated rHL was released from the 
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beads by heating at 95C for 6 minutes in a heating block and spun down at 10,000rcf for 
6 minutes.  The supernatants were transferred and a second spin was done to recover all 
of the supernatant.  The entire supernatants were resolved on a 10% polyacrylamide gel 
under denaturing conditions (1% SDS in the running buffer) using a 14C standard (Sigma 
CFA756) as a marker.  The gel was fixed in 30% methanol, 10% acetic acid for 1 hour or 
more, incubated for 10-30 minutes in 50% methanol, then for 15-30 minutes in 
Enlightning solution at room temperature.  The gel was then dried on the gel dryer (BIO-
RAD Model 583) using a 2 hour slow temperature increase cycle up to 80C, and exposed 
to a Cyclone SR screen for 3 hours or to Kodak X-OMAT AR film at –80C for 6 days. 
4.2.5 Preparation of cytoplasmic cell extract 
This protocol is adapted from Yukht et al. (187) itself adapted from an original 
protocol by Walden et al. (188).  All buffers were prepared in RNase free conditions.  β–
mercaptoethanol was always added fresh immediately prior to use.  The entire procedure 
was achieved in one day without delay, at 0-4C using pre-chilled buffers and equipment.  
For each condition, seven 100mm dishes of cells were grown and treated as indicated.  
After treatment, the cells were washed with ice-cold PBS.  Cells were scraped in fresh 
PBS (2mL/dish) and pooled for each treatment in a 15mL graduated conical centrifuge 
tube.  Cells were pelleted by centrifuging for 10 minutes at 3,000rpm, the supernatants 
were discarded, and the packed cell volume (pvc) was measured using the graduations on 
the tube.  The pvc was resuspended in lysis buffer (50mM Tris-HCl, 35mM KCl, 10mM 
MgCl2, 250mM sucrose, 0.5mM EDTA, pH 7.4, 7mM β-mercaptoethanol) to a final 
volume of 3 times the original pvc.  Cells were allowed to swell on ice for 10 minutes 
and were homogenized in a homogenizer (type B pestle) with ten up and down strokes on 
ice.  Cells were transferred to eppendorf tubes, and mitochondria and nuclei were pelleted 
by spinning at 10,000g for 15 minutes.  The supernatants were spun at 100,000g 
(37,000rpm) for 2 hours in the ultracentrifuge (SW65Ti rotor).  Solid ammonium sulfate 
was added to the cytosolic S-100 (high speed supernatant) fractions to 60% saturation 
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(36.1g ammonium sulfate/ 100mL) and the proteins were precipitated for 30 minutes on 
ice.  Precipitated proteins were collected by centrifuging at 6,000g for 10 minutes in 
eppendorf tubes and the pellets were redissolved in 300µL resuspension buffer (20mM 
Tris-HCl, 20mM KCl, 10% glycerol, pH 7.4, 7mM β-mercaptoethanol) (189).  The 
cytoplasmic cell extracts were aliquoted in tubes, snap frozen, and stored at -80C.  
Protein concentration was determined by Lowry after DOC/TCA precipitation, using 
BSA as a standard (See 3.2.8).  Average yield was ~1mg protein/pool of seven dishes. 
4.2.6 Preparation of a human HL transcript 
The prK5-hHL human HL cDNA expression plasmid, where the hHL cDNA is 
inserted in between the Not1 and HindIII sites (gift from Dr. Chang SF), was amplified 
and purified using a Qiagen midiprep, and was finally resuspend in TE (10mM Tris, pH 
8.0, 1mM EDTA).  Because plasmid purification with this kit yields plasmid 
contaminated with RNase A, the plasmid was further treated with 200µg/mL proteinase 
K for 30 minutes at 55C in 0.5% SDS, 0.1M NaCl, 10mM Tris, pH 8.0, 1mM EDTA.  
Subsequently, the plasmid was submitted to one round of phenol/chloroform extraction.  
Briefly, an equal volume of phenol/chloroform/isoamyl alcohol (25:24:1 v/v/v – from 
EM) was added to the DNA to be purified, the mix was vortexed vigorously for 10 
seconds, and spun down for 2 minutes at top speed at room temperature.  The top 
aqueous phase containing the DNA was transferred to a new tube and extracted with an 
equal volume of chloroform 24:1 isoamyl alcohol using the same procedure as before.  
The DNA was then precipitated at –80C for at least 15 minutes with 1/10th volume of 
RNase-free 5M ammonium acetate and 2 volumes of 100% ice-cold ethanol.  The DNA 
was pelleted by spinning for 5 minutes at top speed, air-dried, and resuspended in 
RNAse-free water at a final concentration of 0.5 to 1mg/mL.  The vector was linearized 
overnight at 37C by digestion with HindIII, and complete linearization was checked on 
agarose gel.  HindIII cut at the very 3’end of the hHL cDNA, right upstream of the 
plasmid polyA signal, leaving a 5’ overhang that does not interfere with phage RNA 
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polymerases.  After linearization, the reaction was terminated by addition of 1/20th 
volume of 0.5M EDTA, 1/10th volume of 5M ammonium acetate, and 2 volumes of 
ethanol.  The mix was chilled at –80C for at least 15 minutes, and the precipitated DNA 
was pelleted by spinning at top speed, 4C, for 15 minutes, before being resuspended in 
RNase-free H2O at a concentration of 0.5-1µg/µL.  RNA was in vitro transcribed from 
this linearized DNA using the Maxiscript SP6 Kit (Ambion).  Sense RNA was generated 
using SP6 RNA polymerase according to the kit’s instructions, extracted with phenol 
chloroform as described above to get rid of DNase1 and other proteins, resuspended in 
40µL RNase-free water, and stored in 5µL aliquots at –70°C.   
4.2.7 In vitro translation experiments 
In vitro translation reactions were carried out using the rabbit reticulocyte lysate 
system, nuclease-treated (Promega L4960) according to the manufacturer’s instructions.  
All reagents were allowed to thaw slowly on ice.  The template mRNA was denatured at 
65°C for 3 minutes and immediately cooled in an ice-water bath.  Redivue™ L-
[35S]methionine (1,200Ci/mmol at 10mCi/mL, Amersham Pharmacia, Cat.# AG1094) 
was used as a source of labeled amino acid.  The 50µL reactions were assembled in 
0.5mL polypropylene RNase-free microcentrifuge tubes and the translation reactions 
were immediately incubated at 30°C for the length of time indicated.  Reactions 
contained 70% Rabbit Reticulocyte Lysate, 20µM Amino Acid Mixture without 
methionine, [35S]methionine at 0.4µCi/µL, RNasin® Ribonuclease Inhibitor (Promega 
N2111) at 0.8U/µL, with or without 0.1µg hHL mRNA or 1µg luciferase mRNA 
template, and with or without 0.1µg cytoplasmic extract (or cytoplasmic extract buffer as 
a control).  The reactions could also be scaled down by half in 25µL final.  After the 
incubations, aliquots of the reactions (25µL for hHL reactions, 3µl for luciferase control 
reactions) were mixed with 50µL of 2X Laemmli gel loading buffer, the mixes were 
boiled for 3 minutes, and the results of the translation reactions were analyzed on a 10% 
SDS-PAGE.  The gel was fixed in 50% methanol, 10% acetic acid for 1 hour or more, 
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soaked 5 minutes in a mixture of 7% acetic acid, 7% methanol, 1% glycerol to prevent it 
from cracking during drying, then in Enlightning for 15-30 minutes for fluorography, and 
was dried for 2 hours using a slow-temperature-increase (up to 80C) cycle on a BioRad 
gel dryer.  The dried gel was subsequently exposed to a Cyclone screen and analyzed by 
phosphorimaging. 
4.3 Results 
4.3.1 Decreased rHL protein synthesis upon cholesterol or 58-035 
treatment 
In order to conclusively show that the observed decrease in rHL secretion could be 
explained by a decrease in protein synthesis, a 20-minute pulse experiment with labeled 
sulfur-amino acids was performed.  In absolute amount of label incorporation per dish of 
cells, cholesterol-treated cells incorporated 70.4% (p<0.05) and 46.9% (p<0.02) of 
control-incorporated label in hepatic lipase protein at 4 and 24 hours respectively.  
Relative to total TCA precipitable counts, the 35S label incorporated in hepatic lipase 
protein was decreased to 74.8% and 57.4% (p<0.02) of control cells in cells treated with 
cholesterol for 4 or 24 hours respectively (Figure 4-1).  Statistical analysis was done 
using Student’s 2-tailed unpaired t-test.  Thus, rHL protein de novo biosynthesis was 
decreased in cholesterol-treated cells compared with control cells in LPDS medium. 
This result was confirmed using a 24-hour ACAT inhibitor treatment as a means of 
increasing intracellular free cholesterol concentration at a stable level of total cholesterol.  
ACAT inhibitor decreased rHL de novo synthesis relative to total precipitable protein to 
66% of control (Figure 4-2).  Of note, this assay was done using a different 
immunoprecipitation protocol and the double immunoprecipitation technique did 
successfully diminish the number of non-specific bands. 
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Figure 4-1 rHL protein synthesis is decreased upon cholesterol treatment 
McA-RH7777 cells were split into 100mm collagen-coated dishes.  At confluency, 
the cells were maintained in 7mL/dish LPDS McA medium (20% horse LPDS, 5% fetal 
bovine LPDS prepared by the Cab-O-Sil method, 2mM L-glutamine in MEM, pH 7.4).  
After four hours the medium was aspirated and replaced by 7mL/dish control LPDS McA 
medium (L) or LPDS McA medium containing 5mM methyl-β-cyclodextrin complexed 
at an 8:1 molar ratio with cholesterol (C).  After 4 or 24 hours, the media were aspirated 
and the cells were submitted to a 20 minutes pulse with Tran-35S-label.  After the pulse, 
the lysates were sonicated and aliquots were removed for TCA-precipitable counts 
determination.  The remaining lysates were immunoprecipitated with polyclonal anti-rHL 
antibody.  Equal amounts of TCA-precipitable counts were loaded on 10% SDS-gels for 
cells treated for 4 hours (Panel A) and 24 hours (Panel B) respectively and the results 
were quantified (Panel C).  Indicated values are relative to control at the respective time-
point.  Statistical analysis was done using Student’s two-tailed unpaired t-test. 
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Figure 4-2 rHL protein synthesis is decreased upon 58-035 treatment 
 Fu5AH cells were treated with LPDS medium (10% LPDS, 2mM L-Glutamine in 
MEM) with DMSO as a carrier control (control) or 5µg/mL 58-035 (ACAT inhibitor).  
After 24 hours, cells were pulsed for 15 minutes in 75µCi Tran-35S-label /mL 
methionine- and cysteine-free DMEM.  After the pulse, the lysates were sonicated, spun 
down, and the supernatant was immunoprecipitated with rHL-conjugated Immunobeads.  
The released lipase was run on a 10% SDS-PAGE and the gel was exposed to a Cyclone 
SR screen (Panel A).  Quantification of total newly synthesized rHL was done by 
densitometry and hepatic lipase protein synthesis is reported relative to total TCA 
precipitable counts (Panel B). 
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4.3.2 rHL protein degradation upon cholesterol treatment 
In order to rule out any sterol regulation of HL at the level of internalization and 
overall protein degradation, the disappearance of rHL in cells and medium upon 
treatment with cholesterol was monitored in the presence of 5µg/mL cycloheximide.  
Cholesterol was delivered in the form of methyl-β-cyclodextrin complexed to cholesterol 
(Figure 4-3).   
When looking at the sum of cell-associated and secreted HL (Figure 4-3), cholesterol 
decreased total rHL mass slightly in the absence of cycloheximide.  However, in the 
presence of cycloheximide, there was no difference in total rHL mass upon cholesterol 
treatment over the course of the experiment, suggesting that protein degradation was not 
affected.  Because the experiment was done in the absence of heparin, this would further 
suggest that re-internalization of HL from the cell surface was not affected by cholesterol 
treatment.   
These findings were replicated twice in Fu5AH cells using a sterol mixture 
(cholesterol and 25-OH-cholesterol) or an ACAT inhibitor treatment as a means to 
increase cell free cholesterol levels (data not shown).  Overall, the results suggest that an 
increase in free cholesterol within the cell does not affect overall rHL protein turnover 
(internalization and degradation). 
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Figure 4-3 rHL protein degradation rate is not affected by cholesterol in McA-
RH7777 cells 
McA-RH7777 cells were split into collagen-coated 35mm dishes.  At confluency, two 
hours before treatment addition, the medium was pre-cleared with Cab-O-Sil-treated 
LPDS McA medium.  At time 0 hour, the cells were treated in LPDS medium without 
(LPDS) or with 5mM methyl-β-cyclodextrin complexed at an 8:1 molar ratio to 
cholesterol (cholesterol).  When indicated, 5µg/mL cycloheximide (CHX) was also 
included in the original treatment (at 0hr).  At the end of the incubation period, medium 
and cells were collected, and assayed for secreted rHL, or cell-associated rHL 
respectively.  Data is presented either as the sum of cell-associated and secreted HL (top 
panel) to monitor overall protein degradation rate, or each is presented individually 
(lower panels).  Average +/- SD are shown, with n=3.  This experiment is representative 
of three independent experiments. 
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4.3.3 Cytoplasmic extract from sterol-treated cells decreases HL 
translation efficiency in IVT assays 
After a four-hour cholesterol treatment, mRNA levels were not altered (see chapter 3) 
but de novo protein synthesis of rHL was already decreased, suggesting that cholesterol 
inhibits rHL at the translational level.  At a similar level of mRNA, rHL RNA could be 
subject to editing such as translation efficiency would be decreased.  Alternatively, if 
mRNA was unaltered, rHL translation initiation, elongation, or termination could be 
altered due to specific binding of a factor to the mRNA.  In order to test whether an 
inhibitory factor was present, we isolated cytoplasmic extracts from cholesterol-treated or 
control cells and used these extracts in in vitro translation reactions using in vitro 
transcribed hHL RNA as a template.  A luciferase RNA transcript was also used as a 
negative control to check for treatment specificity. 
Preliminary assays were conducted to optimize assay conditions.  First, a titration of 
hHL mRNA transcript from 0.001µg to 0.5µg was conducted in a 90-minute reaction.  
This experiment (data not shown) was used to determine the optimal amount of mRNA 
substrate for the IVT reaction (0.1µg).  Second, a time-course of in vitro translation 
reactions was performed with incubation times from 10 to 90 minutes.  From this assay 
(data not shown), it was shown that a 10 minute reaction was enough to observe a 
product, and that by 20 minutes, the incubation time chosen for subsequent assays, the 
bands were both intense and within linear range of product formation.  After 30 minutes, 
the rate of product formation decreased and therefore it became impossible to quantify 
the HL protein synthesis rate upon sterol treatment. 
A typical gel for an IVT assay is presented in Figure 4-4.  A negative control reaction 
containing no mRNA allowed for measurement of background incorporation of labeled 
amino acids, which was not detectable in the range of HL molecular weight.  A positive 
control reaction using luciferase mRNA as a template (Promega) was also included.   
Finally, three reactions with hHL mRNA as a template were performed, one with no 
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extract, one with control extract, and one with extract from cells treated for 4 hours with 
5mM methyl-β-cyclodextrins complexed at an 8:1 molar ratio to cholesterol.  The 
molecular weight of the hHL translation reaction products was checked by graphing the 
ratio of the distance from the well to the band to the distance from the well to the dye 
front as a function of the natural logarithm of the size of the protein molecular weight in 
Daltons.  Using this equation, the size of the observed translated bands was estimated to 
be at 55.83kDa for the major band, and 49.02 and 46.00kDa for the two minor bands.  
Thus, the size of the major band was in very good agreement with the expected size of 
the hHL protein of 55.88kDa as determined by its protein sequence.  The two minor 
bands are most probably hHL synthesis intermediates or hHL degradation products, since 
in independent synthesis experiments where HL was immunoprecipitated, bands 
corresponding to the same sizes were also observed (Figure 4-1).  From the present 
experiment, it appeared that extracts from control cells did not affect protein synthesis 
rate, whereas extracts from cholesterol-treated cells decreased the translation rate of hHL.   
The next assay was designed to quantify the inhibitory effect of sterols on HL 
translation efficiency.  Fu5AH cells were treated for 24 hours with a mix of sterols and an 
ACAT inhibitor, or with LPDS medium as a control before cytoplasmic extracts were 
isolated.  The in vitro translation reaction incubation time was set at 20 minutes, within 
the linear range of HL product formation.  Under these conditions, it was found that 
increasing amounts of extract from sterol-treated cells decreased HL translation 
efficiency in a dose-dependent fashion, down to 47% of control in the presence of 1µg 
extract (Figure 4-5).  In the same experiment, 0.5µg extract from control or treated cells 
did not affect the translation efficiency of a luciferase positive control transcript. 
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Figure 4-4 Cytoplasmic extract from cholesterol-treated cells decreases hHL 
translation efficiency 
McA-RH7777 cells were split into collagen-coated 100mm dishes.  After 24 hours, 
upon confluency, cells were placed on LPDS McA medium (where the LPDS was 
prepared by the Cab-O-Sil method) for 4 hours.  After this pre-incubation, cells were 
placed on control LPDS McA medium (L) or LPDS McA medium containing 5mM 
methyl-β-cyclodextrin complexed at an 8:1 molar ratio with cholesterol (C) for 4 hours.  
After this treatment, the cells were rinsed with PBS and were immediately used for 
isolation of cytoplasmic cell extract.  In vitro translation reactions were carried out using 
the rabbit reticulocyte lysate system in the presence of L-[35S]methionine, RNasin®,  
0.1µg hHL or 1µg luciferase mRNA, and with or without 0.1µg cytoplasmic extract (or 
cytoplasmic extract buffer as a control).  The reactions were immediately incubated at 
30°C for 90 minutes and the results of the translation reactions were analyzed on a 10% 
SDS-PAGE.  The dried gel was exposed to a Cyclone screen and analyzed by 
phosphorimaging. 
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Figure 4-5 Cytoplasmic extract from sterol-treated cells decreases hHL translation 
efficiency in a dose-dependent manner 
Fu5AH cells were split into 100mm dishes.  After 24 hours, upon confluency, cells 
were placed on LPDS medium (10% LPDS prepared by the centrifugation method, 2mM 
L-glutamine in MEM) as control (L) or LPDS medium supplemented with 10µg/mL 
cholesterol, 1µg/mL 25-hydroxycholesterol, and 5µg/mL ACAT inhibitor 58-035 (S) for 
24 hours.  Cytoplasmic cell extracts were isolated immediately after this treatment.  In 
vitro translation reactions were carried out using the rabbit reticulocyte lysate system in 
the presence of L-[35S]methionine, RNasin®, hHL or luciferase mRNA, and increasing 
amounts of cytoplasmic extract (or cytoplasmic extract buffer (B)).  The reactions were 
immediately incubated at 30°C for 20 minutes and the results of the translation reactions 
were analyzed on a 10% SDS-PAGE (Panel A).  The results of this and an independent 
experiment were quantified, averaged, and are presented in panel B. 
B. 
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4.4 Discussion 
As was discussed in chapters 2 and 3, a four-hour treatment with cholesterol 
decreased rHL secretion levels at stable mRNA levels.  In this chapter, we sought to 
explain the observed decrease in rHL secretion.  A 15-20 minutes pulse experiment in the 
presence of 35S methionine confirmed that after a four or twenty-four hour treatment with 
cholesterol, rHL de novo synthesis was decreased.  Additionally, treatment with an 
ACAT inhibitor could also decrease rHL synthesis, suggesting that free cholesterol 
within the cell, and not total cholesterol, is the trigger for the effect. 
Next, we sought to confirm that cholesterol had no effect on HL protein degradation.   
As discussed previously, HL secretion experiments were done in the presence of 
heparin, which prevents HL internalization and subsequent degradation.  These 
experiments suggested that cholesterol downregulation was not due to post-secretion 
degradation.  However, one could not rule out that degradation could occur after protein 
synthesis but before secretion.  In the present experiments, total rHL protein levels 
(intracellular, cell-associated and secreted protein) were monitored upon cholesterol 
treatment in the presence of cycloheximide.  CHX is a peptidyl transferase inhibitor and 
therefore it is commonly used as an inhibitor of protein synthesis.  In the presence of 
cycloheximide (and in the absence of heparin), there was no difference in total rHL mass 
upon cholesterol treatment over the course of the experiment.  Overall, these results 
strongly suggest that HL protein degradation is not affected by cholesterol treatment, 
whether before or after secretion.  While this could be definitively shown by doing a 
pulse-chase experiment in the presence of labeled methionine, in the absence of any 
evidence that this mechanism might be involved, this experiment was not conducted. 
An interesting side observation could be raised from this experiment by looking 
separately at cell-associated protein in control cells not treated with cycloheximide.  
Indeed, cholesterol appeared to have a dual effect on HL cell-associated protein levels.  
Cholesterol decreased cell-associated HL within the first few hours after treatment, but 
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this trend reversed after 12-24 hours suggesting the presence of a compensatory 
mechanism.  A rapid effect of sterols is to decrease HL protein synthesis and thus 
secretion (Figure 4-1).  This level of regulation can be fast since translational regulation 
bypasses the transcription, splicing, and mRNA translocation steps.  The delayed 
compensatory mechanism is unlikely to be due to a change in protein synthesis rate since 
the decrease in protein translation efficiency is maintained throughout 24 hours of 
cholesterol treatment (Figure 4-5).  An appealing hypothesis is that the secondary 
increase in cell-associated rHL after a longer cholesterol treatment could be a secondary 
effect due to a decrease in SREBP levels within the cells, which would release the 
SREBP inhibition of transcription (see chapter 3) and increase HL transcription.  The 
increased synthesis of HL mRNA template would then slowly compensate for the 
decrease in the rate of translation efficiency. 
We chose to pursue the mechanism whereby cholesterol regulates HL protein 
synthesis.  Indeed, the fact that 35S incorporation decreased at stable mRNA levels (after 
four hours of cholesterol treatment, see Figure 4-1 and Figure 3-2) strongly indicated that 
cholesterol inhibits HL at the level of translation.   
Translation could be inhibited at the level of translation initiation, which could be 
determined by doing polysome profile experiments, or at the level of translation 
elongation and termination.  The mechanism could potentially be due to a change in 
mRNA editing (which could affect RNA stability and/or translation) and/or to the binding 
of an inhibitory factor to the mRNA.   
In order to see if mRNA editing was affected, we attempted to isolate polyA-mRNA 
from control and treated cells, and perform in vitro translation experiments using this 
polyA-mRNA as a template.  The synthesized labeled proteins were then 
immunoprecipitated with an anti-rHL polyclonal antibody and the immunoprecipitated 
protein was run on a gel.  Unfortunately, the signal from the 35S-labeled rHL band was 
too weak to draw any reliable conclusion (data not shown).   
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In order to see if translation efficiency was affected, we performed a series of in vitro 
translation experiments.  A common problem of IVT experiments is the presence of 
RNase contamination in the extract preparations.  In the present set of experiments, no 
difference in translation efficiency was observed when using luciferase mRNA as a 
template.  Because the decrease in translation efficiency was specific to hHL, it is 
unlikely that it was to due to excess RNase in the cytoplasmic extract from cholesterol 
treated cells, and therefore suggests that the HL mRNA is specifically responsive to some 
component of the extract from cholesterol-treated cells.   
The prK5-hHL vector used for the in vitro translation experiments (190) included the 
full hHL cDNA sequence (NM_000236) with its short 5’ untranslated region (about 40 
nucleotides), the coding sequence (signal peptide of 66 nucleotides and mature peptide of 
1431 nucleotides), and 60 nucleotides 3’-untranslated region.  Translation regulation in 
general is more often mediated by the 5’ untranslated region of the mRNA, sometimes by 
the 3’ untranslated region, and less commonly by the coding sequence (191).  In general, 
a 5’ untranslated region is thought to have a potential role in translation regulation if it is 
100-140 nucleotides or longer and has the potential for establishing a stable secondary 
structure.  The small size of the hHL 5’UTR makes it highly improbable that it contains a 
regulatory role by providing an Internal Ribosome Entry Sequence.  Thus, it seems more 
probable that HL translation regulation stems from the 3’UTR, or the coding sequence.  
The regulation of HL at the translational level described in this chapter is not without 
precedent.  Of note, the down-regulation of lipoprotein lipase translation by epinephrine 
has been shown to be mediated by binding of the catabolic subunit of protein kinase A to 
the 3’UTR of LPL mRNA (187;192;193).  Also, some examples of translational 
regulation by nutritional factors exist in the literature.  For example, vitamin B12 was 
shown to specifically upregulate the translation of methionine synthase (194).  It will 
remain to be seen if physiological levels of nutrients are effective at regulating HL 
translation.
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Chapter 5 – Future experiments 
 
In rat or human hepatoma cells, cholesterol or the acyl-CoA:cholesterol 
acyltransferase inhibitor 58-035 markedly decreased secreted HL mass and HL mRNA.  
Compactin treatment or overexpression of nSREBP1a decreased HL promoter activity 
and mRNA levels.  Additionally, forced expression of nSREBP1a reversed the USF1-
mediated activation of hHL promoter constructs. Sterol-responsive binding sites for 
HNF1, HNF4 and USF1 were identified within the hHL promoter at -70/-48, -252/-218, 
and -317/-298 respectively.  SREBP1a bound to USF1 in co-immunoprecipitation 
experiments, suggesting that inhibition of HL transcription by cholesterol or compactin 
may occur through SREBP1 interaction with USF1. These experiments have provided 
evidence for a novel aspect of the function of SREBPs.  The next step will be to define 
the molecular mechanism responsible for the inhibitory action of nSREBP.  SREBP may 
bind directly to USF1, thereby inhibiting the binding of USF to the HL promoter and/or 
to its co-activators, and inhibiting initiation of transcription. 
It is now clear that transcriptional activity is not the best indicator of nuclear SREBP 
levels in terms of HL inhibition.  A precise assessment of the levels of each functional 
isoform upon sterol or compactin treatment would be extremely useful to more precisely 
delineate the regulation of HL transcription.  The use of currently available antibodies 
against SREBP1 (non-specific for isoforms 1a and 1c) and 2 in immunoblots could 
already provide an estimate of the levels of SREBP1 and 2 within membranes or nuclear 
extracts.  It may be productive to investigate the possibility of producing peptide 
antibodies specific for SREBP 1a and 1c. 
For practical reasons all the studies reported in this thesis employed liver cell lines.  It 
is well established that the proportions of the various SREBP isoforms in these cell lines 
does not reflect their concentration in liver cells.  In particular, SREBP 1c levels are in 
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general lower in liver cell lines than in primary liver cells.  Future work on regulation of 
HL should be carried out in primary liver cells. 
  HNF1 is a known activator of HL.  Our studies have identified an HNF4 binding site 
within the human HL promoter.  A functional role of HNF4 in regulating HL could be 
assessed in transactivation assays.  Both HNF1 and HNF4 could potentially interact with 
SREBP, as has previously been shown in the case of HNF4 (152).  Co-
immunoprecipitation experiments in HNF1 or HNF4 and SREBP transfected cells could 
determine whether SREBP could decrease binding of these factors to their binding 
elements within the HL promoter in a similar fashion to USF1.   
It would be essential to show that these in vitro experiments have physiological 
significance within cells.  Chromatin immunoprecipitation experiments could be used to 
show direct binding of USF1, HNF1, and HNF4 to the HL promoter and to monitor an 
expected decrease in the binding of these factors upon inhibition by sterol or compactin 
treatment, or nSREBP transfection. 
Post-transcriptionally in rat cells, cholesterol or 58-035 decreased rHL protein 
synthesis, at least partly through a decrease in HL translation efficiency.  The decrease in 
translation efficiency in in vitro translation assays suggested the presence of an inhibitory 
factor in the cytoplasmic extracts from sterol-treated cells.  In order to conclusively show 
that an inhibitory factor binds to the HL mRNA transcript or alternatively that an 
activator is released, an mRNA gel shift experiment could be performed.  Assuming a 
shift was found, this gel shift experiment could also be used to refine the location of 
protein binding on the RNA by using probes spanning different regions of the mRNA.  
The functionality of the identified region of the mRNA could later be confirmed by using 
the sense mRNA as a competitor for binding to the binding protein in in vitro translation 
assays, or by cloning it into a vector to drive the translation of a heterologous reporter 
gene.  The identity of the RNA-binding protein could be probed in supershift 
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experiments.  Alternatively, after partial purification of the extract containing the 
inhibitory activity the protein could be identified by a proteomic approach, using tryptic 
digestion, followed by liquid chromatography-mass spectroscopy. 
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Appendix A- Lipoprotein-deficient serum (LPDS) 
preparation by density gradient centrifugation method 
 
This protocol is adapted from Busch et al., 1990, JBC, 265(36): 22474-9. 
 
1. Thaw required amount of FBS 
 
2. Make 1.006g/mL solution 
Add 11.4g NaCl in 1L volumetric cylinder 
Fill with dH2O to 1L 
 
3. Make ~1.478g/mL solution 
Add 78.32g NaBr to 100mL of (1.006g/L solution) (this will yield a volume 
superior to 100mL) and heat to dissolve if necessary 
Check density of new solution by measuring the mass of 10mL (use volumetric 
pipette in 344 drawer under luminometer) 
Record exact density dD: __________ g/mL 
 
4. Adjust FBS to a final density of 1.21g/mL 
 
VD= Vs(df-di)/(dD-df) =________ 
 
Where  VD = volume of diluent to be added to Vs 
  Vs = initial sample volume 
  df = desired density (1.21g/mL) 
  di = initial density (1.006g/mL) 
  dD = diluent density 
Reference: Havel RJ et al, J Clin Invest, 34:1345 (1955). 
Mix VS (FBS) with VD (diluent solution at dD) to reach a final volume of 
_________ (note 330mL total needed to fill all 8 tubes in rotor). 
 
5. Fill Quick-Seal tubes (Beckman #342414 – 1x3½in) up to the very top (~40mL) 
leaving air only in half of the stem (air bubbles in the tubes may cause the tubes to 
collapse during centrifugation). Using a syringe with a metal adaptor, very fine 
polyethylene tubing can be used and filling can be achieved from the bottle of the 
tube. 
Note: if needed a solution of density 1.21 can be obtained by mixing 10mL of 
solution d1.006 with 7.61mL of solution d1.478. 
Add metal top, and use the machine to heat up the metal, which will transfer the 
heat to the stem and melt the plastic such as it seals. The stem should almost 
disappear as you press down. 
Remove metal top and apply gentle pressure to check for good sealing. 
Rinse the exterior of the tubes with water to prevent damage to the coating of the 
titanium rotor. 
Add the red metal caps and place the tubes in the 60T1 rotor. 
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6. Spin for >40hours (on hold setting- no specification of time) at 55,000rpm, at 15C 
(not too cold!) in the Beckman ultracentrifuge.  
 
7. Make buffer for dialysis: 
To make 10mM K phosphate final at pH 7.4: 
 Final 
molarity 
1L 6L 
K phosphate monobasic (MW 
136.09) 
1.9mM 0.26g 1.55g 
K phosphate dibasic (MW 
174.18) 
8.1mM 1.411g 8.465g
NaCl 120mM 7.0128g 42.08g
KCl 2.7mM 0.201g 1.21g 
Check that pH is 7.4 
Store at 4C 
 
8. Stop the centrifuge –inactivate the brake.  
Record total # of rotations: ____________ 
Remove tubes gently with a pair of hemostats. 
 
9. Make sure tube cutter is greased.  
Set tube cutter to cut the tube at 5.1cm from the bottom of the tube. 
Cut tube, and leave blade in. 
With a 16 gauge needle, make 2 holes in top of tubes and empty the top 
compartment. Remove the top part of the tube and empty the last bit of fluid in the 
upper compartment with a Kimwipe. 
Remove the blade. 
Using a plastic transfer pipette, transfer the content of the lower compartment to a 
glass cylinder on ice. Make sure to rinse the sides of the tubes (either with 
delipidated plasma or with the PBS-K dialysis buffer) to resuspend any aggregated 
protein and recover it. 
Recover all tubes in a total volume slightly below that of the original volume of 
serum used i.e. ___________.  
 
10. Dialyze ON against 2L PBS-K dialysis buffer at 4C. 
Change of buffer in the morning and again after a few hours. 
 
11. Recover dialyzed serum, record total volume:_______________ and filter-sterilize 
in hood for future tissue culture use. Note that total volume should be same as 
starting FBS volume. If not, adjust with PBS-K. 
 
12. Optional: check that osmolarity of solution is around 300mosm. 
 
Note: to separate HDL, first get rid of less dense lipoproteins, then use solvent 
density of 1.21 and spin at 40,000rpm, 40hours, no brake, at 17C. 
Reference: Hatch FT and Lees RS, Adv Lipid Res, 6:33 (1968). 
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Appendix B - Preparation of lipoprotein, fatty acid-deficient 
serum 
 
A. Lipoprotein-deficient serum (LPDS) preparation using the cab-O-sil 
method.  
 
This protocol was adapted from S R Behr’s PhD thesis, 1983. It removes all 
lipoproteins from the plasma (Weinstein DB, A single-step adsorption method for 
removal of lipoproteins and preparation of cholesterol-free serum, Circulation 59 and 
60, Suppl. II, Abstract 204, 1979). 
 
1. Thaw required amount of FBS 
2. Add 2% w/v Cab-O-sil (this is 2g/100mL) to the FBS 
3. Incubate at 4C for 4hours with occasional gentle shaking 
4. Spin for 30 min at 20,000rpm using a Sorvall SS-34 rotor 
(can take 8 tubes with ~35mL each  i.e. total of 280mL at one time) 
5. Filter-sterilize supernatant in tissue culture hood 
 
B. Proceed with an isopropyl ether/n-butanol extraction to eliminate 
remaining free fatty acids  
 
This protocol was used by Hannah et al., JBC, 276(6):4365-72, 2001, and was based 
on an original protocol by Cham and Knowles, JLR, 17:176-81, 1976. 
 
Constituents needed: 
9 800mL isopropyl ether 
9 400mL n-butanol (also called 1-butanol) 
9 500mL FCS 
 
Procedure: 
1. Thaw 500 mL FCS 
2. In hood, pour the FCS in a 2L flask 
3. Add 600mL isopropyl ether and 400 mL of n-butanol (measure solvents in 
glass cylinder) 
4. Incubate in hood 20 minutes at RT, then 20 minutes on ice – swirl regularly to 
ensure good mixing of the aqueous and organic phases 
5.  Centrifuge at low speed (≤ 2000rpm for a few minutes, original procedure 
called for 2000rpm, 2 minutes). (Note: Can use 50mL Pyrex tubes and spin 
them in IEC centrifuge using the 921 rotor, 6 tubes at a time, do not forget 
rubber cushions at the bottom of the gaskets, balance carefully, spin for 10 
minutes at 1000rpm). After spinning, there are 3 phases, an upper organic 
phase, a middle foamy phase, and a lower water-soluble phase. 
6. Aspirate organic phase in aspirator flask, as well as middle phase, which 
should be minimized as much as possible (by spinning harder). 
7. Pool all lower phases together in a flask. 
8. Repeat steps 5 to 7 as needed. 
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9. Add 200mL isopropyl ether to the lower phases mixture. This step is to ensure 
that there is no residual n-butanol in the water-soluble phase. 
10. Repeat steps 4 to 8. 
11. Flush with a stream of N2 for 2 hours. Evaporation under nitrogen gas can be 
achieved with the tubing above or inside the mixture. There should be around 
500mL after this step. 
12. Freeze-dry.  
a. Use the speedvac but bypass the concentrator. Unscrew the tubing 
behind the concentrator and tighten it on the slightly greased glass 
adaptor (Stover lab) that fits the large vacuum flask (holds 500mL 
easily – also from Stover lab).  
b. Shell-freeze the defatted serum. Pour the serum in the vacuum flask, 
add a little grease on the outside of the flask so it seals well with the 
rubber cap, “close”, and place the flask in an ethanol and dry ice bath. 
Swirl so that it freezes in layers, with the maximal surface possible. 
Note that it is worth doing this in several times if the starting volume is 
500mL. 
c. Once frozen, connect the rubber cap to the greased glass tubing. Leave 
in a dry ice bath or else the liquid will thaw on the edges, the whole 
mass will be sucked up. Apply the vacuum. 
13. Resuspend in 200mLdistilled water. 
14. Dialyze against 6L PBS (10mM Pi). 
15. Adjust final volume to 500mL with PBS. 
16. Spin at 10,000rpm, 30 minutes in SS-34 rotor (Sorvall) to pellet insoluble 
protein and filter-sterilize the supernatant. 
17. Store in multiple aliquots at –20C. 
 
NOTES:  
9 this procedure does not affect ionic strength or pH. 
9 In Hannah paper: 
Mean Free Fatty Acids: 840µM before procedure, 4.4µM after 
Mean Cholesterol: 280µg/mL before, 7.5µg/mL after 
Mean Triglycerides: 600 µg/mL before, 23 µg/mL after 
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Appendix C - Preparation of methyl beta cyclodextrin 
solutions 
 
This protocol was derived from the protocol by Christian et al., Use of cyclodextrins 
for manipulating cellular cholesterol content, J. Lipid Res., 38: 2264-72, 1997. 
Methyl beta cyclodextrin (Sigma C-4555, MW 1317-59, average: 1338) 
 
Notes:  
• Store solid tightly sealed at RT. 
• Need 34mg methyl beta CD to make 10mL of 2.5mM. 
• Solutions can be stored several months at 4C. Over a 6-day period, there is no 
loss in the CD: cholesterol complexes if stored at RT in glass containers, but 
there is a 50% loss of cholesterol if stored in plastic containers. 
• Do not add aqueous solutions to the cholesterol-CD complexes but dilute with 
stock CD solutions if complexes with less cholesterol are desired, otherwise 
cholesterol can precipitate out  
 
To make 10mM Methyl beta cyclodextrin solution: 
• 10mM is 13.38g/1000mL MEM 
i.e _____g/_____mL MEM 
• Stir at RT for 30 minutes 
• Filter-sterilize through 0.2um 
• Store at 4C up to several months in glass container 
 
To make 2mM or 5mM Methyl beta cyclodextrin medium: 
 
 2mM Me beta CD 
final 
5mM Me beta CD 
final 
10mM Me beta CD in MEM 20 mL 50 mL 
Cab-o-sil treated FBS (5% final) 5 mL 5 mL 
Cab-o-sil treated horse serum 
(20% final) 
20 mL 20 mL 
L-glutamine (2mM final) 1 mL 1 mL 
MEM 54 mL 24 mL 
 100 mL 100 mL 
Check that pH=7.4 with pH paper (and adjust if necessary, usually not required) 
 
To make 50mg/mL stock solution of cholesterol in 1:1 chloroform:methanol 
50mg/mL (MW: 386.67) is 129.3mM 
• In glass scintillation vial with Teflon lining: 500mg/10mL 
     i.e. ______mg/____mL 
• Flush vial with N2 after each use. 
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To make 5mM Methyl beta CA 8:1 cholesterol molar ratio medium: 
Note that the theoretical final concentration of cholesterol would then be 625uM, in 
practice though, one does not know what the final concentration is b/c the solution is 
saturated in cholesterol and the excess is filtered out. 
• 129.3/0.625=206.9 dilution factor 
• Final volume needed ______mL/206.9 = _______ mL of 50 mg/mL stock 
solution of cholesterol to use in next step 
• Dry the cholesterol from previous step under N2 in a glass ampoule of adequate 
volume capacity – try to get the cholesterol well dispersed on the surface 
• Add the final volume of 5mM Methyl beta CD medium to the dried cholesterol 
• Vortex to help resuspension 
• Sonicate with tissue culture sonicator in waterbath for 3 minutes at 37C 
• Rotate overnight in 37C waterbath under constant low flow of N2 
• Adjust pH to 7.4 (using pH paper strips) 
• Filter-sterilize through 0.2 um filter with prefilter 
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Appendix D - Rat Hepatic Lipase enzyme-linked 
immunosorbent assay (rHL ELISA) 
 
 
This protocol is dapted from Cisar and Bensadoun (Enzyme-linked immunosorbent 
assay for rat hepatic triglyceride lipase, J Lipid Res., 26(3): 380-6, 1985). 
 
Notes: this assay does not cross-react with human hepatic lipase (hHL), chicken 
lipoprotein lipase (cLPL), or human LPL (hLPL). 
 
  
9 0.1M Carbonate-Bicarbonate Coating buffer (pH 9.6): 
Na2CO3  1.59g 
NaHCO3  2.93g 
NaN3  0.2g 
dH2O  fill to 1L 
 
9 PBS-Tween (pH 7.4) 
0.2M NaH2PO4 stock 140 mL 
0.2M Na2HPO4 stock 660 mL 
NaCl   140g 
0.05% tween  8g 
dH2O   fill to 16L 
Add all compounds into 4 liters and pour into Nalgene Lowboy dispenser, then 
add 12L water and check pH. 
 
9 1% BSA PBS-Tween 
10g BSA into 1L PBS-tween 
Filter solution through Whatman #1 filter 
 
9 Substrate buffer (make fresh): 
0.1M citric acid stock  12.15mL 
0.2M Na2HPO4 stock  12.85mL 
ddH2O    25.0 mL    (pH~5) 
Just before use add in this order: 
0-phenylenediamine (OPD) 20mg  (carcinogenic) 
30% H2O2    20µL 
 
9 2.5M H2SO4 
18M H2SO4 stock   69.4mL 
dH2O    430.6mL 
Start with ~400mL water, add acid slowly and swirl (exothermic reaction). Let 
cool then bring up to 500mL. 
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9 4X rHL sample buffer (pH 7.4) 
Note: 1X buffer is 1M NaCl, 1% BSA, 10mM Pi, 0.05% tween 20, pH 7.4. 
NaCl    117g 
BSA (ELISA grade)  20g 
Tween 20    1.0g 
0.2M Na2HPO4 stock  82.5mL 
0.2M NaH2PO4 stock  17.5mL 
dH20    Fill to 500mL 
Filter- sterilize (0.2µm filter) 
Dilute 1:4 in dH20 to obtain 1X rHL sample buffer. 
 
Procedure: 
Each of the following incubation steps may be done either for (2 hrs @ 37C), or 
overnight @ 4C in which case better sensitivity is achieved. 
Note: (96 wells/plate) x (200µL/well) = 19.2mL/plate (always make up extra) 
 
1. Coating 
9 Dilute goat polyclonal anti-rHL in carb-bicarb coating buffer to reach a final 
concentration of 1µg xrHL/200µL (ie 1µg/well, also equivalent to 5µg/mL) 
9 Add 200µL/well 
9 Incubate ON (or up to a week) at 4C or (2hrs, 37C) 
It is not a good idea to try to use old plates. At best coat plates the day before. 
 
2. Blocking with 1% BSA PBS-tween 
9 Wash plates 3x with PBS-tween using the ELISA plate washer 
9 Add 300µL/well (ie 2x 150µL) of 1% BSA PBS-tween 
9 Incubate (2hrs, 37C) or (ON, 4C) 
 
3. Sample addition 
a) Make rHL Standard Curve: 
9 1 tube contains 10µL of 3.5 ng/µL rHL-1/16/97 (-80° freezer) 
9 Add 690 µL 1X sample buffer --> 700 µL 1:70 dilution (10 ng/200µL) 
ng rHL per well 1X sample buffer(µL) 1:70 standard (µL)
0.00 1000 0 
0.02 998 2 
0.05 995 5 
0.10 990 10 
0.15 985 15 
0.20 980 20 
0.30 970 30 
0.40 960 40 
0.55 945 55 
0.70 930 70 
0.85 915 85 
1.00 900 100 
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This will give a range from 0-1ng rHL/well (delivered in 200µL). Use quadratic 
regression fit for analysis. 
b) Dilute samples to be assayed in 1X sample buffer to deliver approximately 
0.5ng/well (i.e. concentration of 2.5ng/mL) 
c) Wash plate 3x with PBS-tween using the ELISA plate washer  
(if no PBS-tween is added to the wells until loading, make sure to load fast such as 
the wells do not dry out) 
d) Add samples to the plate (200µL/well) 
e) Incubate ON @ 4 for better sensitivity (if one step needs to be done ON, this is the 
one) or else 2 hours at 37C. 
 
4. Conjugate 
9 Dilute (goat polyclonal) xrHL-HRP conjugate in 1X sample buffer (depending on 
conjugate batch, usually 1:5000 to 1:20000 dilutions are appropriate) – see 
preparation of HRP conjugate below. 
9 Wash plates 3x with PBS-tween using the ELISA plate washer 
9 Add 200µL/well of diluted conjugate 
9 Incubate (2hrs, 37C) or (ON, 4C) 
 
5. Revelation 
9 Mix buffer for substrate, add OPD and then H2O2 (as described above) 
9 Wash plates 6x with PBS-tween using the ELISA plate washer 
9 Add 200µL substrate buffer/well at timed intervals from top to bottom 
9 Leave plate in the dark (usually ~30minutes) to allow color development 
9 Add 50µL H2SO4/well to stop the color changing reactions, use the same time 
intervals from top to bottom, and record the exact length of revelation 
9 Read absorbance of each well at 490nm. 
 155 
Appendix E - Gluteraldehyde conjugation of horseradish 
peroxidase (HRP) to immunoglobulin G (IgG) 
 
 
Adapted from The Enzyme Linked Immunosorbent assay: a Guide with Abstracts of 
Microplate Application, by Voller A, Bidwell DE, Bartlett A, Dynatech Europe, 
Borough House, Rue du Pre, Guersney, Great Britain, p. 42-50. 
 
Solutions: 
9 0.15M NaCl 
35.06g NaCl in 4L dH20 
 
9 PBS (10mM phosphate-buffered saline), pH 7.4 
o NaCl:  35.06g 
o NaH2PO4: 1.05g 
o Na2HPO4: 8.68g 
o Adjust volume to 4L with dH20 
 
9 Buffer for HRP solubilization, pH 6.9 
o NaCl:  877mg (final 0.15M) 
o NaH2PO4: 621mg (or 10mL of 0.2M stock) (0.1M phosphate final) 
o Na2HPO4: 1.47g (or 40mL of 0.2M stock) (0.1M phosphate final) 
o Add 5mL of gluteraldehyde 25% 
o Adjust volume to 100mL with dH20, adjust pH 
 
9 1M Carb-Bicarb buffer, pH 9.5 
o Na2CO3 (MW 105.99) : 3.18g (i.e. ~0.3M) 
o NaHCO3 (MW 84.01) : 5.86g (i.e. ~0.7M) 
o Adjust volume to 100mL with dH20 
 
9 0.2M lysine 
o 3.65mg lysine in 100µL H2O 
 
9 Saturated (3.9M) ammonium sulfate, 10mM Pi, pH 7.0 
o Ammonium sulfate:  51.48g 
o NaH2PO4:   94mg 
o Na2HPO4:   84mg 
o Dissolve in <100mL dH2O, adjust pH to ~7.5 with NaOH pellets, then 
to 7.0 with HCl 
o Adjust final volume to 100mL with dH2O 
o Filter through Whatman #1 paper 
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Day 1: 
1. Preparation of IgG: use 5mg total, ideally at a final concentration of 5mg/mL in 
0.15M NaCl (a more dilute source of IgG is OK, further in the procedure, volumes 
will need to be adjusted to reach the same final concentrations). Dialyze sample 
overnight in 2 liters 0.15M NaCl at 4C. 
2. Solubilization of HRP: dissolve 10mg HRP in 200µL 0.1M phosphate, 0.15M 
NaCl, 1.25% v/v glutaraldehyde, pH 6.9, (use 11mg in 220µL to be safe). Incubate 
overnight at room temperature. 
 
Day 2: 
1. Pass solubilized HRP down Sephadex G-25M column (PD-10, Pharmacia): 
a. Rinse empty column with ~60mL 0.15M NaCl 
b. Allow liquid to run down to column level 
c. Add HRP solution in thin layer 
d. Wash through with saline (have a tube ready, as HRP goes down quickly) 
e. Collect colored HRP into test tube 
f. Bring HRP sample volume to 1mL (or 1.1mL) with saline 
2. Mix IgG and HRP: 
a. Mix 1mL (or total volume if >1mL) IgG with 1mL (1.1mL) HRP in a 
15mL Falcon tube 
b. Add 100µL of 1M carb-bicarb buffer, pH 9.5 (or if IgG volume is >1mL 
then increase volume to add to yield same final concentration) 
c. Leave at 4C for 24 hours 
 
Day 3: 
1. Add 0.1mL (or adjusted volume) of 0.2M lysine to IgG-HRP solution.  
2. Incubate at room temperature for 2 hours 
3. Dialyze overnight against 4 liters of PBS, pH 7.4, at 4C 
 
Day 4: 
1. Precipitate HRP-IgG 
a. Add equal volume of saturated ammonium sulfate, pH 7.0 
b. Incubate at 4C anytime from 6 hours to overnight 
c. Spin at 3000g for 30min, at 4C, (or 10,000g in eppendorf tubes) 
d. Remove supernatant thoroughly with a drawn Pasteur pipette 
2. Resuspend pellet in 1mL PBS, pH 7.4 
3. Dialyze overnight against 4 liters of PBS, pH 7.4, at 4C 
 
Day 5: 
1. Put sample in eppendorf tube  
2. Spin ~10 minutes at 10,000 rpm, discard sediment 
3. Adjust sample to 1% BSA i.e. add 0.01g ELISA grade BSA to 1mL sample 
4. Aliquot and freeze or add 0.02% thimerosal if kept at 4C 
 
Day 5 or later: 
1. Test various dilutions of conjugate with the ELISA 
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Appendix F - Fluorometric DNA assay 
 
This assay is adapted from Labarca and Paigen, Anal. Biochem., 102: 344-352, 1980. 
It is based on the fact that fluorescence increases upon binding of bisbenzamide to 
DNA. 
 
Notes:   
9 CHAPS lysis buffer does not interfere but other detergents such as Triton 
X100 and NP40 are incompatible with this assay 
9 There is approximately 6pg DNA per cell 
9 In order to be in range, from a 35mm dish of McA cells, a suitable volume to 
assay is 40µL out of 1mL cell extract in CHAPS lysis buffer. 
 
Buffers: 
9 CHAPS lysis buffer:  
(4 mM CHAPS, 50mM NH4OH, 3U/mL heparin) 
615mg CHAPS (4mM final) 
850 µL NH4OH (concentrated) (50mM final) 
750 µL heparin (1,000 U/mL) (3U/mL final) 
250mL dH2O 
pH 8.1 (w/ HCl) 
just prior to use, add:   1µLcocktail I /mL lysis buffer needed 
1µL cocktail II /mL lysis buffer needed 
• cocktail I - stock :1mg/mL leupeptin, 1mg/mL antipain, 10mg/mL benzamidine 
and 10,000 KIU/mL trasylol in trasylol solvent, 
• cocktail II - stock: 1mg/mL chymostatin, 1mg/mL pepstatin in DMSO 
 
9 Phosphate buffer:  
(50mM Na2HPO4, 2mM EDTA, 0.02% NaN3, pH 7.4) 
0.1g NaN3 (alternatively 2mL of 5% NaN3) 
125mL 0.2M Na2HPO4 
0.372g EDTA (disodium MW 372.24) - alternatively use 2mL of 0.5M EDTA stock 
Adjust volume to 500 mL 
 
9 NaCl/phosphate buffer:  
(4M NaCl, 50mM Na2HPO4, 2mM EDTA, 0.02% NaN3, pH 7.4) 
116.88g NaCl 
0.1 g NaN3 (alternatively 2mL of 5% NaN3) 
125mL 0.2M Na2HPO4 
0.372 g EDTA (disodium) – alternatively use 2mL of 0.5M EDTA stock 
Adjust volume to 500 mL 
 
9 Bisbenzimide stock:  
200µg/mL in water (bisbenzimide hydrochloride, Hoechst 33258, Sigma B-2883) 
Store at 4C protected from light 
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9 Calf thymus DNA stock:  
0.307mg/mL in 1N NH4OH (stored in cold room), pH 8.3  
Store at 4C 
 
Protocol: 
1. Dilution of bisbenzamide: 
    X        mL bisbenzamide stock 
  100X  mL NaCl/phosphate buffer 
 
2. Preparation of standard curve with calf thymus DNA:   
9 Add 32.54µL stock DNA to 1.967mL phosphate buffer.  
9 Use this solution to prepare standards according to the table below.  Add as much 
lysis buffer to the standards as is added for each sample. 
 
Preparation of DNA Assay Standard Curve 
 
µg DNA 
Diluted DNA 
(µL) 
Phosphate 
buffer (µL) 
Lysis buffer 
(µL) 
Diluted 
bisbenzamide 
(µL) 
0 0  750 * 750
0.05 10 740 * 750
0.125 25  725 * 750
0.2 40  710 * 750
0.3 60 690 * 750
0.45 90  660 * 750
0.6 120  630 * 750
0.8 160  590 * 750
1.0 200  550 * 750
1.25 250  500 * 750
1.5 300 450 * 750
1.8 360 390 * 750
  
3. Prepare samples in at least duplicates (in 10 x 75 mm tubes): 
750µL     phosphate buffer 
750µL     diluted bisbenzamide 
      µL*  cell lysate (use same volume of lysis buffer for the standards *) 
 
4. Vortex, cover and incubate standards and samples at room temperature for at least 
30 min (in the dark). Incubating overnight may increase the stability of the 
reading. 
 
5. Transfer to black polystyrene, sterile, tissue-culture treated, flat-bottom Costar 96 
well plates with lid. For each sample, pipette 300µl per well in triplicates. 
 159 
Reading of the plate with the SpectraFluor Plus fluorometer: 
a) Check that the fluorometer is on 
b) Open the Magellan3 program via the desktop shortcut. 
c) Insert the plate into the reader as far towards the upper lefthand corner as possible. 
d) Open the file wizard and click “plate in” 
• “obtain raw data” – “OK” - “next” 
• click “customize measurement parameters” 
¾ “general” tab: select “fluorescence” radio button 
¾ “plate” tab: select plate definition GRE96fb.pdf (for these specific Costar 
plates) 
¾ “measurement parameters” tab: select  excitation = 360nm 
emission = 465nm 
Note : if filters are not already installed in the machine, then exit the wizard at 
this point to change the filters. See notes on how to proceed below. 
Use optimal gain at least for reading the first plate.  If more plates need to be 
read under the same conditions as the first, select manual gain, and type in the 
gain value of the first plate 
• Select read mode: top 
¾ integration time= 40µsec 
¾ number of flashes ≤10 – “OK” 
Click “next”, check over the “summary of parameters”, and click “finish” 
e) Default file will be saved to the specified directory path 
f) Click “start” to read the plate, then “raw data” to see results 
g) To print: click “OK”, then “cancel” until file menu is accessible. Under file menu 
select “print” 
h) To save as an Excel file: under edit menu select “copy to excel file” (in options, 
export tab, you can change the orientation of the rows/columns if desired) 
i) To read other plates, go back to the file wizard.  Change to manual gain mode and 
reset gain to the optimal gain value from the readout of the first plate. 
 
Plot the standard curve data (average fluorescence against ng DNA) with a linear fit to 
determine the DNA mass in the samples. 
 
Procedure for changing filters in slides: 
 Magellan, instrument tab, select “Move plate and filter”, then “move filter out”  
 Loosen the screw from the unwanted filter with wrench, then push filter out of 
slide using a clean eraser end of a pencil.  
 Replace with new filter such as when you push it down, the writing on the filter is 
in the correct orientation, then tighten the screw to the filter into the slide.  
 Insert slide back into the machine.  
 Close the Magellan program in order to change the settings for the filters: 
o Under the start menu, select programs- TECAN- RdrOLE4 
o Under instrument menu, select “connect” 
o Under setup menu select “define filter” and update the dialog box, then “OK”  
o Under file menu, select “exit” 
o At this point you can reopen Magellan 
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Appendix G - Protocol for Cholesterol Analysis by Gas 
Chromotography 
 
Principle: Free cholesterol (FC) can be assayed directly using the GC, and total 
cholesterol (TC) can be assayed after saponification of the CE into FC and FA. β-
sitosterol (from soybean) is used as an internal standard as it is absent in mammals. 
(Adapted from Stephen R Behr’s PhD thesis, 1983, pp. 40-41) 
 
Internal standard: 
Make a 0.5mg/mL stock (10mg in 20mL of chloroform) of β-sitosterol (Sigma #S-
9889).  
 
Sample preparation: 
1. Rinse the cells with PBS 
2. Scrape the cells in 4mM CHAPS lysis buffer (use 600µL/35mm dish) 
3. Freeze at -20C 
4. Sonicate the lysates 2x 20seconds with a ≥30 second interval on ice in between 
5. Transfer the 600µL of sonicated cell lysate in lysis buffer into an acid washed 
glass screw cap tube (in drawer at the 338 sink) 
6. Add 10mL (1 volume) of chloroform : methanol (2:1) and vortex 
7. Place on ice for 30 minutes 
Note: this step, while not essential, ensures optimal recovery 
8. Add 25µg β-sitosterol to each tube, that is add 50µl of a 0.5 µg/µl in chloroform 
using a Hamilton syringe (practice dispensing accurate volumes first using solvent 
only) 
9. Add 0.2 volume of water (i.e. 2mL) 
10. Vortex well 
11. Spin at 1000rpm for 5 minutes (at RT or at 4°C) 
12. Discard the upper methanol/water phase. The lower chloroform phase contains the 
internal standard and lipids 
13. At this stage, for each sample, separate this (~6mL) chloroform phase into 2 tubes, 
one for analysis of TC, one for analysis of FC: 
a. Transfer 1.5mL to a new acid washed screw-capped flat-bottomed glass 
tube for analysis of TC (~6µg β-sitosterol) 
b. Keep the rest in original tube for analysis of FC (~19µg β-sitosterol) 
 
Analysis of total cholesterol: 
• Saponification: 
o Place glass tube in sand bath at ~40-60°C to evaporate the chloroform (cap off) 
o Add 2mL of 2% KOH in 95% ethanol (use pellets, 2g/100mL ethanol)  
o Vortex 
o Place tubes back in sand bath and incubate for another1hr at 60°C 
o Allow to cool  
o Add 2mL of hexane and vortex 
o Add 2mL of water and vortex 
o Spin for 5 minutes at 1000rpm at RT 
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o Transfer the upper hexane phase, which contains the saponified lipids, to new 
glass tubes  
Note: because the FA are still in the salt form (basic pH), they are water soluble and 
will not partition in the hexane phase 
• Dry down the hexane phase containing the sterols under nitrogen 
• Redissolve in 50µL chloroform 
• Vortex well 
• Inject 2µL into the GC injection port 
Note: expect a signal of around 40-50,000 for cholesterol based on previous trial 
assays, and a β-sitosterol signal corresponding to 0.24µg 
 
Analysis of free cholesterol: 
• Dry the sample under nitrogen gas 
• Resuspend in 50µL chloroform 
• Inject 2µL into the GC injection port 
Note: expect signal of ~16,000 for free cholesterol, and a β-sitosterol signal 
corresponding to 0.76µg 
 
HP 5890A Gas Chromatograph (GC) settings: 
Use a hydrophobic capillary column: RTX-5, 15M Crossbonded SE-54  
Restek #10221, Lot# 1649A 
Max temperature 325°C 
Internal diameter (ID) of 0.32mm  
DF=0.25micron 
Oven temperature:   220°C 
FID and injection port temperatures 270°C, 250°C 
Column flow rate:    34.5mL/min 
 
Column head: p=18psi 
Split vent: 36.7mL/min and purge vent: 1.1mL/min 
Pressure gauges: {air, 41}, {N2, 43}, {H2 FID, 19}, {H2 column, 41}. 
 
Calculations to determine the initial amounts of cell cholesterol: 
The Rf (response factor) value for β-sitosterol, the internal standard, was set at 1. 
The Rf value for cholesterol was determined to be equal to 1.01.  
Knowing that Ccount/Cmass= Scount/Smass x Rf, for each sample the amount of cell free 
cholesterol (µg/µg DNA) was determined using the following calculation: 
[(FC cholesterol count*25µg)/(RF*sitosterol count)]/ µgDNA (in 600µL lysate) 
Similarly, the amount of cell total cholesterol (µg/µg DNA) was determined as 
follows: 
[(TC cholesterol count *25µg) /(RF*sitosterol count)] /µgDNA (in 600µL lysate) 
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Appendix H - Hepatic Lipase Activity Assay 
 
 
NOTES: 
 
1) The final concentration of NaCl in the 0.5mL assay mixture must be 1M, such as 
the lipoprotein lipase activity is suppressed. 
2) These assays have a very small range of linearity representing the hydrolysis of 
only a few percent of the total substrate.  Therefore, to be quantitative is best done 
using the higher (10X) specific activity substrate, assaying replicates at several 
aliquot levels. 
3) To be in range, 5-10ng of HL should be assayed. 
4) For human HL, activity is normally ~10,000 µeq/hr/mg (i.e.10neq/ng). For rat HL, 
activity is higher, ~40,000µeq/hr/mg. 
5) Control assays (no enzyme) are necessary to determine the effect of all non 
enzyme components of the sample on the substrate and subsequent partition of the 
radiolabeled TO and FFA that may arise.  One should also consider how these 
components affect the inhibition or enhancement of the sample lipase activity. 
6) Preparation of samples to be assayed: 
Total assay volume (sample plus substrate mixture) is 0.5mL. Prior to assaying 
samples, the buffer conditions should be tested for interfering substances (such as 
CHAPS). 
 
9 Media Samples 
a -Incubate cells with fresh media for a specified amount of time (including 
heparin in the medium if desired). 
b -Collect media; centrifuge at 4°C  for 30 minutes at 2000rpm (or 10min at 
14,000rpm) to pellet cells and cellular debris. 
c -Transfer supernatant; store on ice until needed for assay. 
 
9 Cell Extract Samples 
a -Grow cells to desired density; place dishes on ice to collect  
b -Rinse cells 1 or 2x with appropriate volume of ice-cold PBS. 
c -Collect cells by scraping in appropriate volume of Lysis Buffer. Of note, 4mM 
CHAPS lysis buffer does interfere with this assay.  
d -Sonicate cell extracts 2x 30seconds, 100watts using the Braun-sonic 1510 probe 
sonicator (place cells on ice for 30sec. in between pulses). 
e- Spin supernatant for 10 minutes at 14,000rpm at 4°C. 
e -Store on ice until needed for assay. 
 
9 Other Lipase Sources 
The assays may need to be performed on samples from a variety of sources (i.e. 
acetone powders, various steps during purification). In general, check for 
interfering substances, and make sure 1M NaCl/tube is maintained. 
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REAGENTS: 
1) TLC purified 14C or 3H radiolabeled TO in chloroform with 50µg/mL butylated 
hydroxytoluene. The cpm/g chloroform is determined by liquid scintillation 
counting.   
2) Triolein (TO), MW = 885.4, Sigma # T-7140, Sigma Grade.  Prepare a solution 
containing 33.33µEq TO/g reagent grade chloroform (0.75% ethanol).  This is 
29.51mg TO or 100µEq FA/g chloroform. 
3) Oleic acid (OA), Sigma # O-3879, ~99%. 
4) 5% Gum Arabic, from Acacia tree, Sigma # G-9752.  Dissolve 15g to a total 
volume of 300mL with dH2O.  Stir vigorously – may take a long time to 
completely go into solution.  Filter through Whatman #1 paper.  Aliquot ~3mL 
into 5mL screw cap tubes.  Store at -20ºC. 
5) 10% BSA, 2M Tris, pH 8.6.  Dissolve 20g of crystalline Bovine Serum Albumin, 
ICN #810014, and 48.4g of Tris base to ~180mL with dH2O.  Check pH and adjust 
to 8.6.  Adjust volume to 200mL with dH2O; filter through Whatman #1 (or #114) 
filter paper.  Aliquot ~2.2mL into 5mL screw cap tubes.  Store at -20ºC. 
6) Belfrage "killing solution", 4 liters: (all solvents reagent grade) 
 1541mL methanol or 1227g at density 0.796g/mL   (30.8% by weight) 
 1093mL heptane or 748g at density 0.684g/mL   (50.5% by weight) 
 1366mL chloroform or 2012g at density 1.473g/mL   (18.7% by weight) 
~400mg oleic acid in chloroform solution (for a 0.1g/L final concentration) is 
added as a part of the total chloroform, serving as a carrier for the fatty acid 
released by the HL in the assay. Store at RT 
7) Borate buffer, reagent grade components, 2 liters (aqueous): 
 152.8g potassium tetraborate (0.25M for MW = 305.5) 
 69.1g potassium carbonate (0.25M for MW = 138.2) 
pH adjusted to 9.5 
Store at room temperature 
8) Glass mini-vial for substrate preparation, 17x58mm, Wheaton # 98649. 
 
PROCEDURE: 
1) Select: 
 the desired specific activity of substrate (1x which is 50,000ncpm/µeqFA, or 5x 
(250,000), or 10x (500,000)),  
 the volume of sample to assay/tube (0-200µL),  
 and the total number of assay tubes.  
Knowing that the total reaction volume is 0.5mL: 
Total volume of substrate (mL) = number of tubes x 
tube
mesamplevolumL −5.0  
 
2) Successively weigh out appropriate amounts of (100µEq FA/g chloroform 
solution) cold triolein and TLC purified "hot" triolein mixture for the desired specific 
activity into a mini-scintillation vial.  An Excel spreadsheet (with the specific activity 
value of the current batch of hot triolein, and options for the number of tubes and the 
desired specific activity) is available and is routinely used to assemble the substrate. 
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Otherwise, one can calculate the amounts to use such as: 
Cold triolein (g) = 
FA/g) (µeq 100
 FA/tube) (µeq 3.75 x  tubesofnumber  
 
Hot triolein (g) = 
(ncpm/g)in hot triole ofbatch  ofactivity  specific
FA/tube) (µeq 3.75  x   tubesofnumber  x FA) (ncpm/µeq  substrate ofactivity  specific desired  
Note: no matter what the desired specific activity is, the mass of cold triolein is the 
same (such as there is 3.75µeq/tube), and the mass of the labeled TO (which increases 
with increasing specific activity) is always assumed to be a negligible fraction of the 
total mass of cold TO. 
 
3) Evaporate chloroform with a gentle stream of N2 (takes a few minutes).  The 
last stage of this evaporation requires manipulating the stream of N2 in a fashion that 
"moves" the visible TO mass around the bottom perimeter of the vial.  This is 
necessary in order to remove the last traces of chloroform entrapped in the TO mass. 
 
4) Add appropriate volume of the 5% gum arabic solution to the substrate mix to 
reach a 0.5% final concentration in the total assay reaction volume (i.e. add 
0.05mL/tube). 
 
From this point on, make sure substrate mixture is kept on ice. 
5) Sonicate 3x 30 second cycles at 100 watts using the Braun-sonic 1510 probe 
sonicator with 4mm OD microtip.  In between cycles, return the mixture to an ice bath 
for at least 30 seconds.  This sonication step is most important in the substrate 
preparation.  One must be certain to sonicate rather than cavitate (stir air into the mix).  
Cavitation is most likely to occur if the tip is removed from the solution while power 
is applied to the tip. Avoid touching the glass with the probe.  Large droplets of TO 
remaining on the surface of the emulsion indicate that the preparation was not 
sufficiently sonicated. 
 
6) Add appropriate volumes of 10% BSA-2 M Tris pH 8.6 to the substrate mix to 
reach 1% BSA and 0.2M Tris in the final assay reaction (i.e. add 0.05mL/tube). At this 
point, transfer the substrate mix from the glass vial to a 50mL Falcon tube 
 
7) Add appropriate volume of 4M NaCl to the substrate mix – use the solution to 
rinse the glass vial and transfer to the Falcon tube. If sample volume is negligible 
and/or if sample is 1M NaCl, then volume of 4M NaCl to add is total volume of 
substrate mix /4 in order to reach 1M NaCl final – otherwise, sample salt 
concentration needs to be taken into account: 
 
Molarity substrate=[0.5mL x1M NaCl – (Vsample x Molarity sample)]/ Vsubstrate 
Vol. of 4M NaCl to add= (Vsubstrate (mL) x Molarity substrate) / 4 (M NaCl) 
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8)   Add appropriate volume of water  
Vol.  H2O (mL) = number of tubes x ((0.5mL - sample volume)/tube) 
- Vol of gum Arabic - Vol of (BSA/Tris) - Vol of NaCl 
 
9) Cap and mix gently by hand, then aliquot substrate mix to each 13 x 100 mm 
glass disposable assay tube, keep on ice 
 
10) Optional preincubation of samples: add control or anti-HL serum to each 
sample.  (Be sure to add the serum directly into the sample and not on the wall of the 
tube).  Cover tubes with saran wrap.  Shake at 4oC on ice for 45 minutes immediately 
prior to assay. 
 
11) Enzyme Assay: 
a - Place substrate aliquots on ice (or enzyme/serum solution if preincubation step is 
needed) in 13x100mm glass tubes.  
b - Add enzyme solution (or substrate) to the first tube; vortex briefly and begin 
timing as the tube is placed in a 30oC H2O bath with constant agitation. 
c - At timed intervals, repeat step b for the remaining samples. Optimum assay time 
will depend on the sample and substrate specific activity – common assay times 
are 1/2hour or 1hour. 
d - Stop reaction (at timed intervals) by adding 3.25mL (6.5 volumes) Belfage Killing 
solution and 0.75mL (1.5 volume) Borate Buffer, pH 9.5. Vortex vigorously for 
10-20 seconds. Do NOT replace tubes on ice as this will affect the partition 
coefficient. 
e - Spin for 10 minutes, room temperature,   800xg (i.e. 2000rpm @ a radius of 18cm 
in a Model UV IEC centrifuge). 
f - Carefully transfer 1.9mL (P1000 pipetman) of upper layer into 9mL Liquiscint 
liquid scintillation solution in a 20mL glass scintillation vial, mix and count. 
 
12) Liquid scintillation counting and calculations: 
Values are usually determined in units that reflect µEq FA hydrolysed by the lipase 
per mL of sample per hour.  In order to correctly calculate this value it is essential to 
define: 
• the cpm in the assay tube aliquot 
• the partition fraction of fatty acid in the upper layer, as established in a "blank" 
assay by replacing the radiolabeled TO with a known trace of radiolabeled oleic 
fatty acid. 
• the absolute counting efficiency of the liquid scintillation counter should be 
defined for each assay using a known dpm standard prepared in 1.9mL of a blank 
assay upper layer and 9mL counting cocktail.  This allows actual dpm to be used 
in the calculation or for a correction to cpm due to changes in counting efficiency 
• the volumetric fraction of the upper layer taken to count  
• the specific activity of the substrate, defined as the cpm (or dpm) TO/µEq TO in 
the substrate, according to the proportion of hot and cold TO used in making the 
substrate. 
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13) Final calculation of catalytic activity: 
µEq FA / hour / mL sample 
= 
1.9  x  FA) eq(cpm/activity   specific  substrate  x  0.38  x  (hr)  timeincubation  x  (mL) volume
 2  x cpmnet 
µ  
 where : 
 volume is the volume of lipase sample assayed 
 2/1.9 accounts for the fact that only 1.9mL are counted instead of 2mL, 
 0.38 is the recovery fraction of FA in 2mL of upper layer, 
 cpm could also be replaced by dpm. 
 
As a first estimate, one can divide the net cpm (sample gross cpm – buffer blank gross 
cpm) in µeq/hr by either 10,000 (for human HL) or 40,000 µeq/hr/mg (for rat HL) to 
obtain an approximation of the mass of normally active lipase present in the sample 
(in mg). 
 
An ELISA assay performed on the same samples can provide a reliable mass value for 
HL in the sample, in µg/mL. By dividing the activity value (µmol/hr/mL) by the mass 
(µg/mL), one can now obtain the specific activity of the lipase in µmol FA/hr/µg. 
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Appendix I - RNA Isolation Using Trizol™ and RNeasy 
columns 
 
1. Trizol (Invitrogen) extraction 
The yield is generally ~100-300µg RNA/100mm dish for confluent McA-RH7777 
cells, or ~30-45µg RNA/35mm dish. The procedure below is for isolation from 35 mm 
dishes, double the volumes for isolation from 100mm dishes. 
 
a. HARVEST 
 Add 1.25mL Trizol™ to each 35mmdish to lyse the cells  
 Pipette up and down a few times to homogenize 
 Transfer the lysates to RNAse free eppendorf tubes 
 Incubate for 5 minutes at RT 
It is optional to store at –80°C at this step. 
 
b. PHASE SEPARATION  
 Add 0.25mL chloroform, which is 0.2mL/mL Trizol™ 
 Shake the tube vigorously by hand for 15 seconds  
 Incubate for 3 minutes at RT 
 Spin at 11,300 rpm (12000g) for 15 minutes at 4°C 
 
c. RNA PRECIPITATION 
 Transfer the upper aqueous phase to clean eppendorfs 
 Add 0.5mL isopropyl alcohol per 1mL Trizol™, which is 0.625mL/tube 
 Mix by pipeting up and down  
 Incubate the samples for 10 minutes at RT  
 Centrifuge at 11,300 rpm for 10 minutes at 4°C (The gel like pellet that will 
form is the RNA) 
 
d. WASH 
 Remove the supernatant and wash the pellet with at least 1.25mL/tube of 75% 
ethanol. Do NOT vortex 
 Spin at 9000 rpm (7500g) for 5 minutes at 4°C 
 Remove the supernatant 
 Air dry 
 Resuspend the RNA in 100µL RNase-free water 
 
2. Optional: RNeasy columns (QIAGEN) 
The RNeasy kit further purifies the RNA and very good (almost 100%) recoveries 
are achieved.  
RNA isolated from a single 35mm dish or a pool of 2 dishes can be loaded directly 
onto an RNeasy column (QIAGEN). If RNA is extracted from more cells, the RNA 
mass needs to be measured first so that no more than 100µg (the maximum capacity of 
the column) are loaded on the column.  
Follow the manufacturer’s instructions.
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Appendix J - Real-time RT-PCR using the TaqMan probe 
assay 
 
Basic principle: TheTaqMan assays use a fluorogenic probe that anneals within the 
cDNA target sequence during PCR. Because the probe is designed to have a lower 
annealing temperature, it anneals prior to annealing of the primers. A reporter dye 
(FAM) is attached to the 5’ end of the probe, and a quencher dye is attached to its 
3’end. During PCR, the 5’nuclease activity of the DNA polymerase cleaves the probe, 
which releases the reporter dye from the quencher and increases the fluorescence 
intensity. 
 
Preparation of RNA samples: 
RNA was isolated using the Trizol reagent (Invitrogen) and (optionally) further 
purified using the RNeasy mini kit (Qiagen).  
 
Reagents for real-time RT-PCR (Applied biosystems): 
Product # :                    Description:                           
4311235                        Multiscribe RT, 100µL                  
N808-0260                    dNTP mixture, 1mL                        
N808-0128                    Oligo(dT), 100µL                                
4324018 1                     TaqMan Universal PCR mastermix, 5mL 
N808-0234                    TaqMan RT reagents for 200 reactions 
 
Reverse transcription: 
1 or 2µg RNA was reverse transcribed using oligo dT as primers and 
MultiScribe™ Reverse Transcriptase (Applied Biosystems).  
(Note: this is a recombinant Moloney murine leukemia virus (rMoMuLV) reverse 
transcriptase)  
  
Make one blank reaction for no template control (NTC). 
Pick either a 50µL (1µg RNA) or 100µL (2ug RNA) reaction format and calculate 
volumes to be added to the master mix accordingly. 
Component 
µL per 
reaction
µL per 
reaction 
µL for 
master mix 
final 
concentration 
10X TaqMan RT Buffer  10 5 1X 
25 mM MgCl2 22 11 5.5 mM 
dNTPs (2.5mM each) 20 10 500 µM/dNTP 
oligo dT 5 2.5 2.5 µM 
RNase inhibitor 2 1 0.4 U/µL 
Multiscribe RT (50 U/µL) 2.5 1.25 1.25 U/µL 
water + RNA 38.5 19.25    
 100 50  
Aliquot 61.5µL/tube for a 100µL reaction or 30.75µL/tube for a 50µL reaction in 
0.3mL PCR tubes for the robocycler. 
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After making aliquots of the master mix, to each tube, add: 
- 2µg RNA and water to a total volume of 38.5µL if running a 100µL 
reaction 
- 1µg RNA and water to a total volume of 19.25µL if running a 50µL 
reaction 
Mix well 
Anneal primers by incubating for 10 minutes at 25°C (room temperature) 
In robocycler, do the reverse transcriptase reaction at 48°C for 30 minutes, then do a 
5min incubation at 95°C to inactivate the enzyme 
Freeze cDNA at -20°C until real-time PCR is performed 
 
 Real time polymerase chain reaction: 
Real-time PCR using cDNA as a template was performed utilizing a custom-
designed Taqman probe assay (Assays-by-Design(SM) Service, Gene Expression, 
Assay ID 4331348) with two unlabeled PCR primers (SENDAK_RHL-E2E3F :CCA 
TCC ACT TGT CAT GAT CAT CCA and SENDAK_RHL-E2E3R : CTT CCA GAT 
CCA GGT TTC TAG CAA, 18µM each) and a FAM™ dye-labeled TaqMan® MGB 
probe annealing on the same strand as the reverse primer (FAM CAT CCA CCG ACC 
ACC C, 5µM). The assay and cycling conditions were set according to the 
manufacturer’s instructions. 
Notes about the cDNA sequence and the design of the probe: 
The probe was designed based on the corrected cDNA sequence from Sendak. 
The exon/intron junctions are not known for rat, but only those exon/exon junctions 
that bore 100% homology with the human sequence were sent as options for the 
design of a probe. The designed probe overlaps the putative junction of exon2 and 
exon3. 
 
Calculations for standard: 
Calculations of rHL plasmid DNA standard using the following molecular weights: 
A C G T  
267.2 243.2 283.2 242.2 g / mole 
 
The rHL cDNA is inserted in pCDNA3.1 (-)  
 
  
Number of each base 
MW/ 
strand 
Total 
MW  
 A C G T      
rHL insert: 
sense 446 413 389 354 415516
anti-sense 354 389 413 446 414176
829693 
  
Sendak cDNA 
sequence 
pcDNA3.1(-): 
sense 1253 1414 1382 1378 1403820 2812046 
anti-sense 1378 1382 1414 1253 1408225   
Invitrogen 
website 
      3641739 
= MW of 
vector & insert 
1 mole =6.022E+23 copies 
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The number of rHL transcripts was calculated using the following formula: 
rHL transcript number = (rHL standard mass in pg) x 10-12 x (6.022E+23) / MW 
where MW=3641739 
 
 Reaction: 
• For HL, aliquot 16µL master mix to all wells being used, then add 4µL/ 
well of either standard, blank cDNA for the no template control (NTC) 
wells, or cDNA sample. 
• For internal standards such as P0, first dilute the cDNA 1:9 in water, then 
use 9µL of this diluted cDNA in the 20µL reaction. 
Use filter tips for all pipetting and sterile mQ water in baked glassware for the 
master mix and standard dilutions.   
Component 
Vol. (µL) per HL 
reaction 
Vol. (µL) per internal 
standard reaction 
Taqman 2X PCR Master Mix 10 10
20X assay mix 1 1
water 5 0
standard or cDNA 4 9 from 1:9 dilution
Total volume (µL) 20
 
Cover the plate with an optical adhesive cover when finished.  Do not write on the 
plate.  Spin down plate (remaining air bubbles aren’t problematic as they will 
disappear once the machine temperature increases). 
 
Run plate on the ABI Prism® 7900HT thermocycler.  Use SDS 2.0 software with 
“Absolute quantification” for “384 well plate” and rHL FAM as detector. The ABI kit 
uses ROX fluorescence as a passive reference for background. Real time thermal 
profile should have 2 steps, first step should be 1x (95C, 10 minutes), stage 2 should 
be 40x {(95C, 15 seconds), (60, 1 minute)}. 
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Appendix K - Luciferase assays 
 
 
Principle/chemistry of the assay: 
A promoter fragment of the gene under investigation is cloned in an experimental 
vector upstream of a reporter gene to drive its expression. The “experimental” reporter 
is correlated with the effect of specific experimental conditions, while the activity of 
the co-transfected “control” reporter provides an internal control to account for 
sources of variability such as differences in cell viability or transfection efficiency, 
differences in pipetting volumes, cell lysis efficiency and assay efficiency. 
 
In the Dual-Luciferase® Reporter (DLR™) Assay, the activities of firefly (Photinus 
pyralis) and Renilla (Renilla reniformis, also known as sea pansy) luciferases are 
measured sequentially from a single sample. Firefly and Renilla luciferases, because 
of their distinct evolutionary origins, have dissimilar enzyme structures and substrate 
requirements. The firefly luciferase reporter is measured first by adding Luciferase 
Assay Reagent II (LAR II) to generate a stabilized luminescent signal. Immediately 
after quantifying the firefly luminescence, the Stop & Glo® Reagent is added to the 
same tube. Within 1 second of addition, this reagent simultaneously quenches the 
luminescent signal from the firefly reaction by at least a factor of 105 and completely 
activates the Renilla luciferase reaction. The amount of light integrated over a certain 
period of time is proportional to the amount of luciferase reporter activity in the 
sample, which in turn reflects the activity of the promoter driving its expression. 
 
Light intensity is a measure of the rate of catalysis by the luciferases. In the Firefly 
luciferase reaction, photon emission is achieved through oxidation of beetle luciferin 
in a reaction that requires ATP, Mg2+ and O2. The luminescent reaction catalyzed by 
Renilla luciferase utilizes O2 and coelenterateluciferin (coelenterazine). The kinetics 
of the Renilla luciferase reaction provide a stabilized luminescent signal that decays 
slowly over the course of the measurement. 
 
The pRL-TK vector expresses Renilla luciferase under the control of the herpes 
simplex virus thymidine kinase promoter. As an internal control, it should be 
unresponsive to treatment. However, this vector has been shown to vary upon 
treatment with adenoviral 12S E1A oncoprotein in Saos-2 cells (Thavathiru and Das, 
BioTechniques 31: 528-32) or dihydrotestosterone and dexamethasone in CV-1 cells 
(Ibrahim et al., BioTechniques 29: 782-4). Thus, for the study of some transcriptional 
regulators, the pRL-TK vector is not an appropriate control. If the internal control 
expression is affected by the treatment, it may be more accurate to rely on data from 
statistical analyses of replicates in multiple experiments. 
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Standard Protocol   
Materials:  Promega Dual-Luciferase Reporter Assay System 
 
1. Typically, rat hepatoma cells were transfected in 24 well plates with 80ng/well 
total DNA, with a 10:1 molar ratio of experimental luciferase reporter to pRL-TK 
control vectors respectively. Transfection was done in a total volume of 250 µL 
DMEM (no serum) in the presence of 1µL lipofectamine and 2µL Plus reagent 
(Gibco life technologies) according to the manufacturer’s instructions. Three hours 
after transfection, the medium was replaced and the appropriate maintenance or 
treatment medium added to the cells 
2. Freshly prepare a sufficient quantity of the 1X passive lysis buffer (PLB) by 
diluting the 5X concentrate (stored at -20°C) in distilled water. Mix well. 
3. Remove the growth medium from the cultured cells, and gently rinse the cells with 
phosphate buffered saline (PBS). Aspirate the PBS completely. 
4. Dispense 1X PLB into each culture well (100µL/well for a 24-well culture plate, 
65µL/well for a 48-well culture plate, and 20µL/well for a 96-well culture plate) 
5. Shake the culture plates gently at RT on a rocking platform for 15 minutes to 
ensure complete and even coverage of the cell monolayer with 1X PLB. 
Optionally freeze the plates at –80C to achieve active lysis. The firefly and Renilla 
luciferases in PLB are stable at –70°C for over one month. The lysis buffer can be 
pipeted directly from the wells of the culture plate for the assay. 
 
The assays for firefly luciferase activity and Renilla luciferase activity are performed 
sequentially in a single reaction tube. 
6. Reagents preparation: 
Luciferase Assay Reagent II (LAR II):  resuspend the provided lyophilized 
Luciferase Assay Substrate in 10mL of the supplied Luciferase Assay Buffer II. 
LAR II is stable for one month at –20°C or for one year when stored at –70°C. 
Repeated freeze-thawing of this reagent may decrease assay performance. The 
components of LAR II are heat-labile, thaw in a water bath at room temperature. 
Mix the thawed reagent prior to use. 
Stop & Glo® Reagent: Make enough for 100µL per assay. Reconstitute the 50X 
Stop & Glo® Substrate in 50 volumes of Stop & Glo® Buffer in a glass or 
siliconized polypropylene tube. Stop & Glo® Reagent (Substrate + Buffer) is best 
when prepared just before use, but can be stored at –20°C for several weeks. 
7. Predispense 100µL of LAR II into the appropriate number of luminometer tubes 
(12x75mm borosilicate glass tubes) 
8. Program the LUMAT single-cell luminometer to integrate the luminescence over 
10 seconds. 
9. Perform a first reading with just the tube and LARII 
10. Add 20µL of cell lysate to the tube; mix by pipetting 2 or 3 times, and read again. 
11. Add 100µL of Stop & Glo® Reagent and vortex briefly to mix. Read. 
12. Discard the reaction tube, and proceed to the next DLR™ Assay. 
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Protocol for use in 96 well plates using the Dual-Glo™ Luciferase Assay System 
Materials: Dual-Glo™ Luciferase Assay System (#E2920): 
 
Note: When pipeting in a 96 well plate, always pipet on the side of the wells such as 
not to disturb the cell monolayer. Use a 12-channel pipetor. 
1. Collagen coat (50µL/well at 25µg/µL) white-sided, clear bottom, tissue-culture 
treated, polysterene 96 well plates (Costar 3610), and expose to UV light ON (this 
step is actually critical to have a nice cell monolayer with McA cells) 
2. One day before transfection, plate cells in 100µL medium at 40,000cells/well. 
3. Transfection of cells: Typically, McA/Fu5AH cells in 96 well plates were 
transfected with 25ng/well total DNA, with a 50:1 molar ratio of experimental 
luciferase reporter to phRL-TK control vector respectively. Transfection was done 
in a total volume of 70µL MEM in the presence of 0.5µL Lipofectamine and 1µL 
Plus reagent (Gibco life technologies) according to the manufacturer’s 
instructions. Three hours after transfection, the medium was replaced and 100µL 
of the appropriate maintenance or treatment medium was added to the cells. 
4. Luciferase assays were performed 36 – 48 hours after transfection. 
a) Reagent preparation:  
 Reagents (stored at –20C) should be equilibrated to room temperature (in water 
bath) before beginning measurements. Do not thaw at T> 25°C. Mix well.  
 Transfer the contents of one bottle of Dual-Glo™ Luciferase Buffer to one 
bottle of Dual-Glo™ Luciferase Substrate to create the Dual-Glo™ Luciferase 
Reagent. Mix by inversion until dissolved. Can be stored at –70°C for up to 
one month.  
 Calculate the amount of Dual-Glo™ Stop & Glo ® Reagent needed to perform 
the desired experiments. Immediately prior to use, dilute the Dual-Glo™ Stop 
& Glo ® Substrate 1:100 into Dual-Glo™ Stop & Glo ® Buffer. 
b) Cells preparation: Remove plates containing mammalian cells from the 
incubator. Aspirate medium and add 50µL MEM back to each well. 
Equilibrate cells in media to room temperature before performing luciferase 
measurements. 
c) XFluor4 setup: Select “edit measurement parameters”, “luminescence”, “no 
kinetics”, integration time of 5000ms, gain of 200 as a start (from 1-255, can 
be optimized), “no shaking”, “read from top”, “Costar 96ft.pdf” for Corning 
Costar 3610 plates. Remove the emission slide for the duration of the assay. 
Insert the tissue-culture plate in the reader and place the black insert over it to 
minimize cross talk in between wells 
d) Measure firefly luciferase activity: Add a volume of Dual-Glo™ Luciferase 
Reagent equal to the culture medium volume to each well (50µL) and mix. 
This reagent induces cell lysis and acts as a substrate for firefly luciferase, 
producing a stable luminescent signal for two hours. Wait at least 10 minutes 
(but not more than 2 hours), then measure the firefly luminescence by selecting 
“start measurement” under the XFluor4 menu. 
e) Measure Renilla luciferase activity: Add a volume of Dual-Glo™ Stop & 
Glo ® Reagent equal to the original culture medium volume to each well 
(50µL) and mix. This reagent quenches the luminescence from the firefly 
reaction by at least 10,000-fold and provides the substrate for Renilla 
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luciferase. Wait at least 10 minutes (but not more than 2 hours), then measure 
renilla luminescence (in the same plate order as the firefly luminescence when 
appropriate). 
 
Calculations: 
 
Fireflycorr. = Firefly count – (average of ~3 firefly readings from untransfected wells)  
≈ Firefly count – (background count (LARII reading) for same tube) 
 
Renillacorr.= Renilla count – (average of ~3 Renilla readings from untransfected wells) 
 
Firefly to Renilla ratio= Fireflycorr. average/ Renillacorr. Average 
 
Any effect of the treatment on the pGL3 basic vector (without an inserted promoter) 
can be corrected for by expressing the results as a relative increase/decrease of the 
promoter construct expression upon treatment relative to the relative increase/decrease 
expression of the pGL3basic upon similar treatment. 
 
Normalized ratio= 
average corr. basic Renillaaverage/  corr. basicFirefly 
average corr. experim Renillaaverage/  corr. experimFirefly  
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Appendix L - Lowry-Bensadoun Protein Assay 
 
This protocol is an adaptation by Bensadoun and Weinstein (Assay of proteins in the 
presence of interfering materials, Anal. Biochem., 70: 241-50, 1976) of the original 
Lowry et al. procedure (JBC, 193: 265-75, 1951) procedure to assay protein in the 
presence of interfering materials such as lipids. 
 
Buffers/reagents: 
- Lowry A (500mL): 10g Na2CO3, 2g NaOH, 0.1g NaK tartrate 
- Lowry B (500mL): 2.5g CuSO4-H2O 
- Fiolin-Ciocalteu’s phenol reagent 
- 2% deoxycholate 
- 100% trichloro-acetic acid (100g TCA, add water to 100mL final) 
- Standard: 100µg BSA/mL H2O (stock solution frozen in aliquots) 
 
DOC/TCA precipitat ion 
Bring the samples and standards to 0.675mL with H2O- for standards see table below: 
BSA mass Volume BSA stock Volume d H2O 
0 µg - blank 0 µL 675 µL 
2 µg  20 µL 655 µL 
5 µg 50 µL  625 µL  
10 µg  100 µL 575 µL 
20 µg  200 µL 475 µL  
30 µg  300 µL 375 µL  
Add 5µL of 2% deoxycholate 
Add 0.075mL of 100% TCA. Vortex. Optional: incubate on ice for 20-30 minutes. 
Spin at 12,000 rpm for 10 minutes, 4C 
Aspirate supernatant with drawn Pasteur pipette (white pellets will be variable in size) 
 
Lipid extraction (optional, only for lipid bound protein) 
Add 600µL of ethyl ether:ethanol (3:1) (mix 15mL ether with 5mL ethanol in 
scintillation vial and seal with parafilm, store at 4C). Vortex. 
Spin at 12,000 rpm for 10 minutes, 4C 
Aspirate supernatant 
Dry completely in vacuum dessicator 
 
Lowry 
Freshly mix Lowry A with Lowry B (50:1) to make Lowry C (e.g. 12.5mL with 
0.25mL). 
Add 1mL Lowry C to each sample/standard. Vortex. Incubate at room temperature for 
10 minutes. Make sure pellet has dissolved. 
Dilute Fiolin-Ciocalteu reagent 1:1 (v/v) with dH2O 
Add 100µL F-C solution per sample/standard. Vortex and incubate in the dark at room 
temperature for 40 minutes to let color develop. 
Add 300µL/well in Costar 96 well plate and read at 740nM using the ELISA reader. 
Plot using linear standard curve.
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Appendix M - Mobility Shift Assay 
 
This protocol is adapted from Current protocols in molecular biology, pp.12.2.1-11, 
and from Li et al., BBA, 2004, 1679: 141-55. 
 
This protocol can be divided into four stages:  
1. preparation of a 32P-labeled DNA probe containing a specific protein binding site;  
2. preparation of a nondenaturing gel;  
3. binding reaction in which a protein mixture is bound to the DNA probe; 
4. electrophoresis of protein-DNA complexes through the gel, and autoradiography. 
 
1. DNA probe preparation 
DNA fragments from 10-20 to 300bp long may be used as probes. Longer fragments 
are likely to contain multiple protein-binding sites, making interpretations more 
difficult.  
a. Get reverse phase cartridge purified complementary oligos to use as probes (5’OH 
ends) 
b. Order [γ-32P]-ATP, (3000Ci/mmole, 500µCi, 10mCi/mL, Perkin Elmer 
#BLU502A500UC) 
Order 250µCi /4 probe labeling reactions. 
c. Resuspend oligos in mQ H2O at: 
• 100µM stock: resuspend X nmoles primer in 10X µL mQ H2O 
• 10pmoles/µL (i.e. 10µM) stock, i.e. 1:10 dilution from 100µM stock 
d. Prepare 5pmole/µL and 1pmole/µL double-stranded cold probes to use as specific 
competitors: 
• Mix reverse (10pmoles/µL stock) and forward  (10pmoles/µL stock) primers 
of each set at a 1:1 molar ratio 
• Anneal equimolar amounts of complementary oligos: (95C, 2min), (37C, 
30min) 
• Dilute double stranded probe 1:5 to reach 1pmole/µL final 
e. Preheat 2 heat blocks at 37C and 95C respectively 
f. End-label single-stranded complementary probes with [γ-32P]-ATP and T4 
polynucleotide kinase (NEB M0201S, 500U at 10U/µL): 
• In a 0.5mL eppendorf, mix: 
Synthetic oligonucleotide (10pmoles/µL)  0.5µL  
10X bacteriophage T4 polynucleotide kinase buffer 1µL 
[γ-32P]-ATP, 20pmoles    3µL 
mQ H2O      4.5µL 
At this point, mix well by tapping the tube, then add: 
Bacteriophage T4 polynucleotide kinase (10U) 1µL 
Mix well  
• Incubate 1hr at 37C 
• Stop the reaction by adding 1µL of 0.5M EDTA  
g. Anneal equimolar amounts of labeled complementary oligos: 
 (95C, 2min), (37C, 30min) 
h. Purify probe on a nondenaturing polyacrylamide gel. 
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Prepare the gel 
• The migration distance (D) of double-stranded DNA through a nondenaturing gel 
is D≈ –log(MW) (depends slightly on the sequence). Prepare the gel solution (1X 
TBE, 10% such as Bromophenol blue will migrate to ~30bp). For a nondenaturing 
10% polyacrylamide gel of 18 cm × 16 cm × 1.5 mm, make 60mL (6mL 10× TBE 
buffer, 20mL of 30% Protogel (37.5:1 acrylamide/bisacrylamide), 33.5mL H2O). 
Mix. Add 400µl of 10% (w/v) APS (stock <1 month old stored at 4°C) and 30 µl 
TEMED and mix thoroughly. Pour and insert the comb.  
• Allow the gel to polymerize for ~30 min 
• After polymerization is complete, remove the comb and wash the outside of plates. 
Fill the lower and upper reservoirs of the electrophoresis tank with 1× TBE buffer, 
and remove air bubbles trapped under the gel, if any. 
• Prerun and warm the gel for at least 30 min at 5V/cm (constant voltage) (~100V). 
Run the gel 
• Add 10× loading buffer to DNA samples (to 1× final). Load. 
• Run the gel at ~2-10 V/cm, taking care to avoid excessive heating.  If needed to 
avoid overheating, shorter electrophoresis times may be achieved by using a fan or 
running the gel at higher voltages in a cold room 
• Turn off the power supply. Carefully pry apart the plates so that the gel is still 
attached to one plate. Wrap the gel and plate with plastic wrap. Expose to X-ray 
film (~10 seconds) to yield a thin grey band. Make sure orientation is known. 
• After exposure, develop the film 
• Use the film to precisely localize the area of the gel that contains the full-length 
probe (most slowly migrating most intense band). 
• Align film and gel. Invert and circle the band on the glass plate. 
• Turn the gel back over and excise the band using a razor blade 
• Transfer the band with clean forceps to a microfuge tube. 
Elute the DNA from the gel 
• Crush gel with p1000 tip (gel is quite brittle) 
• Add ~2 volumes elution buffer (10mM Tris, 50mM NaCl, 1mM EDTA) 
• Incubate at 37C for 4 hours for fragments <500bp, vortexing regularly if possible 
• Wrap with parafilm and spin at 12,000g for 1minute 
• Transfer supernatant to a new screw cap tube and rinse pellets once or twice 
(<0.5mL total) 
• Add 5µL Glycoblue, 1/10th volume of 3M sodium acetate, and 2 volumes of ice-
cold ethanol 
• Place overnight at -20C 
• Spin at 12,000g for 20minutes, 4C to pellet 
• Rinse with 70% EtOH – spin again and discard supernatant (repeat if necessary) 
• Air-dry 
• Resuspend in 250µL TE, pH 8.0 
i. Count 1µl for Cerenkov counts in a scintillation counter to determine specific 
activity (cpm/µl). Store probes at 4C for up to 2 weeks. Avoid repetitive 
freeze/thaw cycles.  
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2. Prepare the nondenaturing gel 
a. Dilute 10× electrophoresis buffer 1:20 to prepare 0.5X TBE electrophoresis buffer  
b. Assemble washed glass plates and 1.5mm spacers for casting the gel. All detergent 
must be removed to avoid disrupting protein-DNA interactions. 
c. Prepare 60mL of nondenaturing gel mix/gel (4% in 0.5X TBE – made fresh): 
3mL 10X TBE electrophoresis buffer  
8mL of Protogel (30% - 37.5:1w/w acrylamide/bisacrylamide) 
1.875mL of 80% glycerol 
46.57mL mQH2O 
Add 400µL of 10% ammonium persulfate and 30µL TEMED  
d. Immediately pour the gel mix between the plates and insert a comb. Allow the gel 
to completely polymerize for 20 min. Use a comb with teeth that are ≥7 mm wide. 
e. Remove any air bubbles trapped beneath the gel and flush out the wells. 
f. Prerun the gel 30 to 60 min at 100 V.  
 
3. Prepare the binding reactions 
Thaw frozen extract aliquots on ice. 
Option 1: Regular/competition Mobility Shift Assay 
a. Add PMSF to 10X binding buffer (500mM KCl, 100mM HEPES, pH 7.9, 1mM 
EDTA) at 2.5mM final in 10X buffer 
b. While the gel is prerunning, assemble the binding reaction by combining the 
following in a 0.5 or 1.5mL microcentrifuge tube:  
Amounts in µL Free 
probe 
Probe 
+ 
extract 
Probe + 
extract + cold 
specific probe  
Probe + extract 
+ cold non-
specific probe 
Water 9.5 To 20 To 20 To 20 
80% glycerol 2.5 2.5 2.5 2.5 
Cold probe (1pmole/µL) 0 0 1 1 
10X binding buffer 2 2 2 2 
1µg/µL poly(dI:dC)-
poly(dI:dC) 
2 2 2 2 
3µg/µL 10X BSA stock 2 2 2 2 
10µg crude extract (last) 0 <3 <3 <3 
10,000cpm/µL 32P probe 2 2 2 2 
Total 20 20 20 20 
c. Mix gently by tapping the bottom of the tube with a finger without introducing air 
bubbles. 
d. Incubate at 10-15C for 20minutes in a constant-temperature water bath.  
e. Proceed to running the gel 
 
General notes: 
• A typical binding reaction will contain about 5,000-20,000cpm and about 10-
100fmol probe (10fmol/10µL i.e 1nM). 
• Amount of DNA and protein must be titrated (0.1 to 20µg crude extract for 
titration), usually need up to a 5 fold molar excess of binding protein to DNA 
• One usually needs 0.1-2µg poly dI /2-3µg crude protein 
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• For crude extracts, use incubation at 4-15C, up to 25C. Optimal incubation 
temperatures (up to 37°C) for different proteins can vary. Incubate up to one hour. 
• To assess the sequence specificity of protein-DNA interactions, the nonspecific 
competitor can be essentially any fragment with an unrelated sequence, but it is 
useful to roughly match the probe and specific competitor for size and 
configuration of the ends. Perhaps the best control competitor is the probe with a 
mutation in the binding site. Assuming there is not a huge excess of binding 
protein to probe, typical amounts of competitor are 10-1000X molar excess 
relative to the labeled probe. 
 
Option 2: Antibody Supershift Assay 
If the protein that forms the complex is recognized by the antibody, the antibody can 
either block complex formation, or it can form an antibody-protein-DNA ternary 
complex and thereby specifically result in a further reduction in the mobility of the 
protein-DNA complex (supershift). 
a. Add PMSF to the 10X antibody binding buffer (1M NaCl, 100mM HEPES, pH 
7.9, 1mM EDTA, 30mM MgCl2, 1mg/mL BSA) at 2.5mM final in 10X buffer 
b. Assemble the binding reaction:  
Amounts in µL Free 
probe
Probe 
+ 
extract  
Probe + 
extract + 
rabbit 
IgG 
Probe + 
extract + 
rabbit 
antibody 
Probe + 
extract + 
goat IgG 
Probe + 
extract + 
goat 
antibody 
Water 11.7 To 18 To 18 To 18 To 18 To 18
80% glycerol 2.5 2.5 2.5 2.5 2.5 2.5
10X antibody binding 
buffer 
1.8 1.8 1.8 1.8 1.8 1.8
1µg/µL poly (dI:dC)- 
poly (dI:dC) 
2 2 2 2 2 2
10µg crude extract 0 <3 <3 <3 <3 <3
2µg appropriate 
antibody 
0 0 1-10 1-10 1-10 1-10
Total 18 18 18 18 18 18
c. Tap to mix and incubate at 4C for 2 hours 
d. Add 2µL/tube of 10,000cpm/µL 32P probe 
e. Incubate at 10-15C for 20 minutes while pre-running the gel 
f. Proceed to running the gel 
 
General notes: 
• Start with a 1:1 molar ratio antibody to protein – titrate antibody if necessary.   
• Results may be different depending upon whether the antibody is added before or 
after the protein binds DNA (particularly if there are epitopes on the DNA-binding 
surface of the protein). 
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4. Run the gel 
a. Load each binding reaction into a well of the pre-ran gel. Load a small volume of 
10X loading buffer with dyes into a separate well, or add it only to the negative 
control sample without extract. There is no stacking gel in this system; so precise 
loading with little mixing with the gel buffer is necessary to obtain sharp bands. 
Allow the sample to fall along one side of the well and avoid bubbles.  
b. Electrophorese at 35mA for the minimum time required to give good resolution. 
Stop the gel before the bromophenol blue approaches the bottom of the gel (~1hr 
for a 16-cm gel). Longer run times may cause a weaker signal due to partial 
dissociation of complexes during electrophoresis. Place gel apparatus in cold room 
or use a fan if glass plates become more than slightly warm. 
 
5. Analyze the gel 
a. Slowly open and remove a glass plate with a spacer, using water to help if needed 
b. Wrap the gel on one plate with plastic wrap and directly expose to a 
phosphorimager screen at room temperature (~1-24hours in general). If immediate 
exposure is not possible, force gel to lie flat (e.g. in a cassette). 
 
Buffers and materials/chemicals: 
10X TBE (Tris/borate/EDTA) electrophoresis buffer: 
0.89M Tris   108g Tris base 
0.89M boric acid  55g boric acid 
20mM EDTA   40mL 0.5M EDTA pH 8.0 
mQ H2O to 1L 
 
10× loading buffer with dyes: 
250mM Tris-HCl (pH 7.5) 5mL of 1M Tris-HCl, pH 7.5 
0.2% bromophenol blue 0.04g bromophenol blue 
40% glycerol   8mL glycerol 
mQ H2O to 20mL 
 
poly(dI-dC):poly(dI-dC) -Amersham#27-7880-01 for 10A260U i.e.~500µg 
 
10X binding buffer (200mL): 
500mM KCl (MW 74.56)  7.456g     
100mM HEPES (MW 249.3)  4.99g   
1mM EDTA    0.4mL of 0.5M EDTA, pH 8.0 
Adjust pH to 7.9, adjust volume with mQ H2O, filter-sterilize 
Add PMSF to 2.5mM final just prior to use 
 
10X antibody binding buffer (200mL): 
1M NaCl (MW 58.44)  11.688g    
100mM HEPES (MW 249.3)  4.99g   
1mM EDTA    0.4mL of 0.5M EDTA, pH 8.0 
30mM MgCl2 (MW 203.3)  1.2198g  
1mg/mL BSA    2mL from 100mg/mL stock 
Adjust pH to 7.9, adjust volume with mQ H2O, filter-sterilize 
Add PMSF to 2.5mM final just prior to use
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Appendix N - Determination of 35S incorporation in TCA 
precipitable fraction 
 
This procedure is adapted from Miller and Carrino, 1980, JBC, 255(11): 5490-500. 
This is to monitor the incorporation of radioactivity into total cellular proteins. 
Proteins are precipitated with TCA using BSA as a carrier protein. 
 
Note: Samples to be assayed are in lysis buffer, 10mM Tris-HCl, 1% Triton X-
100, 1% deoxycholate, antiproteolytic agents cocktail 1 and 2 
 
BUFFERS: 
• 1mg/mL BSA (ELISA grade) (make 100mg/mL stock i.e. 5g/100mL, then 
1:100 dilution i.e. 0.5mL and fill to 50mL) 
• 100mM L-methionine (MW 149.2 – 100mM solution is 1.492g/100mL) 
• 100% Trichloro-acetic acid 
• 0.1M NaOH (MW 40.0 – 0.1M is 1g/250mL) 
• 10% Trichloro-acetic acid 
 
1. Prepare 22.5mL total (or adjust proportionally as needed) of:  
9 2.5mL (1mg/mL BSA),  
9 250µL (100mM Met),  
9 19.75mL dH2O 
2. Aliquot 0.9mL/tube of the mix prepared in step 1to the 5µL/tube aliquots of each 
cell lysate (after sonication but before centrifugation) or 5µL of blank lysis 
buffer 
3. Add 0.1mL/tube of 100% TCA 
Note: final concentrations in tubes are 10%TCA, 0.1mg/mL BSA (used as a 
carrier) and 1mM methionine 
4. Chill on ice for 30-60 minutes – or overnight 
5. Eppendorf centrifugation for 10-15 min at 13,000 rpm, at 4C 
6. Remove supernatant 
7. Dissolve in 75µL 0.1M NaOH  
8. Add 1mL of 10% TCA 
9. Chill on ice for 30-60 minutes 
10. Eppendorf centrifugation for 10 minutes at 13,000 rpm, at 4C 
11. Remove supernatant, be cautious not to aspirate the pellet but try to remove as 
much as possible such as the remaining acid will not neutralize the base added in 
the next step 
12. Dissolve in 200µL 0.1M NaOH (add 50-100µL more/tube if pellets do not 
dissolve – do not add more than needed as the NaOH can cause some quenching) 
13. Following these 2 precipitations the solubilized protein is transferred to 
scintillation vials filled with 10mL scintillation fluid rinsing the tubes three times 
with 150µL dH2O 
14. Count. 
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Appendix O - Preparation of rHL-conjugated Immunobead 
Matrix 
 
 
Day 1 
1. Make all required buffers as indicated on the manufacturer’s protocol, store at 4°C 
2. Dialyze 5mg antibody overnight vs. 6L coupling buffer (0.003 M phosphate, pH 
6.3)  
 
Day 2 
Coupling 
1. Re-hydrate the 200mg matrix bottle with 20mL distilled water.  This makes a 
10mg/mL suspension of coupling buffer plus 0.01% NaN3.  
2. Remove 10mL of the suspension with a sterile 10cc syringe and transfer to a 50mL 
conical tube.  
3. Wash the matrix twice to remove the azide i.e. add coupling buffer, resuspend, 
centrifuge at 1,500g for 10 minutes, decant supernatant, repeat.  
4. After the 2nd spin, resuspend the beads in approximately 3mL coupling buffer, add 
the dialyzed antibody, and adjust the volume to 10mL with coupling buffer.  
5. Incubate for 1 hour at 4°C. 
6. Add 20mg EDAC (BioRAD) to the mixture (stored in dessicator at 4°C). Mix very 
well. 
7. Incubate for at least 3 hours at 4°C. 
 
Wash (keep buffers on ice during washes) 
8. Divide material into two 50mL conical tubes for wash procedure. 
9. Fill and balance tubes with PBS. 
10. Spin at 1,500g for 10 minutes. 
11. Decant the supernatant (by inverting the tube immediately after the spin), 
resuspend in a small volume of PBS, vortex vigorously, fill up the tubes with PBS, 
and mix. 
12. Spin and remove supernatant. 
13. Resuspend the pellet in a small volume of 1.4 M NaCl-PBS.  Fill the tubes to 
capacity, mix, balance and spin as before. 
14. Decant and drain briefly. 
15. Repeat the high salt wash. 
16. Spin, and decant. 
17. Repeat the PBS wash above twice. 
18. Resuspend in PBS and leave at 4°C for at least 3 hours to renature the antibody. 
19. Spin and resuspend the beads in 0.005 M phosphate, pH 7.2, pool the beads and 
spin. 
20. Wash beads twice (total) with the 0.005 M phosphate, pH 7.2 and resuspend in 
0.005 M phosphate-1% BSA buffer, 10mL final volume.  Add 0.02% NaN3 when 
solution is stored (that is add 40µL of a 5% NaN3 stock solution (1:250 dilution)).   
21. Store at 4°C for months and/or at –20°C for several years. 
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Appendix P - Cytoplasmic cell extract preparation 
 
 
This protocol is adapted from Yukht et al., J. Clin. Invest., 96:2438-44, 1995, who 
cited an original protocol by Walden et al., JBC, 264: 13765-9, 1989, and from 
Current protocols in molecular biology, pp.12.1.1-9. 
 
 
BUFFERS AND REAGENTS 
 
Lysis buffer (pH 7.4) 
(50mM Tris-HCl, 35mM KCl, 10mM MgCl2, 250mM sucrose, 0.5mM EDTA, 7mM β 
-mercaptoethanol) 
 
component  final  FW  for 500mL 
Tris-HCl  50mM  157.6  3.94g 
 KCl   35mM  74.56  1.3048g 
 MgCl2   10mM  203.3  1.0165g 
 Sucrose  250mM 342.3  42.788g 
 EDTA   0.5mM    0.5mL of 0.5M stock 
Weigh powders in 50mL RNase free conicals. Fill with DEPC-treated mQH2O, and 
transfer to baked graduated container, adjust pH to 7.4 with pH paper strips and adjust 
final volume to 500mL with DEPC mQH2O 
Autoclave 
Store at 4C 
Just prior to use, to the desired amount of buffer add: 
β-mercaptoethanol 7mM  78.13  0.4895µL/mL 
Note: commercial stock is 14.3 moles/L 
 
 
Resuspension buffer (pH 7.4) 
(20mM Tris-HCl, 20mM KCl, 10% glycerol, 7mM β -mercaptoethanol) 
 
component  final  FW  for 1L 
Tris-HCl  20mM  157.6  3.152g 
 KCl   20mM  74.56  1.491g 
 Glycerol  10%    100mL 
Weigh powders in 50mL RNase free conicals. Fill with DEPC-treated mQH2O in 
baked glassware, adjust pH to 7.4 with pH paper strips and adjust final volume to 1L 
with DEPC mQH2O 
Store at 4C 
Just prior to use, to the desired amount of buffer add: 
β-mercaptoethanol 7mM  78.13  0.4895µL/mL 
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Buffer for dialysis (pH 7.4) 
(20mM Tris-HCl, 20mM KCl, 0.1mM EDTA, 10% glycerol, 7mM β -
mercaptoethanol) 
 
component  final  FW  for 4 L 
Tris-HCl  20mM  157.6  12.608g 
 KCl   20mM  74.56  5.965g 
 EDTA   0.1mM    0.8mL of 0.5M stock 
 Glycerol  10%    400mL 
Weigh powders in 50mL RNase free conicals. Fill with autoclaved mQH2O in baked 
glassware, adjust pH to 7.4 and adjust final volume to 4L with mQH2O 
Store at 4C 
Just prior to use, to the desired amount of buffer add: 
β-mercaptoethanol 7mM  78.13  0.4895µL/mL 
 
 
PROCEDURE 
The entire procedure should be achieved in one day, without delay. In particular, 
dialysis (if done) should be as short as possible. 
 
Day before: 
1. Pre-chill the SW65Ti rotor at 4C 
2. Split cells 1:2 such as cells are confluent (but not overgrown) the next day 
Day of: 
3. Prepare control and treated cells for experiment (use 7x100mm 
dishes/condition): 
4. Optional: Clean 3 centrifuge tubes (Seton 7022, 13x51mm, polyclear) for the 
SW65Ti rotor using RNAzap and then rinse with DEPC mQH2O, invert to dry 
5. Wash the cells with ice-cold PBS and aspirate the PBS off the cells 
6. Add 2mL/dish fresh PBS and scrape the cells. Pool all cells from one treatment 
together in a 15mL graduated conical centrifuge tube 
This procedure should be performed at 0-4C, in cold room. Use prechilled 
buffers and equipment/rotors. 
7. Pellet the cells by centrifuging 10min at 3000rpm (IEC centrifuge) at 4C 
8. Decant the supernatants and discard 
9. Measure the packed cell volume (pvc) using graduations on tube 
10. Add 3 last components to the desired volume of hypotonic lysis buffer (needed 
in next three steps) 
11. OPTIONAL: if at all, RAPIDLY resuspend the cell pellets in a volume of lysis 
buffer ~5 times the pvc. Spin 5 minutes at 3000rpm (IEC centrifuge)  
Note: this step removes salt from the PBS such as more swelling can occur in the 
next steps, it needs to be performed quickly because swelling will begin at this 
step already and proteins which leak out of the cells will be discarded in the 
supernatant 
12. Discard supernatant 
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13. Resuspend the packed cells in hypotonic buffer to final volume of 3 times the 
original pvc and allow to swell 10minutes on ice. The cells should swell at least 
2 fold. 
14. Homogenize in a baked glass homogenizer with 10 up and down strokes on ice, 
perform the homogenization slowly, particularly the down strokes 
Note: an aliquot can be taken so lysis can be observed under the microscope 
using Trypan blue, and should be >80-90% 
15. Transfer cells to RNase free 1.5mL eppendorf tubes 
16. Pellet mitochondria and nuclei at 10,000g for 15 minutes at 4C  
17. The supernatant is used for isolation of the S-100 fraction (high speed 
supernatant fraction): 
a. Spin at 100,000g (37,000rpm) for 1-2 hours at 4C in the ultracentrifuge 
using the SW65Ti rotor (fits 3x5mL tubes, can go up to 300,000g if tubes 
are filled at least up to 1/2cm from top) and tubes (Seton 7022, 13x51mm, 
polyclear) 
b. Add solid ammonium sulfate to the cytosolic S-100 fraction to 60% 
saturation (that is add 36.1g ammonium sulfate per 100mL solution) 
c. Precipitate for 30min on ice 
d. Collect precipitated proteins by centrifuging at 6,000g for 10 minutes at 0C  
(or 4C if 0 is not achievable) in RNase free 1.5mL eppendorf tubes 
e. Redissolve the pellet in 300µL resuspension buffer (Ranganathan et al., 
JBC, 277: 38669, 2002). Alternatively , redissolve the pellet and dialyze 
against 50 volumes of dialysis buffer (dialyze the extract for the minimum 
amount of time – one can check when to stop by measuring the 
conductivity of the extract (5-10µL/mL water) vs. that of a similar dilution 
of the dialysis buffer). 
18. Aliquot in tubes (including aliquots for protein assay) 
19. Snap freeze in liquid nitrogen or dry ice + ethanol and store at -80C 
20. Determine protein concentration by Lowry (after DOC/TCA precipitation) using 
BSA as a standard 
 
Notes: 
• Observed yield was ~1mg protein/pool of 7x100mm dishes 
• ~3-5 hours are needed prior to dialysis, dialysis takes ~4-6hours, do not let it go 
ON. After dialysis the procedure can be completed in ~1hour before freezing 
• Use ~0.1µg/reaction in IVT system (rabbit reticulocyte lysate system -Promega) 
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Appendix Q - human HL promoter map 
 
 
 
 187 
 
 
 
 188 
 
Legend: 
 
Putative transcription factor binding sites (Matinspector (1)), and common hHL 
promoter variants are indicated 
Known DNase1 covered sites (2-3) are highlighted in grey 
 
          Probe used in gel-shift assays 
 
          Confirmed transcription factor binding site (by supershift assays) 
 
(1) Quandt et al., Nucleic Acids Res. 1995;23:4878-84. 
(2) Hadzopoulou-Cladaras et al., Biochemistry 1993;32:9657-67.  
(3) Oka et al., Gene 1996;180:69-80. 
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